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Abstract 
 
Growth hormone (GH) is an anabolic hormone that regulates linear growth during critical 
developmental stages, and maintains healthy metabolism throughout life. The ultradian 
rhythm of GH secretion is orchestrated by intricate actions of hypothalamic stimulatory 
growth hormone-releasing hormone (GHRH) and inhibitory somatostatin (SST), acting on 
somatotrophs in the anterior pituitary gland (APG). The interplay between GHRH and SST 
generates the pulsatile pattern of GH release. This patterned release is defined by the 
amount of GH secreted per burst (amplitude of GH release) and the secretory pulse 
frequency and regularity (as denoted by pulse number and approximate entropy (ApEn); 
defined using deconvolution analysis). The patterned release of GH is entrained to meet 
physiological demands, with numerous central and peripheral factors regulating GHRH 
and SST actions. For example, key modulators of food intake and peripheral factors that 
signal adiposity are thought to override GHRH- and SST-mediated GH release, entraining 
the amount and pattern of GH release relative to calorie provision and peripheral factors 
associated with food intake and adiposity. Therefore, it is firstly hypothesised that the 
suppression of GH secretion in obesity does not occur in response to endocrine 
dysfunction, rather it occurs alongside progressive weight gain, and thus changes in GH 
feedback to promote the progressive suppression of GH relative to increased fat mass.  
 
Data within this thesis confirms the suppression of peak and total GH release in 
obese mice, further demonstrating a progressive suppression of GH release relative to 
increased body weight and adiposity in both obese and non-obese mice. Thus, it is 
proposed that GH deficiency in obesity may represent physiological changes in the 
regulation of GH release, rather than pathological changes that culminate with the 
development of obesity. To clarify the association between metabolic or peripheral factors 
that signal adiposity with spontaneous release of GH, correlation analyses revealed an 
inverse relationship between epididymal fat mass, leptin (secreted proportionally to 
adiposity) and insulin, and parameters associated with the amount of GH released in wild-
type (WT) male mice. No association was observed specific in GH pulse patterning, 
confirming that GH patterning (represented by the interactions of hypothalamic pulse 
generators – GHRH and SST) remains intact regardless of feedback pressure to reduce 
the amount of GH release. 
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Given compelling evidence from pharmacological studies and modified-ghrelin 
animal models demonstrated that acyl-ghrelin (biologically active form of ghrelin) has the 
capacity to induce adiposity and amplify peak GH release, and the level of acyl-ghrelin in 
circulation is age-dependent, it is hypothesised that acyl-ghrelin modulates the pulsatile 
release of growth hormone relative to adiposity and age. To address the endogenous role 
of acyl-ghrelin relative to the pulsatile pattern of GH secretion, spontaneous GH release in 
ad libitum (ad lib) fed, conscious and free-moving male mice with germline deletion of 
ghrelin-o-acyltransferase (goat) was assessed. These animals (goat-/-) do not have acyl-
ghrelin, and thus offer a unique opportunity to define the importance of acyl-ghrelin in 
regulating the amount and pulsatile pattern of GH secretion. Measures were extended to 
include transcript expression for key hypothalamic regulators of GH release, and 
peripheral factors modulated relative to GH release. As anticipated, data shows a 
significant reduction in the amplitude of GH release in goat-/- mice compared to age-
matched WT mice. Data demonstrate comparable levels of adiposity in WT and goat-/- 
mice. Moreover, the negative association between adiposity and GH release is conserved 
in both genotypes. As such, further studies were conducted to interrogate the in vivo role 
of acyl-ghrelin in regulating GH release relative to age. 
 
The amplitude of GH release was remarkably low in younger goat-/- mice compared 
to age-matched WT mice. Although it is thought that the reduction in GH release is 
coupled to an age-associated decline in acylated ghrelin levels, this was not observed in 
goat-/- mice when compared with age-matched WT mice, potentially due to low levels of 
GH release at a young age. Moreover, as epididymal fat weight from age-matched WT and 
goat-/- mice was comparable, the reduction in the amount of GH secreted in young goat-/- 
mice likely occurred independent of feedback that is specific to adiposity. An increase in 
GH pulse frequency was observed alongside irregular pulse patterning in goat-/- mice. This 
was characterised by an increase in the number of GH pulses and ApEn observed during 
extended secretory events. This overall change in GH patterning in goat-/- mice did not 
coincide with changes in hypothalamic Ghrh, Sst, Neuropeptide Y (Npy) or Gh 
secretagogue receptor (Ghsr) gene expression, or pituitary GH content, suggesting that 
loss of acyl-ghrelin does not alter the presence of components of central systems thought 
to contribute to the synthesis and release of GH. Rather, it is proposed that loss of acyl-
ghrelin may alter interactions between these hypothalamic components of GH release. Of 
interest, despite reduced GH release, body length remained similar between goat-/- and 
WT mice. Furthermore, peripheral levels of insulin-like growth factor 1 (IGF-1) in goat-/- 
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mice were positively correlated with an increase in GH pulse frequency. Thus, sustained or 
increased IGF-1 release in goat-/- mice may compensate for the effects of reduced peak 
GH release (in young adult mice) on linear growth.  
 
In summary, observations within this thesis demonstrate that, 1) weight gain and 
increased adiposity contributes to a progressive reduction in the amount of GH release; 2) 
altered secretion of leptin (as an adipostat) and insulin (a metabolic modulator of glucose 
metabolism) may not directly impact GH pulse patterning, rather these factors are 
proposed to contribute to progressive reduction in GH release relative to fat mass, and 
thus may contribute to the feedback regulation of peak and total GH release as obesity 
develops;  3) germline loss of acyl-ghrelin contributes to derangements in the amount and 
patterning of GH release independent of adiposity and 4) the loss of acyl-ghrelin results in 
a rise in the frequency and irregularity of GH pulses, which in turn may recover peripheral 
levels of IGF-1 to sustain linear growth. While these factors largely entrain the amount and 
patterning of GH release, contributing to progressive changes to meet physiological 
needs, derangements in GH release may be detrimental to the long-term anabolic actions 
of GH. 
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Chapter 1 Brief introduction, literature review, hypothesis and aims 
Brief introduction 
Growth hormone (GH) plays a vital role in the maintenance of healthy body composition 
and energy homeostasis. The GH axis is comprised of two key regulators – growth 
hormone releasing hormone (GHRH) and somatostatin (SST) that govern the 
characteristic pattern of pulsatile GH release (Frohman, et al. 1992). While GH deficiency 
is associated with increased adiposity (de Boer, et al. 1995), it is thought that increased 
adiposity contributes to a reduction in GH release following aging and excessive food 
intake (Vahl, et al. 1997; Veldhuis, et al. 1991; Veldhuis, et al. 1995). Moreover, factors 
produced in proportion to adiposity or changes in endocrine functions are thought to 
contribute to impaired GH secretion. Correlative studies assessing the relationship 
between adiposity and the secretion of GH provide essential information to identify 
potential factors that suppress GH secretion in obesity (Gill, et al. 1997a; Vahl et al. 
1997; Veldhuis, et al. 2009; Veldhuis, et al. 2011). In this instance, the decline in 
circulating levels of ghrelin in obesity (Tschop, et al. 2001b) may contribute to low GH 
levels. Given that ghrelin primarily drives hunger signals (Wren, et al. 2001a) and 
amplifies GH secretion (Kojima, et al. 1999), low levels of ghrelin in obesity may be 
favourable to prevent hyperphagia (Wren, et al. 2001b) whilst indirectly contributing to 
GH deficiency. Although pharmacological observations show that acyl-ghrelin regulates 
the release of GH by amplifying GHRH-induced GH secretion (Kojima et al. 1999), some 
studies have found conflicting observations on the relationship between pulsatile GH 
secretion and ghrelin (Nass, et al. 2008a; Tolle, et al. 2002). While the loss of all 
preproghrelin-derived signalling through deletion of the Ghrelin gene contributes to a 
reduction in peak GH release in young mice (Hassouna, et al. 2014), selective 
contribution of acyl-ghrelin to peak endogenous GH release, or ultradian and circadian 
GH patterning warrants further investigation. 
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Literature review 
1.1 Brief overview of the historical understanding of the growth hormone (GH) axis 
The treatment with anterior pituitary gland (APG) extracts in rats was first recognised to 
promote growth (Evans and Long 1921). Accordingly, the administration of the same 
anterior pituitary extract demonstrated growth restoration in hypophysectomised rats 
(Smith, et al. 1927). It was also found that hypophysectomised mice were responsive to 
metabolic factors after the administration of pituitary extracts (Houssay 1936). It was later 
discovered that a growth-releasing factor (GRF) released from the hypothalamus into the 
portal blood circulation potentially acts on the APG. This is evident in rats (Muller, et al. 
1965) and guinea pigs (Muller and Pecile 1965), demonstrating that intra-carotid injection 
of stalk median eminence (ME) extracts results in the release of a growth factor from the 
APG into the peripheral blood circulation. This corroborates that the function of the APG 
is dependent on hypothalamic factors that are released in the portal blood supply. 
  
The first development of a method to measure plasma growth hormone (GH) level 
made it possible to identify circulating levels of GH in children and adults with 
hypopituitarism or acromegaly, as well as the assessment of GH levels in response to 
physiological or metabolic changes (Glick, et al. 1963). In the earlier years, the 
association between the lack of a growth-stimulating factor and severe proportionate 
short stature in humans was established, thus human GH extracts were consequently 
used as a treatment to recover optimal growth in short stature individuals (Raben 1958). 
To date, the tools of current technologies and refinement of assays enable us to fill the 
gaps in the understanding of the hypothalamo-pituitary-GH axis, and this allows for the 
development of refined therapies to improve GH secretion and action. Discovery of key 
factors that contribute to the GH axis are summarised in Table. 1.1. 
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Table 1.1 Discoveries of key components that contribute to the hypothalamo-
pituitary-growth hormone (GH) axis 
 
Year Key Events References 
1963 
Development of a radioimmunoassay 
(RIA) for measurement of plasma GH 
(Glick et al. 1963) 
1973 Identification of somatostatin (SST) (Brazeau, et al. 1973) 
1979 Cloning for growth hormone (GH) gene 
(Roskam and Rougeon 
1979) 
1980 
Identification of growth hormone secretagogue 
(GHS) 
(Bowers, et al. 1980) 
1980 Cloning for somatostatin (SST) gene (Goodman, et al. 1980) 
1983 
Cloning of growth hormone releasing hormone 
(GHRH) gene 
(Mayo, et al. 1983) 
1987 
Cloning of growth hormone receptor (GH-R) 
gene 
(Leung, et al. 1987) 
1992 
Cloning of growth hormone releasing hormone 
receptor (GHRH-R) gene 
(Mayo 1992) 
1992 Cloning for somatostatin receptor (SST-R) gene (Yamada, et al. 1992) 
1994 Identification of leptin (Zhang, et al. 1994) 
1995 Identification of leptin receptor (LepR) (Tartaglia, et al. 1995) 
1996 
Cloning of growth hormone secretagogue 
receptor (GHS-R) 
(Howard, et al. 1996) 
1999 
Identification of ghrelin, and demonstration of 
stimulatory effects of ghrelin on GH release 
(Kojima et al. 1999) 
2000 
Discovery of the effect of ghrelin on feeding and 
metabolism 
(Tschop, et al. 2000) 
2008 Identification of ghrelin-o-acyltransferase (goat) (Yang, et al. 2008) 
 
 
1.2 Brief overview of pulsatile growth hormone (GH) secretion 
Growth hormone (GH) is essential for somatic growth during early life until puberty is 
reached, and subsequently plays a homeostatic role throughout life, thereby maintaining 
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the equilibrium of the body’s physiological system when challenged with external stimuli 
(Davidson 1987; Furuhata, et al. 2002). Intricate interactions between hypothalamus and 
somatotrophs located within the APG regulate the synthesis and release of GH (Giustina 
and Veldhuis 1998; Murray, et al. 2015). As illustrated in Fig 1.1, the classic pulsatile 
release of GH from somatotrophs is predominantly governed by GH-releasing hormone 
(GHRH) in the arcuate nucleus (ARC), alongside intermittent suppression by 
somatostatin (SST) from the periventricular nucleus (PeVN) (Bluet-Pajot, et al. 1998; 
Muller, et al. 1999). These factors will be discussed in the subsequent sections. 
 
 
Figure 1.1 Classic regulation of pulsatile growth hormone (GH) secretion 
The release of growth hormone (GH) from somatotrophs within the anterior pituitary 
gland (APG) is mediated through reciprocal stimulatory (blue solid arrows) and inhibitory 
(red dotted arrows) actions of the GH-releasing hormone (GHRH) neurons located within 
the arcuate nucleus (ARC), and the somatostatin (SST) neurons located within the 
periventricular nucleus (PeVN), respectively. GHRH and SST are release into the median 
eminence (ME) and travel to the APG via the hypophyseal portal system. It is thought 
that GHRH neurons may stimulate SST neuronal activity, while SST inhibits GHRH 
activity in the hypothalamus. 
 
 
Studies have shown the existence of morphological synaptic interactions between 
the two key hypothalamic pulse generators, GHRH and SST (Horvath, et al. 1989; 
Liposits, et al. 1988), wherein peak and trough levels of GH release are regulated 
GH 
ME 
GHRH 
SST 
ARC 
PeVN 
Hypothalamus 
Somatotrophs 
APG 
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respectively (Morimoto, et al. 1988; Russell-Aulet, et al. 2001). This implies that 
hypothalamic GHRH elicits the synthesis and secretory burst of GH from somatotrophs at 
the level of APG during a period of diminished SST secretion (Hartman, et al. 1991), 
thereby giving rise to peak secretory pulses within basal levels of GH. This may trigger 
the inhibitory action of hypothalamic SST or GHRH itself may exert feedback to stimulate 
SST release in a dose-dependent manner (Lumpkin, et al. 1985), thus gradually ceasing 
the release of GH from the somatotrophs. This subsequently switches off the inhibitory 
action of SST, thus allowing GHRH to once again stimulate the release of GH. The 
complexity of modulating GH secretion is made possible via the hypophyseal portal 
system. This system bridges the interaction between hypothalamic GHRH and SST 
neurons, and the somatotrophs of the APG, specifically through the fenestrated structure 
of the ME to facilitate the transport of these hormones (Sato, et al. 1990).  
 
Simultaneously, the predominant expression of GH receptor (GHR) on the liver 
instigates the physiological actions of GH via the Janus kinase-signalling transducer and 
activator of transcription (JAK-STAT) pathway (Smit, et al. 1996). This leads to the 
production of GH-induced hepatic IGF-1 that acts on the pituitary and/or SST-expressing 
neurons to further inhibit GH production, as well as promoting growth (Ohlsson, et al. 
2000). 
 
1.3 The pulsatile mode of growth hormone (GH) secretion 
Pulsatile GH secretion have been demonstrated and conserved in essentially all 
mammalian species studied to date, from rodents to humans (Giustina and Veldhuis 
1998). The pulsatile profile of GH release comprises of pulse amplitude, frequency and 
regularity (an indicator of orderliness and uniformity). It is characterised by low basal GH 
levels that are dispersed by several dominant pulses that occur at periodic intervals 
(Tannenbaum and Martin 1976; Winer, et al. 1990) as illustrated in Fig. 1.2. The 
combination of amplitude, frequency and regularity of pulsatile GH release is sexually 
dimorphic, and is necessary to drive optimal growth and metabolic rate by conveying 
physiological signals such as GH-receptor (GH-R) turnover, intracellular downstream 
signalling, transcription and translation, metabolic responses and negative feedbacks to 
targeted tissues (Achermann, et al. 1999; Giustina and Veldhuis 1998; Pellegrini, et al. 
1996). 
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An early study has demonstrated that approximately eight GH peaks occur 
predominantly at night and undetectable daytime GH levels over a 24 h blood-sampling 
period in healthy human (Plotnick, et al. 1975). However, the use of relatively insensitive 
GH immunoradio-metric assays leads to gaps in our understanding of the distinctions in 
day time and night time GH pulse profiles. Subsequently, the development of increasingly 
sensitive GH assays allowed for more detailed interrogation of the patterns of GH 
secretion in human and conscious free-moving animals, giving rise to the observation of 
natural variations in GH pulse profile (Clayton, et al. 2014). This allowed the investigation 
of peak and troughs levels of GH, and how these are influenced by endogenous and 
exogenous stimuli (Veldhuis, et al. 2008a). Providentially, the use of sophisticated 
deconvolution analyses has allowed us to define the parameters of GH release, including 
the assessment of regularity (a measure of orderliness and uniformity) detected by 
approximate entropy (ApEn) across various species (Hindmarsh, et al. 1990). Hence the 
characterisation of pulsatile GH secretion in physiological and pathological states is 
achievable (Klerman, et al. 2003; Veldhuis et al. 2008a).  
 
 
Figure 1.2 Schematic diagram of a classic pulsatile profile of GH in males and 
females 
The schematic diagrams depict classic pulsatile profile of GH secretion in males (A) and 
females (B). Pulsatile pattern of GH comprises of peak GH secretory pulses (a) and low 
basal levels (b). The frequency and regularity of pulsatile GH secretion are discriminated 
between males and females. In males, long intermittent lower GH basal levels that 
separate peak GH secretory bursts. In females, peak amplitude of GH secretory bursts 
are clustered within shorter duration, more frequent and higher basal GH levels relative 
to males. These differences are important in conveying physiological signals unique to 
individual gender. 
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In healthy men, peak pulsatile GH secretion has a tendency to be secreted in the 
evening, with the occurrence of maximal GH release generally during periods of slow-
wave sleep (Holl, et al. 1991; Matsuno, et al. 1998), and an average of 8 pulses in a 24 h 
period (Ionescu and Frohman 2006; Stolar and Baumann 1986). The pulsatile release of 
GH displays a distinctive combination of low amplitude high frequency volleys every 30 to 
60 min, complemented with high amplitude GH secretory bursts approximately every 2 to 
3 h (Farhy and Veldhuis 2003; Hartman et al. 1991). While women tend to have higher 
GH pulse amplitude and baseline secretion, pulse frequency is similar between genders 
(Jaffe, et al. 1998; van den Berg, et al. 1996; Winer et al. 1990). Similarly, distinct GH 
secretory pulses with relatively low inter-peak volleys occur at approximately 3 to 3.5 h 
intervals in male rats, whilst female rats exhibit lower irregular pulses with higher inter-
peak levels (Jansson, et al. 1985; Pincus, et al. 1996; Tannenbaum and Martin 1976). 
The elevation of pulsatile GH secretion observed in females may primarily be attributed 
to the endogenous estrus cycle associated with ovulation (Kasa-Vubu, et al. 2005) 
alongside an elevation in estrogen, contributing to the secretory dynamics of GH (Faria, 
et al. 1992). 
 
In mice, observations of pulsatile GH release were traditionally limited to 
infrequent repeated measures (Medrano, et al. 1991) or one-off measurements due to 
their physical and blood volume restrictions (Luque and Kineman 2007). These 
assessments do not reliably reflect the overall pulsatile profile of GH secretion, and thus 
interpretations from mice may be misleading, therefore undermining the physiological 
significance of pulse frequency and regularity. Although an early attempt was been made 
to evaluate the pulsatile GH secretion profile in mice (MacLeod, et al. 1991), this 
approach was not widely adopted. A recent development of methodology provided a 
refined approach to study the pulsatile profile of GH release in transgenic mouse lines 
(Huang, et al. 2014; Steyn, et al. 2011; Tan, et al. 2016). As with humans and rodents 
(MacLeod et al. 1991; Pincus et al. 1996; Robinson, et al. 1998; Tannenbaum and Martin 
1976), this methodology demonstrated that the archetypal pulsatile secretion of GH in 
mice is characterised by peak secretion periods and inter-pulse stable baseline secretion 
periods (Hassouna et al. 2014; Huang, et al. 2012; Steyn et al. 2011; Steyn, et al. 2012; 
Tan, et al. 2013). 
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Frequent blood sampling techniques with measurements taken approximately 5 to 
20 min intervals over a period of 12 to 24 h are methods to characterise the pulsatile 
profile of GH patterning in human (Brandenberger and Weibel 2004; Clark, et al. 1987; 
Hartman, et al. 1993; Stolar and Baumann 1986) and rodents (Clark, et al. 1986; 
Tannenbaum and Martin 1976). However, the physiological values of GH pulse 
frequency and regularity are complicated and incompletely understood (Goldbeter, et al. 
2000). Although attempts have been made to understand the actions of GHRH and SST 
on the pulsatility of GH release from the hypophyseal portal blood of larger animals 
(Frohman, et al. 1990; Guillaume, et al. 1994), it is currently not feasible to assess the 
physiological concentrations of GHRH and SST from hypophyseal-portal blood at 
frequent intervals in humans and rodents. Thus, mathematical models of GH secretion 
are useful to tease apart the interactions between basal synchrony of GHRH and SST 
that represent the observed endogenous pulsatile patterns of GH release (Farhy and 
Veldhuis 2003; MacGregor and Leng 2005). Moreover, this model can be substantiated 
by pharmacological observations involving exogenous GHRH and SST administration 
(MacGregor and Leng 2005). 
 
1.4 The key regulators of pulsatile growth hormone (GH) secretion 
1.4.1 Growth hormone releasing hormone (GHRH) 
The identification of the GHRH as a potential hypothalamic factor regulating GH secretion 
was originally demonstrated in rats, showing that lesions of the ventromedial 
hypothalamic nucleus (VMH) led to retarded growth and reduced GH content (Reichlin 
1961), whereas electrical stimulation of the VMH elicit the release of GH (Frohman, et al. 
1968). Furthermore, the incubation of hypothalamic extract in cultured rat pituitaries 
stimulate GH secretion (Schally, et al. 1965), but no effect was observed with rat cerebral 
cortex extract (Deuben and Meites 1964). Hence evidence implies the existence of a 
potential hypothalamic GH-releasing factor in regulating the release and synthesis of GH 
from the APG. 
 
 The GHRH was first characterised from human pancreatic tumour extracts 
(Guillemin, et al. 1982) and subsequently the gene was identified (Gubler, et al. 1983; 
Mayo et al. 1983). It was named following the identification of GRF-(1-44)-NH2 within the 
human hypothalamus (Ling, et al. 1984). The population of GHRH-expressing neurons is 
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located within the ARC of the hypothalamus. Dense projections of these neurons are 
projected into the ME where GHRH is released into pituitary portal vasculature 
(Balthasar, et al. 2003). Here, GHRH travels via the pituitary portal vasculature to the 
APG from the ME thereby gaining access to GHRH receptors (GHRH-R) located on the 
plasma membrane of somatotrophs. Within the APG, GHRH binds to its 7-
transmembrane G-protein coupled receptor (GPCR) on somatotrophs (Bloch, et al. 1983) 
to elicit the production and release of GH within and from the somatotrophs (Barinaga, et 
al. 1985). The binding of GHRH to its receptor leads to membrane depolarisation of the 
somatotrophs, resulting in an increase of intracellular [Ca2+] via voltage-gated calcium 
channel (Cuttler, et al. 1992; Mayo, et al. 2000) and the activation of a cascade of 
downstream signalling events that promotes the activation of adenylate and cyclic 3,5-
adenosine monophosphate (cAMP), which initiates GH gene transcription and the 
release of GH secretory vesicles (Frohman et al. 1992; Tsaneva-Atanasova, et al. 2007), 
thus culminating in the release of GH (Mayo, et al. 1995). 
 
Binding of GHRH-R (class B (secretin receptor) GPCR superfamily (Mayo et al. 
2000)) activates the heterotrimeric stimulatory G protein (Gs), composed of α-, β-, and γ-
subunits. The binding of guanosine-5-triphosphate (GTP) triggers the dissociation of the 
Gα subunit from the Gβ and Gγ complex, leading to the activation of membrane-bound 
adenylyl cyclase (AC). This process increases the production of intracellular cAMP. The 
rise in cAMP levels triggers the protein kinase A (PKA) signalling pathway. This leads to 
the phosphorylation of cAMP-response element binding protein (CREB) and thus 
stimulates the de novo GH production via the transcription of Gh1 gene (Lin-Su and 
Wajnrajch 2002). Consequently, this series of event initiates the transcription of GHRH-
R, and allows the recycling of GHRH-R onto the cell surface. In addition, the binding of 
Gβ and Gγ subunits triggers the phospholipase C/inositol phosphate 3 (PLC/IP3) 
pathway, instigating the release of intracellular [Ca2+] from the endoplasmic reticulum 
(ER) to further facilitate the release of stored GH from secretory granules (Chen, et al. 
2000). While GHRH induces the production and release of GH within and from the 
somatotrophs (Barinaga et al. 1985), the ablation of GHRH gene reduces pituitary GH 
gene and protein content in mice (Alba and Salvatori 2004). 
 
In humans, treatment with GHRH antagonist suppresses spontaneous GH release 
(Jaffe, et al. 1993; Ocampo-Lim, et al. 1996) and blunts the response to GH-releasing 
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stimuli (Jaffe, et al. 1996; Pandya, et al. 1998). Similarly, anti-GHRH antiserum or GHRH 
antagonists block the production of GH, resulting in the loss of pulsatile GH release in 
rats (Wehrenberg, et al. 1982a). In contrast, exogenous GHRH promotes the release of 
GH in healthy humans (Gelato, et al. 1983) and the continuous infusion of GHRH 
amplifies the natural-occurring amplitude of endogenous GH secretory pulses (Vance, et 
al. 1985). These observations suggest that endogenous GHRH is likely a major 
stimulatory regulator of GH secretion. Given these compelling effects of GHRH and 
GHRH-antagonists on GH release, GHRH may be used to treat conditions where GH 
deficiency develop as a consequence of hypothalamic defects (Sassolas 2000). As the 
responsiveness of GH release to bolus infusion of GHRH is maximal at the time of day 
that corresponds to spontaneous nocturnal release of GH (Jaffe, et al. 1995), it is thought 
that well-timed GHRH treatment might recover the diurnal pattern of GH release. 
However, intravenous (i.v.) pulsatile or continuous infusion of GHRH elicits similar effects 
on the pulsatility of GHRH-induced GH secretion (J. Anthony, et al. 1986). Moreover, 
prolonged impairment of GHRH significantly reduces the amplitude of GH release without 
altering pulse frequency (Maiter, et al. 1991). Given that GHRH neurons itself do not 
exhibit regular spontaneous rhythmic activity (Baccam, et al. 2007), the modulation of 
GHRH-induced GH surges most likely requires interaction essential afferent inputs (such 
as SST) to modulate episodic GH secretory pulses. 
 
1.4.2 Somatostatin (SST) 
Somatostatin (SST) was the first inhibitory hypothalamic factor identified to regulate GH 
release from hypothalamic extracts (Brazeau et al. 1973). It was found to inhibit GH 
release from cultured rat pituitary cells. The identification of a 14-amino acid SST after 
purification and sequencing from an isolated fraction of sheep hypothalamic fragments 
was successfully confirmed to suppress of GH release in humans (Siler, et al. 1973; 
Spoudeas, et al. 1992) and rats (Wagner, et al. 1998) by inhibiting the pituitary response 
to GHRH. An early study demonstrated the action of SST in reducing GH levels in 
acromegaly (Reichlin, et al. 1976). The SST gene was first cloned in 1980 via alternative 
slicing (Goodman et al. 1980), producing two distinct peptides known as SST14 and 
SST28 in mammals. While SST is predominantly located within the PeVN of the 
hypothalamus, the expression of SST is widely distributed throughout the central nervous 
system (CNS), and peripheral tissues (Barnett 2003; Fodor, et al. 2006; Polak and Bloom 
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1986), and act on multiple organs including the brain, pituitary, gut, pancreas and kidney 
(Luque, et al. 2008; Murray et al. 2015).  
 
In the 1990s, The SST receptor (SST-R) was first cloned (Yamada et al. 1992), 
and thereafter a total of five different Sst-r genes (SST-R1-5), which are widely 
expressed in the brain, were identified and cloned by 1994 (Patel, et al. 1995). The size 
of the SST-R ranges from 356 to 391 amino acid and are generally the family of GPCRs 
with 7-transmembrane domains in addition to extracellular and intracellular domains. 
Essentially, SST-R1-4 are partially selective for SST14 while SST-R5 has higher binding 
affinity to SST28 than SST14 (Patel et al. 1995). The binding of SST to its receptor on 
somatotrophs leads to the opening of potassium ions (K+) channels and membrane 
hyperpolarization, thereby supressing GH secretion (Tsaneva-Atanasova et al. 2007). 
This mediates the inhibitory effects on GH release by limiting AC activity and reduces 
cAMP accumulation. The opening of membrane K+ channels consequently leads to a 
hyperpolarisation of voltage-gated calcium ions (Ca2+) channels thus inhibiting Ca2+ 
influx. The reduction in intracellular [Ca2+] maintains basal levels of GH release from 
somatotrophs in the APG (Cervia, et al. 2002; Tentler, et al. 1997; Yang, et al. 2005; 
Yang, et al. 2007). 
 
An early in vitro study using pituitary cell lines first demonstrated that SST might 
influence the production of its receptors (Presky and Schonbrunn 1988). Subsequent 
studies showed that SST itself could simulate the expression of SST-R5 specifically from 
primary pituitary cultures from rats (Park, et al. 2003), pigs (Luque, et al. 2004) and 
pituitary cell lines (Berelowitz, et al. 1995). Moreover, SST-Rs are expressed on both 
hypothalamic GHRH-expressing neurons and SST-expressing neurons (Bertherat, et al. 
1992) and on somatotrophs in the APG. The antagonistic actions of SST on GH release 
from the somatotrophs of the APG in rodents are primarily mediated through SST-R2 and 
SST-R5 (Barnett 2003; Shimon, et al. 1997) and SST-R1 and SST-R2 on the GHRH 
neurons (Lanneau, et al. 1998; Viollet, et al. 1997). 
 
The synaptic interactions between SST-expressing and GHRH-expressing 
neurons mediate the pulsatile release of GH at the level of hypothalamus is substantiated 
by the projection of axons of SST-expressing neurons from the dorsomedial of ARC into 
the ventrolateral area of the nucleus (Horvath et al. 1989; Liposits et al. 1988; 
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Willoughby, et al. 1989). Moreover, SST-expressing neurons project into the ME whereby 
SST is released from neurosecretory terminal into the portal vasculature to inhibit GH 
release from somatotrophs at the level of APG (Frohman et al. 1992). This is supported 
by in vitro studies demonstrating that high dosage of SST suppresses GHRH-stimulated 
Gh expression and release (Cordoba-Chacon, et al. 2012) and treatment of perifused 
hypothalamic tissue with SST inhibits basal GHRH release (Yamauchi, et al. 1991). 
Basal SST activity may determine the frequency of GH pulses given that a peak in GH 
secretion coincides with a simultaneous GHRH release and low levels of SST 
(Tannenbaum and Ling 1984). Accordingly, studies using rats and sheep demonstrate 
the continuous release of SST into the hypophyseal portal circulation reaches low levels 
at a peak amplitude of GH pulse (Plotsky and Vale 1985) while SST tone contributes to 
intermittent trough levels of GH (Miki, et al. 1988; Thorner, et al. 1990). Likewise, GH 
pulsatility persisted during infusion of SST-like peptide (octreotide) even though GH pulse 
amplitude is suppressed (Dimaraki, et al. 2003; Dimaraki, et al. 2001). The immediate 
withdrawal of endogenous SST prompts hypothalamic release of GHRH and thus 
determines the interval of a GH surge (Miki et al. 1988; Thorner et al. 1990). Evidence 
shows that central infusion of SST increases GH levels whereas i.v. GHRH antiserum 
alongside central delivery of SST blocks GH release (Murakami, et al. 1987). This 
suggests that a coordinated release of SST and GHRH are essential to generate an 
episodic release of GH. 
 
The activation of SST-R on GHRH neurons (Horvath et al. 1989) may indicate a 
tonic inhibition of GHRH neuronal activity by SST (Plotsky and Vale 1985). This is 
evident in a recent study demonstrating prolonged irregular episodes of spike firing from 
GHRH neurons following activation of both SST-R1 and SST-R2 (Osterstock, et al. 
2016). While agonists of SST-Rs suppress GH release (Ren, et al. 2003), antagonism of 
SST-R does not affect basal GH levels on primary pituitary cells (Kreienkamp, et al. 
1999). This implies that the control of pulsatile GH secretion is predominantly at the level 
of hypothalamus. Moreover, it has been reported that SST dampens the activity of GHRH 
neurons (Dickson, et al. 1994; Lanneau, et al. 2000; Tannenbaum, et al. 1998c; Zheng, 
et al. 1997), and suppresses in vitro basal GHRH-stimulated Gh expression in a dose-
dependent manner (Luque et al. 2008).  
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Following the ablation of SST, hypothalamic Sst-r2 and Sst-r5 messenger 
ribonucleic acid (mRNA) levels and circulating GH levels were elevated (Low, et al. 2001; 
Ramirez, et al. 2002), implying the existence of a GH feedback regulatory loop relative to 
the expression of hypothalamic SST-R. Additionally, Sst-r2 and Sst-r5 knockout (KO) 
mouse models did not show increased GH levels (Norman, et al. 2002; Zheng et al. 
1997). This suggests that the presence of other SST-R subtypes may compensate for the 
inhibitory actions of SST on GH release. While up-regulation of pituitary gene expression 
of Sst-r2 and Sst-r5 were observed in mouse model of GH excess (Peng, et al. 2001), 
pituitary Sst-r2 mRNA levels were elevated but Sst-r5 mRNA levels were reduced in GH-
deficient rats (Park, et al. 2000). Hence it is plausible that an intrinsic regulatory 
mechanism may attempt to maintain circulating GH levels in a homeostatic range by 
modifying the expression of pituitary SST-R. Additionally, in vivo acute suppression of 
SST by immunoneutralisation does not impact pituitary SST-R subtypes mRNA levels. 
While administration of SST antiserum increases trough levels of GH (Wehrenberg, et al. 
1982b) but did not influence the amplitude, burst frequency or mean GH levels in rats 
(Terry and Martin 1981), the pulse frequency and circulating levels of GH are elevated in 
Sst KO mice (Low et al. 2001; Pedraza-Arévalo, et al. 2015). Collective observations 
suggest that SST is a long-term regulator that contributes to the intrinsic circhoral rhythm 
of GH pulsatility at the level of hypothalamus. 
 
Elevated GH levels were observed alongside reduced Ghrh expression in Sst KO 
mice (Luque and Kineman 2007) whereas central deletion of Sst did not change Ghrh 
expression levels (Pedraza-Arévalo et al. 2015). In contrast, Ghrh expression in rats was 
elevated (Bertherat, et al. 1991). The assessment of gene expression levels alone 
however could not interrogate the hypothalamic neuronal activities between GHRH- and 
SST-expressing neurons in modulating the pulsatile release of GH. Moreover, withdrawal 
of SST coupled with increased GHRH levels does not generally relate to the 
augmentation of GH pulses (Dimaraki et al. 2003; Dimaraki et al. 2001) as it is plausible 
that low doses of SST can stimulate GH release (Luque, et al. 2006a). An early in vivo 
study demonstrated a rise in SST production rate (Mitsugi, et al. 1990) elicited by 
intracerebroventricular (icv) injection of GHRH reduces spontaneous GH release 
(Katakami, et al. 1986). Likewise in vitro exposure to GHRH promotes SST release from 
primary hypothalamic cells (de los Frailes, et al. 1992). However, modification of GHRH-
mediated SST levels does not necessarily precede GH release (Cataldi, et al. 1994; 
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Thomas, et al. 1991). Thus, the existence of other factors (such as IGF-1 (Hynes, et al. 
1987), leptin and ghrelin – as discussed in subsequent chapters) may contribute to the 
complexity of the interactions between GHRH and SST. Collectively, GHRH and SST are 
thought to act in concert to regulate the production and release of GH via the modulation 
of synthesis and secretion of each other through bidirectional hypothalamic interactions. 
These interactions are then shaped through feedback of regulators of SST and GHRH 
action, including IGF-1. 
 
1.4.3 Insulin-like growth factor (IGF-1) 
Insulin-like growth factor 1 (IGF-1) is an endocrine feedback modulator of pulsatile GH 
release. Circulating IGF-1 is predominantly derived from the liver (Sjögren, et al. 1999), 
however low levels are expressed in other tissues including the pituitary gland (Fagin, et 
al. 1989) and muscle (Philippou, et al. 2007). IGF-1 is part of the IGF family (also known 
as somatomedin-C), which comprises of cell surface receptors for ligands including IGF-
II, insulin and IGF-1 binding proteins (IGFBPs) 1-6 (LeRoith, et al. 1995). IGFBPs have 
high binding affinity for circulating IGF-1 thereby regulating the actions of IGF-1 on target 
tissues such as the development of muscle and bone (Jones and Clemmons 1995). 
Given that IGF-1 augments the growth-promoting action of GH (Le Roith, et al. 2001), 
systemic administration of IGF-1 promotes growth in GH deficient humans, and rodents 
with GH deficiency or disrupted GH signalling (Guler, et al. 1988; Holder, et al. 1981; 
Laron, et al. 1992; Walker, et al. 1991). Hence IGF-1 is thought to contribute to growth 
(Isaksson, et al. 1987; Isgaard, et al. 1988b; Laron 2001; Schlechter, et al. 1986). 
Consequently, systemic deletion or disruption of IGF-1 or IGF-1 receptor signalling in 
mice and humans results in severe growth retardation (Baker, et al. 1993; Liu, et al. 
1998; Liu, et al. 1993; Powell-Braxton, et al. 1993). These observations suggest that IGF-
1 is essential in sustaining optimal linear growth. On the contrary, while liver-specific 
deletion of IGF-1 in mice does not impair postnatal growth (Sjogren, et al. 2002; Sjögren 
et al. 1999; Yakar, et al. 2001), elevated plasma GH levels (based on single GH 
measures) and sustained free IGF-1 levels are observed in these mice.  Presumably, 
postnatal growth in liver-specific deletion of IGF-1 mice occurs in response to the actions 
of endogenous GH, or via autocrine/paracrine effects of locally derived IGF-1. Hence it is 
plausible that IGF-1 production from tissues such as muscle and bone are important for 
somatic growth. 
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Under the influence of pulsatile GH secretion, the production of hepatic IGF-1 is 
initiated by the downstream signalling of GHR on the liver, which induces intracellular 
signalling by activating the JAK-STAT pathway (Davey, et al. 2001; Smit et al. 1996). 
Studies in the rat show that IGF-1 induces the release of hypothalamic SST (Berelowitz, 
et al. 1981; Tannenbaum, et al. 1983), confirming the presence of IGF-1 receptors in the 
central nervous system (Lesniak, et al. 1988). IGF-1 is abundantly expressed throughout 
the hypothalamus (Garcia-Segura, et al. 1997), including the ARC and ME (Werther, et 
al. 1989). While it is thought that SST is the primary feedback mechanisms for the 
release of GH in rodents (Yamashita and Melmed 1986a), the actions of IGF-1 are 
generally reflected by inhibitory effects on somatotrophs within the APG and GHRH 
neurons, and stimulatory effects on SST neurons to perturb GH release (Farhy and 
Veldhuis 2004)(Fig. 1.3). 
 
 
Figure 1.3 Feedback system of hepatic insulin-like growth factor 1 (IGF-1) on 
growth hormone (GH) release. 
The release of growth hormone (GH) from somatotrophs located in the anterior pituitary 
gland (APG) is regulated by the hypothalamic stimulatory action (blue solid arrows) of 
hypothalamic GH-releasing hormone (GHRH) and inhibitory action (red dotted arrows) of 
somatostatin (SST) located in the arcuate nucleus (ARC) and periventricular nucleus 
(PeVN) respectively via the median eminence (ME) and the hypophyseal portal system.  
Hepatic IGF-1 mediates the suppression (solid arrow) of GH release through the 
stimulation of hypothalamic SST while inhibiting (dotted arrows) the release of GHRH, 
and the inhibition of GH release directly on somatotrophs at the level of pituitary. 
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While central administration of IGF-1 suppresses Ghrh and elevates Sst gene 
expression levels in GH-deficient rats, peripheral injections of IGF-1 does not impact Sst 
or Ghrh gene expression (Sato and Frohman 1993). This suggests independent actions 
of IGF-1 on GH release at the level of hypothalamus and pituitary. The suppression of 
GHRH synthesis and secretion from sliced rat hypothalamic fragments following IGF-1 
treatment (Shibasaki, et al. 1986) suggests that IGF-1 may reduce GHRH-induced GH 
release. Similarly, IGF-1 promotes a dose-dependent release of hypothalamic SST, 
contributing to an overall decline in GH release (Berelowitz et al. 1981). It is thus 
plausible that IGF-1 predominantly exerts its feedback at the level of the hypothalamus 
(presumably mediated through the alterations of GHRH and/or SST tone) to truncate the 
release of GH.  
 
Circulating levels of IGF-1 generally reflect GH activity, being high in acromegaly 
and low in GH deficiency (Hall and Sara 1984). In acromegaly, the derangement of GH 
secretory patterns may account for the persisting elevation of peripheral IGF-1 (Peacey, 
et al. 2001). This suggests that IGF-1 in circulation is dependent on the pulsatile pattern 
of GH release. In vitro, IGF-1 reduces Gh gene expression and GH release from 
somatotrophs (Morita, et al. 1987; Yamashita, et al. 1987), whereas the in vivo ablation of 
IGF-1 receptors on somatotrophs increases GH release in mice (Gahete, et al. 2011). 
Similarly, the ablation of liver-derived IGF-1 is associated with increased pituitary Gh, 
Ghrh and Ghrh-r gene expression and serum levels of GH in mice (Sjogren et al. 2002). 
In contrast, overexpression of IGF-1 on somatotrophs attenuates the release of GH 
(Yamasaki, et al. 1991). Although high levels of circulating IGF-1 were observed in 
somatotroph-specific IGF-1 receptor KO (SIGFRKO) mice, the gene expression and 
protein levels of GH are elevated (Romero, et al. 2010). This suggests that the loss of 
IGF-1 feedback is confined to the anterior pituitary gland given that the reduction in 
hypothalamic Ghrh and Sst mRNA expression observed in these mice indicates an intact 
hypothalamic IGF-1 signalling. Furthermore, the attenuation of GH pulse-dependent 
STAT5b signalling is associated with the diminution of IGF-1 concentration, which in turn 
leads to in growth failure, suggesting that circulating levels of IGF-1 are strongly 
correlated with the pattern of GH release (Davey, et al. 1999; Veldhuis and Bowers 
2009).  
 
Although the single measurement of elevated GH release in these studies (Gahete 
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et al. 2011; Romero et al. 2010; Sjogren et al. 2002) may not accurately reflect the 
pulsatile nature of GH secretion in these transgenic mouse models of the deletion of IGF-
1, studies have demonstrated that central administration of IGF-1 in rat results in a 
reduction in GH pulse amplitude (Abe, et al. 1983) while continuous infusion of IGF-1 
diminishes spontaneous GH pulse amplitude and pulse frequency in man (Bermann, et 
al. 1994). Besides IGF-1, it is thought that many peripheral factors contribute to the 
modification of the archetypal pulsatile GH release relative to physiological changes. 
 
1.5 Negative determinant of growth hormone (GH) secretion 
1.5.1 Obesity 
The development of obesity generally results from an imbalance of energy input (i.e. 
excess calorie intake) and energy output (i.e. sedentary lifestyle). As such, excessive 
calories are stored as body fat, resulting in a chronic positive energy balance, and this is 
associated with the impairment of peak GH release (Iranmanesh, et al. 1991; Veldhuis et 
al. 1991). Consequently, stimulated and spontaneous GH secretions are markedly 
blunted (Scacchi, et al. 1999). Hence in obesity, prolonged weight gain (as adiposity) 
from excessive calorie intake is thought to be the underlying cause for diminished GH 
levels, and ultimately GH deficiency. In humans, the reduction in GH release is often 
observed during periods of excess calorie intake (Cornford, et al. 2011; Iranmanesh et al. 
1991; Veldhuis et al. 1991), while the decline in peak GH release correlates relative to 
increased total and visceral adipose mass (Clasey, et al. 2001; Iranmanesh et al. 1991; 
Veldhuis et al. 1991). Furthermore, the blunted spontaneous and stimulated GH release 
is exemplified by reduction in GH half-life, peak amplitude and frequency of GH secretory 
pulses in obese individuals (Iranmanesh et al. 1991; Kopelman and Noonan 1986; 
Tanaka, et al. 1990; Veldhuis et al. 1991). In contrast, weight loss in obese individual 
recovers spontaneous peak GH secretion (Rasmussen, et al. 1995; Riedel, et al. 1995a). 
Observations thus suggest that metabolic alterations associated with increased adiposity 
alongside weight gain are major reversible determinants of impaired GH secretion. 
Additionally, the response of GH release to all pharmacological stimuli acting at the level 
of hypothalamus (Scacchi et al. 1999) and the level of pituitary (Williams, et al. 1984) is 
impaired in obesity while the reduction in circulating levels of GH in obese individuals is 
accompanied with a diminished pulsatile or continuous GHRH-stimulated response on 
somatotrophs (Davies, et al. 1985; Kopelman and Noonan 1986). 
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As observed in humans, genetically modified animal models of obesity exhibit low 
levels of circulating GH (Ahmad, et al. 1993; Dubey, et al. 1988; Johnson, et al. 1991). 
Measures of GH levels in obese-prone rats revealed paucity of GH secretion when 
compared to obesity-resistant rats (De Schepper, et al. 1998). Notably, this occurs prior 
to weight gain and the onset of obesity (Lauterio, et al. 1998). Moreover, the reduced GH 
levels correspond with decreased hypothalamic Ghrh mRNA expression and GHRH 
protein content in obese rats (Ahmad et al. 1993). Subsequent findings reported that 
blunted GH secretion is observed alongside decreased Ghrh-r and Gh mRNA expression 
and GH content in obese leptin-deficient mice (Ob/Ob), and dietary-induced obese (DIO) 
mice (Luque and Kineman 2006). In contrast, DIO mice (Luque and Kineman 2006) and 
rats (Cattaneo, et al. 1996) did not display alteration in hypothalamic Ghrh and Sst gene 
expression when compared to respective lean controls. However, DIO rats were 
unresponsive to i.v. GHRH treatment (Cattaneo et al. 1996) while reduced Ghrh-r gene 
expression was observed in DIO mice (Luque and Kineman 2006). These observations 
suggest that alterations in pituitary function may be initiated by systemic factors (such as 
insulin and non-esterified free fatty acids; NEFAs). This however should not exclude the 
possibility that the functionality of GHRH is altered independent of changes in 
hypothalamic gene expression. As such, altered GHRH neuronal output may be 
implicated in the suppression of GH release in response to energy in excess. Moreover, 
observations from humans (Williams et al. 1984) suggests that impaired GH secretion in 
obesity may be attributed to an overall reduction in pituitary GH expression as well as 
defects in the capacity of somatotrophs to respond to GHRH stimuli. 
 
The administration of either exogenous pyridostigmine or arginine given together 
with GHRH improves the amplitude of GH released (by lowering SST feedback (Cordido, 
et al. 1989; Ghigo, et al. 1994; Ghigo, et al. 1990)). Such treatments in obese adults 
evoked a GH response but did not completely recover the magnitude of GH as seen in 
normal weight individuals. Moreover, alterations in hypothalamic Sst mRNA or protein 
content may not solely contribute to the decline in GH secretion in obese rodents 
(Cattaneo et al. 1996; Luque and Kineman 2006; Tannenbaum, et al. 1990), whereas a 
passive immunisation with specific SST antiserum fails to restore peak GH release in 
obese rats (Tannenbaum et al. 1990). Collectively, these observations suggest that 
diminished GH secretion in obesity may occur as a consequent of a combination of 
hypersecretion of hypothalamic SST and impairment in GHRH release. Given the 
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impairment in central regulators of GH axis contributes to obesity-associated GH 
deficiency, circulating IGF-1 presumably should be subnormal. However, measurements 
of total IGF-1 levels are reported to be normal (Frystyk, et al. 1995; Nam, et al. 1997) or 
elevated (Hochberg, et al. 1992; Loche, et al. 1987) in obese individuals. Likewise, the 
restoration of GH secretion in obesity is coupled with reduced total and free IGF-1 levels 
(Frystyk, et al. 1999; Frystyk et al. 1995). In line with this, measurements of free IGF-1 
levels, which deemed to be the metabolically active form of IGF-1, are elevated in obese 
humans (Frystyk 2004; Frystyk et al. 1995; Nam et al. 1997). Therefore, it is proposed 
that elevated or sustained bioavailability of free IGF-1 in obesity contributes to the 
suppression of GH secretion, although underlying mechanisms responsible for the 
suppression of GH in obesity have yet to be determined. 
 
A clinical study demonstrates that the reduction of pulsatile GH secretion following 
overeating occurs prior to dietary-induced weight gain (Cornford et al. 2011). This 
suggests that low levels of GH release could further exacerbate the accumulation of body 
fat thereby culminating in the manifestation of obesity. While reduced peak GH release 
was observed, observations demonstrate that patterned GH release was not affected 
(Cornford et al. 2011). Moreover, the suppression of GH secretion is thought to 
ameliorate the action of insulin following a meal, thereby promoting the uptake of glucose 
and lipid from the circulation into storage (Cornford, et al. 2012). This suggests that the 
reduction in GH release may be a response of physiological adaptions to keep blood 
glucose and lipids levels at bay.  
 
1.5.2 Glucose 
Glucose homeostasis is maintained through a complex series of neuro-hormonal 
interactions. In an event of low blood glucose, it is thought that GH reduces glucose 
oxidation and promotes lipid utilisation to prevent hypoglycemia (Moller and Jorgensen 
2009). As such, hypoglycemia generally occurs alongside an increase in circulating GH 
levels. For example, insulin-induced hypoglycaemia has the capacity to mediate GHRH-
induced GH release (Jaffe, et al. 1999) in humans (Ho, et al. 1992) and in sheep 
(Frohman et al. 1990; Jaffe et al. 1999). Conversely, insulin-induced hypoglycaemia or 
calorie restriction/fasting suppress pulsatile GH release, and perturb GHRH-induced GH 
response in adult rats (Tannenbaum, et al. 1979). This was accompanied by a rise in Srif 
  43 
mRNA and content without altering hypothalamic Ghrh mRNA (Murao, et al. 1994; 
Painson and Tannenbaum 1985; Steyn et al. 2012; Tannenbaum et al. 1979). An 
increase in hypophyseal-portal SST concentrations in sheep following systemic insulin 
injections (Frohman et al. 1990) may indicate that the drop in glucose level augments the 
inhibitory effect of SST, and hence impairing GH release. Contrariwise, insulin-induced 
hypoglycaemia does not alter pulsatile GH secretion and hypothalamic Ghrh and Srif 
mRNA expression in mice (Tamaki, et al. 1995). This may suggest that low glucose 
levels may not directly modify GHRH and/or SST neurons to impede GH release, while 
the release of counter-regulatory glucose-sensitive hormones may contribute in 
maintaining physiological blood glucose levels. Moreover, the reduction in GH release 
observed in hypoglycemic mice (Steyn et al. 2012) is mediated by selective activation of 
NPY neurons (Huang et al. 2014). Hence the GH axis neuronal integration with other 
glucose-sensing systems, including NPY expressing neurons, may override the 
responses of GHRH-induce GH release during hypoglycemia (Huang et al. 2014). 
 
In human, the impairment in maintaining glucose homeostasis displays differential 
GH levels according to the classification of diabetes. An increased GH release (Asplin, et 
al. 1989; Hayford, et al. 1980) is observed in type 1 (T1) diabetic individuals (without 
significant obesity), alongside an increase in somatotrophs sensitivity to GHRH 
(Pietschmann, et al. 1987). This might be due to a fall in SST output from hypothalamus 
to pituitary gland (Ismail, et al. 1993). In type 2 diabetes mellitus (T2DM) with obesity, GH 
levels are reduced significantly compared to lean individual, but also to non-obese T2 
diabetic individuals (Giustina, et al. 1994; Kopelman, et al. 1988; Richards, et al. 1984). 
This suggests that the impact of obesity in diabetes contributes to the perplexities in GH 
release. On the contrary, glucose clamp studies demonstrated that hyperglycemia does 
not impact spontaneous and stimulated (by GHRH, arginine to inhibit STT, and hexarelin) 
GH secretion in humans (Grottoli, et al. 1996; Maccario, et al. 1995; Topper, et al. 1984), 
suggesting that the impairment of GH release may be at the level of pituitary. 
  
In streptozotocin-diabetic rats, studies have shown that the direct inhibitory actions 
on isolated pituitary cells blunt GH secretion in response to GHRH stimulation 
(Olchovsky, et al. 1990). Similarly, indirect inhibitory actions such as hyperglycemia-
induced hyperinsulinemia and hypersomatostatinaemia (by elevated plasma levels of 
somatostatin-like immunoreactivity) perturb GH release (Patel, et al. 1980). While 
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impaired GH release and blunted GH response to GHRH were reported in T1 or T2 
diabetic rat models (Bluet-Pajot, et al. 1983; Ndon, et al. 1992), the administration of 
somatostatin antiserum leads to an increase in GH plasma level (Tannenbaum, et al. 
1981). This suggests that the responsiveness of pituitary somatotrophs to SST may 
contribute to the impairment of GH secretion. While GH content in the pituitary and 
hypothalamic GHRH content are significantly decreased (Olchovsky et al. 1990), a rise in 
pituitary Ghrh-r gene expression levels which coincides with a fall in hypothalamic Ghrh 
mRNA levels are observed in streptozotocin-induced diabetic rats when compared to 
control rats (Bedard, et al. 2008). Observations suggest that hyperglycemia-induced 
suppression of GH secretion may be a result of a combination of low GH content in the 
pituitary gland and elevated release of SST from the hypothalamus or high SST activity in 
the pituitary. However, elevated insulin secretion within these diabetic models may 
account for reduced pituitary-sensitivity to GHRH stimulation, and diminished GHRH 
synthesis. Thus, the neuroendocrine mechanisms involving insulin-glucose studies 
require concomitant measurements of hypophyseal-portal GHRH and SRIF outputs and 
further investigations. 
 
1.5.3 Insulin 
Insulin is synthesised and secreted from pancreatic β-cells in a post-prandial state, 
thereby regulating blood glucose homeostasis and lipid mobilisation (Saltiel and Kahn 
2001) by promoting adipogenesis (Wang and Sul 1998), lipogenesis, and inhibiting 
lipolysis (Kahn and Flier 2000). In the instance of insulin resistance, the expansion of 
pancreatic β-cells mass is accompanied with hypersecretion of insulin (which is 
commonly known as hyperinsulinemia) to keep blood glucose levels within physiological 
range, thus maintaining glucose homeostasis. Consequently, the metabolic pressure on 
the enlarged pancreatic β-cells could precede hyperglycaemia, culminating in severe 
pancreatic β-cells dysfunction hence the development of T2DM (Cerf 2013). Although it 
was initially thought that insulin does not influence the endogenous pulsatile GH release 
in rats (Tannenbaum, et al. 1976), the opposing fluctuations of the secretion of insulin 
and GH may exist across metabolic statuses. For example, fasting (Hunter, et al. 1968), 
malnutrition (Miller 2011), and insulin-dependent type 1 diabetes mellitus (T1DM) (Asplin 
et al. 1989; Hansen and Johansen 1970; Hayford et al. 1980) are associated with low 
levels of insulin and an increased GH release, whereas reduced GH release is 
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associated with hyperinsulinemia in obesity (Nam and Marcus 2000; Rasmussen et al. 
1995; Veldhuis et al. 1991). This coincides with an inverse correlation between insulin 
levels and measures of GH in obese individuals (Lanzi, et al. 1999; Veldhuis et al. 2011). 
Moreover, evidence from individuals with T1DM also demonstrates an inverse 
relationship between circulating levels of insulin and GH secretion (Amiel, et al. 1984). 
Importantly, rigorous insulin treatment to reverse hyperglycemia in T1DM individuals is 
associated with a recovery of IGF-1 in circulation when compared with non-diabetic 
individuals (Amiel et al. 1984). This observation suggests that normalised glucose levels 
following insulin treatment may be the overriding factor that serves as a critical modulator 
of GH axis function relative to hyperglycemia. Of interest, the suppression of GH release 
following overeating in adults was accompanied by a rise in postprandial levels of insulin 
(Cornford et al. 2011). While not directly assessed, high levels of insulin may contribute 
to the progressive decline in GH secretion.  
 
In DIO mice, the progressive decline in GH secretion correlates with a rise in 
circulating levels of insulin (Huang et al. 2012). This is also observed in obese rats 
(Tannenbaum et al. 1990). By contrast, the impairment of GH release occurs prior to 
weight gain in humans is accompanied with elevated circulating levels of insulin following 
excessive calorie consumption (Cornford et al. 2012; Cornford et al. 2011). However, in 
lieu of suppressing insulin levels following GH treatment (presumably via the restoration 
of physiological levels of GH), further increment of post-prandial circulating levels of 
insulin is observed (Cornford et al. 2012). Furthermore, long-term exposure to GH 
impairs insulin-stimulated glucose uptake and suppresses hepatic glucose production, 
resulting in insulin resistance in both humans (Hansen, et al. 1986; Moller, et al. 1993; 
Rizza, et al. 1982) and rodents (Hettiarachchi, et al. 1996; Smith, et al. 1997). These 
observations suggest that the suppression of GH is essential to maximise the 
physiological efficiency of insulin action on glucose uptake during sustained periods of 
calorie excess. While not directly addressed, the effects of indirect stimulation of 
hypothalamic SST may account for the inverse relationship between insulin and the 
suppression of GH release in response to altered glucose balance. Moreover, GH is a 
regulator of insulin sensitivity and may impede glucose uptake (Clemmons 2004), 
suggesting that elevated insulin levels may exert an inhibitory effect on GH release in 
response to food consumption. As illustrated in Fig 1.4, it highlights the existence of a 
potential feedback-mechanism in which insulin may mediate GH release. 
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Figure 1.4 Inhibitory actions of pancreas-derived insulin on pulsatile growth 
hormone (GH) release 
The inhibitory effect of insulin secreted from the pancreas acts on the somatotrophs 
located in the anterior pituitary gland (APG) to suppress the release of GH (dotted arrow). 
Altered levels of GH release in obesity may be a physiological adaptation that sustains 
insulin sensitivity mainly through the modification of pituitary response to hypothalamic 
GHRH and/or SST signals. The action of insulin on the hypothalamic neurons in 
regulating pulsatile GH secretion is however still poorly understood. 
 
 
Compelling evidence demonstrate that the exposure of insulin has the capacity to 
suppress Gh expression (Yamashita and Melmed 1986a, b) and reduce GH secretion 
from isolated rat somatotrophs within the pituitary cells (Melmed 1984; Melmed, et al. 
1985; Melmed and Slanina 1985). Given that insulin receptors (INS-Rs) are expressed 
throughout the hypothalamus, including the ARC and PeVN (Folli, et al. 1996; Kar, et al. 
1993; Unger, et al. 1989; Werther, et al. 1987), it is thought that the inhibitory actions of 
insulin on GH release may also be mediated via altered hypothalamic pathways. 
 
However, the suppression of GH release in response to hyperinsulinemia is 
accompanied by a reduction in pituitary Gh and Ghrh-r expression without altering the 
hypothalamic Ghrh and Sst expression (Luque and Kineman 2006) in DIO mice. 
Similarly, unchanged hypothalamic Ghrh and Sst expression in DIO rats are observed 
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regardless of pituitary insensitivity to the effect of GHRH (Cattaneo et al. 1996). This 
suggests that altered GH secretion in obesity may occur independently of hypothalamic 
GH regulators. In addition, observations imply that somatotrophs may remain responsive 
to insulin despite the development of peripheral insulin resistance in obesity (Luque and 
Kineman 2006), thereby deteriorating physiological levels of GH alongside 
hyperinsulinemia. Given no evidence has suggested that insulin predicts the patterns of 
GH release, the actions of insulin on the GH axis may be limited to the alteration of the 
amplitude of GH release. Moreover, GHRH pre-treatment alongside arginine fail to 
improve somatotrophs sensitivity to recover GH release in obese individuals (Ghigo, et 
al. 1993). Hence the action of insulin on GH release might be limited to the level of the 
pituitary gland, contributing to blunted responsiveness of stimuli of GH release. 
 
Studies in rodents show that insulin acts on INS-Rs within the APG to inhibit GH 
release from isolated somatotrophs (Luque and Kineman 2006; Melmed 1984), and the 
deletion of somatotroph-specific INS-Rs in mice led to an elevation in pituitary GH 
content, thus increased circulating GH levels (Gahete, et al. 2013b). This however is 
assessed based on single GH measurement, and thus results cannot be used to interpret 
the effects of insulin on pattered GH release. Furthermore, the deletion of somatotroph-
specific INS-Rs could not prevent the suppression of GH release associated with 
excessive dietary intake (Gahete et al. 2013b). Hence insulin may not solely be 
responsible for the impairment of GH release from the somatotrophs. Despite the 
controversial inhibitory role of insulin on GH release, it is plausible that the rise and fall of 
insulin levels relative to calorie consumption is closely related to its essential role in 
regulating GH release relative to long-term metabolic demands. Consequently, the rise in 
NEFAs driven by the lipolytic effect of GH on adipose tissue is thought to further 
compromised insulin sensitivity in obesity (Kahn, et al. 2006; Karpe, et al. 2011). 
Therefore, the maintenance of insulin sensitivity during periods of low GH levels following 
excess food consumption is thought to be a physiological adaptation that promotes 
insulin-driven lipogenesis to prevent dyslipidaemia (Cornford et al. 2012). 
 
1.5.4 Non-esterified free fatty acids (NEFAs) 
The anabolic effect of GH is commonly known to prompt lipolysis and thus the release of 
NEFAs by adipose tissue (Hartman, et al. 1992; Ho, et al. 1988; Moller, et al. 2003). By 
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contrast, lipid-heparin infusion studies in humans and rodents demonstrated an inhibitory 
effect of NEFAs on GH release, presumably directly from somatotrophs (Alvarez, et al. 
1991; Casanueva, et al. 1987) or indirectly from the hypothalamic level (Briard, et al. 
1998; Imaki, et al. 1986). As illustrated in Fig 1.5, NEFAs exert its inhibitory effect on GH 
release by acting on the somatotrophs within the APG or the SST-expressing neurons. 
While an increased in NEFA concentrations coincides with reduced GH secretion in 
obesity, pharmacological studies demonstrate that an antilipolytic drug (acipimox) has the 
capacity to reduce circulating levels of NEFAs, thereby recovering spontaneous and 
stimulated GH release in obese individuals (Andreotti, et al. 1994; Cordido, et al. 1996; 
Nam, et al. 1996; Pontiroli, et al. 1996). Thus, it was proposed that impairment of GH 
secretion observed in obesity might occur as a consequence of an elevation in circulating 
levels of NEFA (Girod and Brotman 2003). 
 
Given that elevated levels of NEFA are associated with hyperinsulinemia and 
consequently insulin resistance in obesity (Kahn et al. 2006), lowering levels of insulin in 
circulation by acipimox improves insulin sensitivity (Andreotti et al. 1994; Pontiroli et al. 
1996; Santomauro, et al. 1999). Hence, restoration of insulin to physiological levels may 
also contribute to the recovery of GH secretion, rather than lowering levels of circulating 
NEFAs. Moreover, a recent meta-analysis reported relatively stable circulating levels of 
NEFAs regardless of the severity of obesity (Karpe et al. 2011). Accordingly, a reduction 
in GH release does not correspond to an increased NEFAs levels following dietary-
induced weight gain in mice (Huang et al. 2012). Moreover, chronic elevation in NEFAs 
levels is associated with impaired insulin sensitivity in GH-deficient individuals following 
excess calorie consumption (Jensen 2008; Karpe et al. 2011). It is thus plausible that 
NEFAs may not directly alter the release of GH in obesity or progressive weight gain. 
Rather, the suppression of GH in obesity may reflect counter-regulatory response to 
buffer the NEFAs flux, and consequently to ameliorate insulin sensitivity (Cornford, et al. 
2013). 
 
1.5.5 Leptin 
Leptin is an adipocyte-derived anorexigenic hormone secreted in proportion to fat mass 
(Considine, et al. 1996; Frederich, et al. 1995b; Friedman and Halaas 1998; Maffei, et al. 
1995a). Its primary role of coordinating appetite (promote satiety) and energy utilisation is 
mediated by hypothalamic feeding circuitry and efferent signals to the periphery, thus 
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maintaining energy balance including the regulation of body weight and total fat mass 
(Grill 2010; Havel 2001; Kalra, et al. 1999). Accordingly, central or peripheral 
administration of leptin decreases food intake whilst increases energy expenditure 
(Schwartz, et al. 1996a; Schwartz, et al. 1996b). However, the elevated levels of 
circulating leptin in obese individuals do not suppress appetite (Klok, et al. 2007) and 
coincides with a reduction in GH secretion (Molero-Conejo, et al. 2006). These suggest 
that the impairment in GH release in obesity may be attributed to impaired leptin 
signalling, and/or the development of central leptin resistance (Dardeno, et al. 2010; 
Enriori, et al. 2006; Myers, et al. 2008; Myers, et al. 2010; Zhou and Rui 2013). 
 
Compelling evidence demonstrated that exogenous leptin stimulates GH release 
from pituitary explants (Accorsi, et al. 2007; Shimon, et al. 1998) and enhances GH 
secretion (Luque, et al. 2007) while icv leptin infusion augments both GHRH-stimulated 
GH release and spontaneous pulsatile GH secretion in rats (Tannenbaum, et al. 1998a). 
Additionally, in vitro studies demonstrate a direct stimulatory role of leptin on GH release 
using pituitary slices or co-incubated with stalk ME by reducing SST tone (Saleri, et al. 
2004). Observations imply that leptin may directly regulate GH secretion at the level of 
pituitary or via leptin receptors (LepR) expressed within the hypothalamus including 
PeVN and ARC, particularly on GHRH-expressing neurons (Hakansson, et al. 1998). 
Moreover, central leptin infusion promotes GH secretion by acting simultaneously on 
GHRH and SST neurons in rodents (Tannenbaum et al. 1998a; Watanobe and Habu 
2002) while administration of leptin in leptin-deficient mice restores impaired GH 
secretion (Luque et al. 2007). These observations suggest that the actions of leptin on 
GH secretion are likely to be mediated by GHRH and/or SST. Hence leptin may play a 
vital role in regulating the GH axis by facilitating the hypothalamic release of stimulatory 
GHRH, and inhibitory SST during GH trough periods, or by directly acting on the 
somatotrophs within the APG (Fig. 1.5). 
 
In humans, impairments in leptin signalling, resulting from congenital loss of leptin 
or mutations of the LepR leads to the development of obesity. This is coupled with 
reduced GH secretion (Clement, et al. 1998) and blunted response to GH stimuli (Ozata, 
et al. 1999). Likewise, deletion of somatotroph-specific LepR results in a fall in GH 
immuno-positive cell numbers, which eventually led to diminished levels of GH and 
obesity in mice (Childs, et al. 2011). Studies using obese mice with deletion of leptin or 
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LepR have demonstrated a reduction in proliferation of somatotrophs (Lloyd, et al. 2001). 
These observations imply that leptin may directly regulate the release of GH from 
somatotrophs. Although in vitro studies show a reduction in GHRH-stimulated GH 
secretion from leptin-treated cultured ovine pituitary cells (Roh, et al. 1998; Roh, et al. 
2001), the inhibitory effect of exogenous leptin may rely on nutritional status of the 
animals (Kirsz, et al. 2014). Moreover, central administration of leptin restores pulsatile 
GH secretion in fasting rats (Carro, et al. 1997; LaPaglia, et al. 1998) by reducing 
hypothalamic Neuropeptide Y (Npy) expression that is thought to suppress GH releases 
during periods of negative energy balance (Huang et al. 2014; Vuagnat, et al. 1998). 
Thus, leptin may act as a metabolic signal to modify the hypothalamic interactions 
between the GH axis and feeding circuitry, thereby mediating GH output relative to 
nutrient status (Steyn 2015). Furthermore, altered ghrelin, an orexigenic hormone, 
signalling may account for reduced GH secretion in positive energy balance (Briggs, et 
al. 2014). Hence changes in leptin signalling may not solely account for altered GH 
release in altered energy balance. 
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Figure 1.5 The role of adipose-derived leptin and non-esterified fatty acids (NEFAs) 
on pulsatile growth hormone (GH) secretion 
Leptin stimulates the release of growth hormone (GH) by acting directly on pituitary 
somatotrophs. At the level of hypothalamus, leptin stimulates or inhibits the release of 
hypothalamic growth hormone releasing hormone (GHRH) and somatostatin (SST), 
respectively via leptin receptors expressed on these neurons. The release of NEFAs may 
act directly on somatotrophs within the anterior pituitary gland (APG) to suppress 
pulsatile GH secretion. 
 
1.6 Ghrelin 
1.6.1 Identification of ghrelin and its ghrelin-o-acyltransferase (GOAT) 
Ghrelin was first identified as a stomach-derived hormone that potently stimulates GH 
release in rats (Kojima et al. 1999), ensuing the discovery of its receptor, growth 
hormone secretagogue (GHS) receptor (GHSR)(Howard et al. 1996). The 28-amino acid 
ghrelin peptide is encoded by exons 2 and 3 of the ghrelin gene, following a 
posttranslational proteolytic processing of the 94-amino acid preproghrelin polypeptide at 
the N-terminal by prohormone convertase 1/3 (Sato, et al. 2012; Seim, et al. 2009; 
Zhang, et al. 2005). Subsequently, proghrelin is subjected to further post-translational 
attachment of an octanoic acid on the hydroxyl group of 3rd N-terminal serine residue 
(Kojima and Kangawa 2005). The enzyme responsible for the acylation of ghrelin 
(referred to as acyl-ghrelin in this thesis) is the ghrelin-o-acyltransferase (GOAT) 
(Gutierrez, et al. 2008; Yang et al. 2008). Substantial evidence confirmed that GOAT is 
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the only known enzyme to acylate ghrelin. Consequently, the generation of Goat deficient 
mice demonstrated a complete absence of acyl-ghrelin in circulation (Kirchner, et al. 
2009; Zhao, et al. 2010). This post-translational octanoyl modification is thought to be 
mandatory for the activation of its canonical receptor, GHS-R1a (Kojima et al. 1999). This 
essentially drives the functionality of ghrelin (Hosoda, et al. 2000), such as its synergistic 
action with GHRH and stimulatory effect on GH secretion (Arvat, et al. 2001; Smith 
2005). This is well conserved amongst vertebrates, and particularly the mammalian 
species (Kaiya, et al. 2008). 
 
The enzyme GOAT belongs to the superfamily of membrane bound o-
acyltransferases (MBOATs) (Chang and Magee 2009) discovered simultaneously by two 
separate groups using complementary deoxyribonucleic acid (cDNA) transfection 
techniques (Yang et al. 2008) and gene silencing technology (Gutierrez et al. 2008). The 
amino acid sequences of GOAT are highly conserved across humans and rodents 
(Muller, et al. 2011). Both protein and mRNA of GOAT are expressed in ghrelin-
containing cells in the stomach (Sakata, et al. 2009; Stengel, et al. 2010). In line with this, 
total ghrelin is highly expressed in the X/A-like cells within the gastric oxyntic mucosa 
which are predominantly located in the fundus of the stomach (Ariyasu, et al. 2001; 
Dornonville de la Cour, et al. 2001; Kojima et al. 1999), and the gastrointestinal tract 
(Date, et al. 2000; van der Lely, et al. 2004). Therefore, gastrectomy is associated with a 
rapid decline in total ghrelin (Leonetti, et al. 2003), indicating that the stomach is a major 
source of circulating levels of ghrelin (Ariyasu et al. 2001). Given that ghrelin is 
expressed in the pituitary (Korbonits, et al. 2001), pituitary expression of Goat is 
correlated to circulating levels of acyl-ghrelin (Gahete, et al. 2010). This evidence 
suggests that local systemic production of ghrelin may exert a paracrine and/or autocrine 
regulation of GH release (Gahete et al. 2010; Luque, et al. 2006b). Hence stomach-
derived acyl-ghrelin may not be the sole regulator of GH release from somatotrophs. 
Although early studies showed that ghrelin was produced in brain (Cowley, et al. 2003; 
Mondal, et al. 2005), an updated study has discovered negligible levels of ghrelin in the 
brain by assessing a group of ghrelin-GFP mice with rigorous testing of antibodies 
(Furness, et al. 2011). 
 
GHSRs are highly expressed in the hypothalamus, the pituitary gland 
(Gnanapavan, et al. 2002; Guan, et al. 1997; Mitchell, et al. 2001; Muccioli, et al. 2001; 
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Yokote, et al. 1998) as well as the stomach (Gnanapavan et al. 2002), thereby 
suggesting the possibilities of direct and indirect biological actions of ghrelin. The Ghsr 
gene codes for a full-length 7-transmembrane functional protein, GHS-R1a, and a non-
functional truncated isoform, GHS-R1b. The latter does not bind to ghrelin but has been 
described to modify the function of GHS-R1a (Leung, et al. 2007), potentially through 
interference with a homodimeric form of GHS-R1a by heterodimerisation (Jiang, et al. 
2006). It has been well documented that GHS-R1a is the endogenous ligand of acyl-
ghrelin, and the unique binding of both is essential for all physiological actions of ghrelin. 
This allows ghrelin to exert its stimulatory effect on GH secretion (Kojima et al. 1999; 
Kojima and Kangawa 2005) at the level of hypothalamus and APG (Guan et al. 1997). 
Although octanoylation is essential for the activation of GHS-R1a, acyl-ghrelin accounts 
for approximately <10% of total blood ghrelin (Hosoda et al. 2000) whereas desacyl-
ghrelin represents over >90% of total blood ghrelin levels. The functional activity of 
truncated GHS-R1b (Camina 2006) however remains to be fully understood. The binding 
of acyl-ghrelin to GHS-R1a on somatotrophs within the APG activates the PLC/IP3 
signaling cascade and increases intracellular [Ca2+], thereby resulting in the release of 
GH (Chen, et al. 1996; Khatib, et al. 2014). Indeed, the in vitro stimulatory effect of acyl-
ghrelin on GH secretion have been demonstrated in rodents (Tolle, et al. 2001), pigs 
(Glavaski-Joksimovic, et al. 2003; Malagon, et al. 2003), baboons (Kineman and Luque 
2007) and humans (Arvat et al. 2001; Broglio, et al. 2008; Hataya, et al. 2001; Nagaya, et 
al. 2001a; Takaya, et al. 2000; Veldhuis, et al. 2008b). 
 
1.6.2 Desacyl-ghrelin 
Desacylated ghrelin (desacyl-ghrelin) is one of the abundantly encoded variants (Kojima 
and Kangawa 2005) by the ghrelin gene, and is recognised as an inert degradation 
product of acyl-ghrelin. An estimated ratio of plasma acyl-ghrelin to desacyl-ghrelin 
exceeds 1:9 (Bang, et al. 2007; Hosoda, et al. 2003), which the latter accounts for 
approximately 90% of the total ghrelin level (Kojima and Kangawa 2005). This is 
presumably attributed by the slow systemic clearance of infused desacyl-ghrelin relative 
to acyl-ghrelin (Tong, et al. 2013). Although desacyl-ghrelin does not compete with acyl-
ghrelin for the binding site of GHS-R1a (Veldhuis and Bowers 2010), exogenous desacyl-
ghrelin has been shown to activate the receptor (Gauna, et al. 2007; Heppner, et al. 
2014; Portelli, et al. 2015). Also, some findings proposed that desacyl-ghrelin acts on 
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undetermined GHSR subtypes (Broglio, et al. 2004; Delhanty, et al. 2014). 
 
In the recent years, studies have debated on the role of desacyl-ghrelin. Although 
the physiological significance is not completely understood (Seim et al. 2009), it may 
modulate the effect of acyl-ghrelin (Inhoff, et al. 2009). For example, desacyl-ghrelin 
blunts the effect of acyl-ghrelin on mouse pancreatic islets (Kumar, et al. 2010), and 
attenuates acyl-ghrelin-induced neuronal activity in the hypothalamus, including a subset 
of ARC neurons (Inhoff, et al. 2008; Stevanovic, et al. 2014), and NPY-expressing 
neurons, in a GHSR-independent manner in rodents (Fernandez, et al. 2016). 
Conversely, central administration of desacyl-ghrelin induces activation of the orexin-
expressing neurons in the lateral hypothalamic region thereby stimulates food intake 
independent of GHSR (Toshinai, et al. 2006). While an early study demonstrated that 
central and peripheral administration of desacyl-ghrelin inhibits food intake in fasting mice 
(Asakawa, et al. 2005), a subsequent study reported no effect on food intake when 
administrated peripherally (Neary, et al. 2006). Moreover, an electrophysiological study 
demonstrated that peripheral administration of des-acyl ghrelin has no effect on the vagal 
afferent nerve (Date, et al. 2002). Likewise, peripheral injection of desacyl-ghrelin does 
not alter the intensity of c-Fos positive cells in the nucleus tractus solitaries, while the c-
Fos positive cells in the paraventricular nucleus is significantly increased when compared 
to vehicle-injected controls (Chen, et al. 2005). This suggests that desacyl-ghrelin, unlike 
acyl-ghrelin, does not pass the vagal afferent pathway; and may cross the BBB directly to 
modify the neuronal interactions that govern food intake and GH release in the brain. The 
overexpression of desacyl-ghrelin in mice acts independently of acyl-ghrelin via the 
hypothalamus to significantly decrease food intake, gastric motility and body fat mass, as 
well as moderately decreased linear growth compared to WT counterparts (Asakawa et 
al. 2005). Furthermore, central and peripheral injections of desacyl-ghrelin disrupt motor 
activity in the stomach during fasting (Chen et al. 2005). These may imply that the 
reduced body weight and fat mass accompanied by stunted linear growth may be a 
consequential effect of low calorie consumption rather than a direct impact by the 
supraphysiological concentrations of desacyl-ghrelin. 
 
Of interest, several studies have reported the protective effects of exogenous 
desacyl-ghrelin against oxidative stress on endothelial cellular level (Shimada, et al. 
2014) and cardiac dysfunction in mice (Pei, et al. 2015; Pei, et al. 2014), as well as 
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lowering the risk of cardiovascular disease in humans (Yano, et al. 2014). Moreover, 
infusion of desacyl-ghrelin alleviates the glycaemic state in high-fat induced mice 
(Delhanty, et al. 2013) and obese individuals (Ozcan, et al. 2014), possibly by enhancing 
insulin sensitivity (Zhang, et al. 2008). In humans, a combined administration of acyl- and 
desacyl-ghrelin strongly improved insulin sensitivity compared to acyl-ghrelin 
administration alone (Gauna, et al. 2004). Furthermore, overnight i.v. desacyl-ghrelin 
infusion was found to display a glucose-lowering effect (Benso, et al. 2012). While 
evidence may suggest a biologically active role of desacyl-ghrelin in modulating food 
intake and glucose metabolism via an uncharacterised pathway, no concrete evidence of 
desacyl-ghrelin has been found to modulate GH secretion despite having the same 
precursor as acyl-ghrelin (Muccioli, et al. 2002). Hence its activities on a questionable 
receptor have yet to be elucidated and warrant further investigations (Muller, et al. 2015). 
 
1.6.3 Ghrelin in appetite and energy balance 
The orexigenic effect of ghrelin has been well-documented. In humans, peripheral acyl-
ghrelin administrations have shown to enhance appetite and food intake (Schmid, et al. 
2005; Shintani, et al. 2001; Wren et al. 2001a). Studies using rodents have also 
demonstrated that ghrelin stimulates food intake (Sun et al. 2004a; Wren, et al. 2000a) 
as well as promoting adiposity and weight gain (Tschop et al. 2000). The latter is 
predominantly contributed by the accumulation of fat mass without altering longitudinal 
skeletal growth or lean mass (Tschop et al. 2000). Moreover, circulating ghrelin levels are 
inversely associated with adiposity and weight gain in humans hence the reduction in 
ghrelin levels observed in obese individuals (McLaughlin, et al. 2004; Tschop et al. 
2001b). By contrast, ghrelin levels rise during periods of negative energy balance (Kim, 
et al. 2003; Toshinai, et al. 2001). As such, dietary-induced weight loss (Cummings, et al. 
2002) or pathologic conditions including anorexia nervosa and cachexia are positively 
correlated with circulating levels of ghrelin (Nagaya, et al. 2001b). These observations 
sum up the plausible role of ghrelin in the regulation of long-term energy balance.  
 
Several early studies revealed that circulating levels of ghrelin rise during pre-
prandial state (Ariyasu et al. 2001; Cummings, et al. 2001; Sugino, et al. 2002; Tolle et al. 
2002), and fall during post-prandial state (Morinigo, et al. 2004; Tschop, et al. 2001a). 
Moreover, the secretory pattern of ghrelin surges prior to a meal (Liu, et al. 2008). It was 
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therefore proposed that ghrelin triggers meal anticipation (Drazen, et al. 2006) possibly 
through the activation of sympathetic central nervous system (Mundinger, et al. 2006). In 
healthy humans, i.v. administration of ghrelin demonstrates an increase in neural activity 
in response to food pictures in specific brain regions (Malik, et al. 2008). Furthermore, it 
has been demonstrated that the orexigenic effects of ghrelin are specifically modulated 
through the GHS-R1a, thereby activating the orexigenic hypothalamic NPY- and/or 
agouti-related peptide (AgRP)-producing neurons in the ARC (Kamegai, et al. 2001; 
Kohno, et al. 2003), whereby GHS-R is highly expressed in these population of neurons 
(Nakazato, et al. 2001). Moreover, the co-localisation of GHSR-1a on of NPY- and AgRP 
neurons (Willesen et al. 1999) in the ARC indicates that ghrelin contributes to the 
physiological response to meal initiation (Cummings, et al. 2004) via the orexigenic 
pathway (Toshinai, et al. 2003). While studies showed that bolus i.v. administration of 
ghrelin rises plasma NPY levels (Coiro, et al. 2006; Coiro, et al. 2008), administration of 
ghrelin fails to increase food intake in mice lacking both NPY and AgRP (Chen, et al. 
2004). These imply that NPY may play a role in food intake alongside ghrelin. 
Furthermore, NPY neurons may modulate GH secretion via neuronal connections to 
SST-expressing neurons in the PevN (Huang et al. 2014), thereby providing a potential 
possibility in the regulation of ghrelin-mediated GH release. 
 
Evidence from peripheral and central ghrelin administrations have demonstrated 
an increase in the number of stimulatory synapses on NPY/AgRP-expressing neurons in 
rodents (Nakazato et al. 2001). Similarly, electrophysiological recordings of ex vivo 
hypothalamic slices have demonstrated that ghrelin enhances the spontaneous activities 
of NPY/AgRP neurons, and thus indirectly inhibits the effects of anorexigenic neurons by 
facilitating the pre-synaptic release of γ-aminobutyric acid (GABA) (Cowley et al. 2003). 
In addition, the presence of GHS-R1a on vagal afferent neurons (Date et al. 2002) 
suggests that ghrelin communicates with hypothalamic NPY neurons via the vagus 
nerve. This is in concordant with the loss of orexigenic effect following ligation of the 
vagus nerve (vagotomy) in rodents (Asakawa, et al. 2001; Date et al. 2002), and that 
ghrelin infusion did not recover appetite in vagotomy patients (le Roux, et al. 2005). 
These suggest that an intact vagus nerve is necessary for acyl-ghrelin to instigate food 
intake. Moreover, gastric bypass hinders prandial-related fluctuations of circulating 
ghrelin levels (Cummings et al. 2002). While twice daily continual injections of ghrelin 
have shown to stimulate food intake (Adachi, et al. 2010), single ghrelin infusion did not 
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restore appetite in gastrectomy patients (Huda, et al. 2009). This suggests that 
continuous systemic infusion of ghrelin might prompt a compensatory mechanism to 
restore appetite with the premise of an intact central nervous system. Although 
exogenous acyl-ghrelin induces overeating in ad libitum (ad lib) fed rats, this is not 
demonstrated in animals following periods of negative energy balance (e.g. fasting or 
long-term food restriction) despite elevated ghrelin levels (Alen, et al. 2013). By contrast, 
acyl-ghrelin has been shown to increase energy consumption in instances such as 
impaired appetite or cachexia (Molfino, et al. 2013). These suggest that the regulation of 
food intake exerts by acyl-ghrelin may be dependent on the metabolic status or the 
sensitisation of GHS-R1a.  
 
In rodents, the antagonism of GHSR impairs food intake and body weight 
(Asakawa, et al. 2003) whilst sc administration of ghrelin has been shown to increase 
body weight and body fat mass (Tschop et al. 2000). Accordingly, the expression of Ghsr 
antisense RNA in the ARC results in decreasing body weight and fat mass plausibly 
attributed to reduced food intake (Shuto, et al. 2002). These observations suggest that 
acyl-ghrelin induces overall positive energy balance by increasing energy input and 
decreasing energy expenditure, hence promoting an increase in body weight and 
adiposity. On the contrary, ablation of ghrelin did not lower body weight, adiposity, or 
food intake when compared to controls (Sun et al., 2003; Wortley et al., 2004). However, 
when challenged with high fat diet (HFD), young ghrelin-deficient mice display a 
resistance to weigh gain as adiposity despite comparable amount of food consumed 
(Wortley, et al. 2005). This suggests that the subtle rise in energy expenditure in ghrelin 
deficiency might be beneficial against excess calorie intake. Therefore the fall in 
circulating levels of ghrelin in obese individual (Tschop et al. 2001b) might be a counter-
regulatory mechanism to hyperphagia. Moreover, the suppression of circulating levels of 
total and acyl-ghrelin is coupled with a reduction in stomach ghrelin and Goat expression, 
as well as hypothalamic Ghs-r1a, Npy and Agrp expression in DIO mice (Briggs, et al. 
2010).  
 
Studies have demonstrated that central or peripheral ghrelin administration does 
not induce food intake in obese mice (Briggs et al. 2010; Perreault, et al. 2004). 
Moreover, a blunted GH response to ghrelin is seen in obese individuals (Alvarez-Castro 
et al. 2004; Tassone, et al. 2003), as well as a diminished transport of i.v. ghrelin across 
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the BBB in obese, aged mice (Banks, et al. 2008). Furthermore, ghrelin fails to alter the 
expression of hypothalamic Npy or Agrp in DIO mice (Briggs et al. 2010). These suggest 
that the alterations in ghrelin transport across the BBB in obesity may blunt the response 
of NPY/AgRP-expressing neurons to ghrelin; thereby impacting neuronal feeding 
circuitry. Consequently, alterations in ghrelin signalling alongside low levels of ghrelin in 
circulation in obesity may contribute to the development of hypothalamic ghrelin 
resistance (as observed in DIO mice (Briggs et al. 2010)), and possibly contributing to 
obesity-associated GH deficiency. Indeed, given that negative correlations have been 
reported between adiposity and 24 h GH release (Clasey et al. 2001) or basal ghrelin 
concentrations (Katsuki, et al. 2004; Sondergaard, et al. 2009), low levels of ghrelin in 
circulation may directly contribute to GH deficiency in obesity. Accordingly, the reduction 
in circulating ghrelin in obesity is coupled with the decline in Ghs-r1a and Ghrh-r 
expression in the pituitary gland (Briggs et al. 2010). Although an early study has shown 
to stimulate the GH axis by administrating oral ghrelin mimetic (MK-677) in obese 
individuals, it did not lower excess adiposity (Svensson, et al. 1998). Similarly, no change 
in total fat mass following oral administration of MK-677 was observed even though GH 
secretion was increased (Nass et al. 2008b). Conversely, blunted responsiveness to 
ghrelin alone or supplemented with GHRH-induced GH release is observed in obese 
individuals (Alvarez-Castro et al. 2004). Again, this suggests that reduced ghrelin 
signalling in the hypothalamus might contribute to GH deficiency in obesity. Visceral fat 
mass predicts basal ghrelin concentrations (Katsuki et al. 2004; Sondergaard et al. 
2009), and similar inverse correlations have been found for visceral abdominal fat and 
24-h GH release (Clasey et al. 2001). Accordingly, the rise in circulating levels of ghrelin 
following dietary-induced weight loss in previously obese individuals (Williams et al. 
1984) suggests that the stimulatory effect of acyl-ghrelin on GH release is closely linked 
to food intake and adiposity (Cummings et al. 2002). 
 
Although the regulation of food intake (Cowley et al. 2003; Cummings 2006) is one 
of the main roles in the ghrelin system (Nakazato et al. 2001; Wren et al. 2000a), 
discrepancies in the regulatory role of ghrelin in food intake observed across genetic 
deletion of ghrelin or Ghsr or goat could be due to differences in genetic background, the 
ages of the mice or the development of compensatory mechanisms. Although different 
genetic mouse lines targeting various forms of ghrelin or ghrelin receptors such as 
preproghrelin-/-, ghrelin-/-, ghsr-/- and goat-/- mice were generated over the years to study 
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the significance of endogenous ghrelin actions and its biologically relevance in the GH-
ghrelin system (Sun et al. 2003; Sun, et al. 2008; Sun, et al. 2004b; Zhao et al. 2010), the 
true endogenous role of acyl-ghrelin in regulating GH pulsatility, and the actions of GH on 
body composition and growth needs to be addressed. For instance, adult preproghrelin-/- 
mice have no major weight or growth alterations under balanced feeding environment 
(Sun et al. 2003), whereas ghsr-/- mice are presented with mildly lower body weights and 
reduced IGF-1 levels (Sun et al. 2004b). On the contrary, induction of a postweaning 
reduction in circulating ghrelin levels in mice, through expressing human diphtheria toxin 
receptor (DTR) in ghrelin-secreting cells and treating these mice with DTR, does not 
impact body weight, body (nasoanal) length and plasma IGF-1 levels (Ariyasu, et al. 
2010). It is thus plausible that compensatory mechanisms may have emerged during the 
developmental period in mice with congenital loss of ghrelin. While overall measurement 
of food intake and body weight is not altered in goat-/- mice (Zhao et al. 2010), a study 
suggests that ghrelin may play a role in regulating the portion size and frequency of food 
intake (Lin, et al. 2014b). Furthermore, carbohydrate-rich food intake was reduced in 
goat-/- mice (Kouno, et al. 2016a; Kouno, et al. 2016b) while a moderate reduction in 
weight was observed when fed with an octanoate-rich diet (Kirchner et al. 2009). Hence 
the development of compensatory mechanisms may defend against growth retardation or 
negative changes in body composition in goat-/- mice. However, when challenged on a 
60% caloric restriction, young goat-/- mice are unable to maintain normal blood glucose 
(Zhao et al. 2010). Given that GH is essential in regulating glucose metabolism (Moller 
and Jorgensen 2009), low levels of GH in goat-/- mice may contributes to the impaired 
glycaemic state. This study has therefore demonstrated the importance of acyl-ghrelin in 
sustaining blood glucose in times of insufficient calories and allows survival. 
 
1.6.4 Acyl-ghrelin – a positive modulator of pulsatile GH secretion 
Acyl-ghrelin is thought to act through an established bidirectional and intricate interaction 
primarily with the two key GH modulators (GHRH and SST) to refine the regulation of GH 
release. When ghrelin was first discovered to augment GH release in rats (Kojima et al. 
1999), in vitro studies demonstrated that exogenous ghrelin markedly elicits GH release 
in rodents (Kojima et al. 1999; Seoane, et al. 2000; Yamazaki, et al. 2002) and humans 
in a dose-dependent manner (Arvat, et al. 2000b; Hataya et al. 2001; Takaya et al. 
2000). Besides increasing overall pulsatile GH secretion, healthy individuals display no 
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rapid diminishing of GH response during a 24 h continuous ghrelin infusion (Veldhuis et 
al. 2008b). Earlier studies with GHS, as well as studies with ghrelin itself, have also 
shown substantial and reproducible stimulatory effects on GH (van der Lely et al. 2004). 
While pharmacological studies in humans have clearly demonstrated that a single bolus 
of ghrelin elevates total circulating levels of ghrelin, the pharmacokinetics of exogenous 
acyl-ghrelin however is rapidly cleared (Akamizu, et al. 2004; Druce, et al. 2006; 
Enomoto, et al. 2003; Nagaya et al. 2001a). Hence ghrelin does not offer specific 
benefits over administration of GH itself for treating GH deficiency due to its short half-
life. 
 
The vagus nerve is by far the most important route to exert a holistic GH-releasing 
activity of ghrelin. Indeed, experimental animal models with disruption of vagal 
connections display a reduced GH response to peripheral and central ghrelin injections 
(Al-Massadi, et al. 2011). Similarly, studies have shown that gastric derived acyl-ghrelin 
signals to the hypothalamus via the vagus nerve to augment the release of GHRH (Date 
et al. 2002; Feng, et al. 2011; Wagner, et al. 2009). On the contrary, GH is released in 
response to i.v. ghrelin administration in both gastrectomised (Huda, et al. 2007; Popovic, 
et al. 2005) and vagotomised patients (Takeno, et al. 2004). This suggests that gastric 
derived ghrelin may act at the level of APG to stimulate the release of GH. Accordingly, 
damage to pituitary stalk or PG have shown to reduce GH response to exogenous ghrelin 
(Maghnie, et al. 2007; Popovic, et al. 2003). Therefore, as illustrated in Fig. 1.6, acyl-
ghrelin may potentially exert its action onto the APG and/or the hypothalamus. This may 
also provide an avenue for ghrelin bolus administration as a GH stimulation test in 
diagnosing pituitary GH deficiency (Gasco, et al. 2013).  
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Figure 1.6 Regulatory role of acyl-ghrelin on pulsatile growth hormone (GH) 
secretion 
To modulate the release of GH, peripheral acyl-ghrelin acts on its receptor on 
somatotrophs in the anterior pituitary gland (APG), and hypothalamic GH-releasing 
hormone (GHRH) and neuropeptide Y (NPY) within the arcuate nucleus (ARC) via vagus 
nerve to cross the blood brain barrier (BBB). It is thought that the hypothalamic 
interaction between NPY and SST neurons allows acyl-ghrelin to indirectly modify SST 
activity within the periventricular nucleus (PeVN) via NPY. 
 
 
In an early study, KP-102 (GH-related peptide) has been shown to stimulate the 
release of GH by acting on a subpopulation of GRF neurons in the ARC of the 
hypothalamus (Kamegai, et al. 1996). Studies have reported that GHS treatment 
enhances GHRH activity and induces c-fos expression in GHRH neurons in rats (Bailey, 
et al. 1999; Dickson and Luckman 1997). While short-term subcutaneous (sc) or central 
infusion of a selective GHS-R antagonist, BIM-28163, significantly reduced the amplitude 
of GH secretory peaks in rats (Zizzari, et al. 2005), long-term administration of MK-677 
(acts as a ghrelin mimetic) in humans increased GH pulse amplitude (Nass, et al. 2008b). 
This implies that endogenous ghrelin acts primarily as an amplifier of GH release. 
Accordingly, the secretory pattern of GH is not significantly altered following treated with 
a GHS-R1a antagonist (Zizzari et al. 2005) or in young ghrelin-/- mice even though the 
amplitude of GH secretory peaks is diminished when compared to age-matched WT 
GH 
ME 
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SST 
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littermates (Hassouna et al. 2014). Furthermore studies in animals have proposed an 
interaction of the GHRH and ghrelin systems in the regulation of GH secretion (Muller et 
al. 1999), thus suggesting that ghrelin may potentially increase hypothalamic GHRH-
induced GH release. For instance, co-administration of GHRH with ghrelin potentiates a 
greater synergistic GH-releasing effect than that of GHRH alone in humans (Alvarez-
Castro, et al. 2004; Arvat et al. 2001; Hataya et al. 2001; Veldhuis, et al. 2012). Given 
that GH response to ghrelin bolus is more robust following a GHRH bolus injection (Arvat 
et al. 2000b; Broglio, et al. 2002), the signal transduction pathways of ghrelin and GHRH 
are undoubtedly complementary (Korbonits, et al. 2004). However, ghrelin can only 
release stored GH, whereas only GHRH prompts the synthesis of GH (Castaneda, et al. 
2010). 
 
Although a small subset of ghrelin-producing cells exists in the ARC of the 
hypothalamus (Date et al. 2000), localised ghrelin immunoreactivity is present (Kojima et 
al. 1999; Sato, et al. 2005). Likewise, Ghs-r1a is expressed on a fraction of GHRH 
neurons in the ARC, (Tannenbaum, et al. 1998b; Willesen, et al. 1999), thus implying that 
ghrelin may act directly on GHRH neurons. This is corroborated by experiments 
demonstrating that down regulated Ghs-r expression in the ARC of the hypothalamus in 
transgenic rats is associated with a reduction in GHRH-containing neurons (Mano-
Otagiri, et al. 2006), presumably due to the alteration in ghrelin signalling. In line with this, 
ghrelin modulates the activity of GHRH neurons to mediate the release of GH 
(Tannenbaum, et al. 2003), as well as stimulates the release of GHRH from hypothalamic 
explants (Wren, et al. 2002). However, alteration in GH response to ghrelin occurs 
following treatment with anti-GHRH antiserum (Tannenbaum et al. 2003). As 
demonstrated in vitro rodent studies, ghrelin excites most of the ARC neurons projecting 
to the ME (Mori, et al. 2010) in hypothalamic slices, as well as increases GHRH neurons 
excitability by increasing their firing rate (Osterstock, et al. 2010). 
 
Central administration of acyl-ghrelin stimulates the release of GHRH secretion 
and impedes SST (Feng et al. 2011; Wagner et al. 2009). This proposes that ghrelin has 
an antagonistic effect on SST (Broglio et al. 2002). While SST infusion slightly blunts GH 
response to ghrelin bolus (Di Vito, et al. 2002), exogenous ghrelin is capable of 
stimulating the release of GH during either high or low endogenous SST tone, thereby 
suppressing SST release from perifused rat hypothalamus (Tolle et al. 2001). While 
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ghrelin seems refractory to SST inhibitory action, its GH-releasing activity at the pituitary 
level is not dependent on inhibiting endogenous SST release (Tannenbaum et al. 2003). 
This suggests that acyl-ghrelin may modify the interaction between and the release of 
GHRH and SST into the hypophyseal portal blood to act onto the APG, thereby 
contributing to a GH surge. However, studies show that SST inhibits the action of ghrelin 
on rat hypothalamic slices (Mori et al. 2010) and at the level of pituitary gland 
(Tannenbaum et al. 2003). Similarly, in humans, SST could potentially enhance its 
inhibitory tone to suppress circulating levels of ghrelin regardless of the GH status 
(Norrelund, et al. 2002). In contrast to central action of ghrelin, pituitary-derived ghrelin 
exerts its stimulatory effect directly onto the PG, suggesting a paracrine role in the 
regulation of GH release (Kamegai, et al. 2004). The molecular action of acyl-ghrelin on 
the APG involves the binding of acylated-ghrelin to GHS-R1a on pituitary somatotrophs, 
thereby initiates and activates the PLC/IP3 signalling cascade, resulting in the release of 
GH (Chen et al. 1996). 
 
The portal blood measurements of GHRH and SST in rodents have shown that 
while the majority of GH pulses are closely dependent on the GHRH pulses, about 30% 
of GH pulses are completely disassociated (Frohman et al. 1990). Despite the inactivated 
mutations of the GHRH-R, these patients notably have sustained rhythmic GH pulses. 
This hence reinforces the role for acyl-ghrelin in sustaining the pulsatility of GH secretion 
(Maheshwari, et al. 2002). As with the pulsatile release of GH secretory pattern, ghrelin 
fluctuates in a periodic pattern in accordance with circadian light-dark cycles under a 
classic physiological condition (LeSauter, et al. 2009). In humans, a 24 h continuous 
infusion of ghrelin stimulates peak GH amplitude, frequency of GH secretory rate and 
entropic modes of GH secretion (Veldhuis et al. 2008b). The significant correlation 
between pulses of GH secretory rate and acyl-ghrelin in a 1 h interval during and before 
the GH pulse (Nass et al. 2008a) suggests that acyl-ghrelin acts as a positive modifier of 
GH release during fed state. It is also found that there is a significant association 
between ghrelin and GH levels in circulation in fasted state during night time (Koutkia, et 
al. 2004). On the contrary, no significant correlation between acyl-ghrelin and GH 
secretion in fasted subjects (Nass et al. 2008a). Deconvolution analysis also revealed 
that fasting levels of ghrelin is an independent predictor of basal GH secretion and GH 
secretory burst frequency (Misra, et al. 2005). Similarly, several studies show no 
relationship between GH and circulating levels of ghrelin in fed state (Avram, et al. 2005; 
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Espelund, et al. 2005; Norrelund et al. 2002). Although most of the available studies 
measured total ghrelin and did not distinguish between acyl- and desacyl-ghrelin, studies 
have demonstrated that neither the release of circulating levels of total nor acyl-ghrelin 
coincides with pulsatile GH release in rats (Tolle et al. 2002; Zizzari, et al. 2007). 
Moreover, these studies are limited to either inadequate number of samples collected, or 
long sampling intervals during repeat sampling. These observations thus cannot reliably 
identify the relationship between acyl-ghrelin release and GH secretion. Indeed, 
improved sampling frequency suggests a proportionate association between acyl-ghrelin 
and GH secretion in humans (Nass et al. 2008a).  
 
Although several in vivo studies have adopted the use of ghrelin-/- and ghsr-/- mice 
(Hassouna et al. 2014; Sun, et al. 2003; Sun, et al. 2004a; Wortley, et al. 2004) to 
evaluate the physiological significance of ghrelin on the GH/IGF-1 axis, reliable 
assessment of pulsatile GH secretion in goat-/- mice was limited. Given that the goat gene 
(encoding the enzyme that acylates ghrelin) is responsible to generate the structure of a 
functional acyl-ghrelin by modifying the fatty acid residue on the third position Serine, a 
recent study has reported negligible level of circulating acyl-ghrelin in mouse models with 
the deletion of goat gene (goat-/- mice) (Zhao et al. 2010), thus these mice may offer a 
more appropriate model to investigate the specific role of endogenous acyl-ghrelin in the 
regulation of GH secretion. 
 
Collectively, growing evidence supports the notion that the ghrelin system plays 
crucial roles by regulating multiple biological functions, revealing the complexity through 
which multiple ghrelin gene-derived variants, receptors, and interrelated enzymes such 
as GOAT may modulate physiological function. Complementary to GHRH and SST, the 
overall role of circulating acyl-ghrelin levels in the regulation of GH release is still 
emerging. To date, whether acyl-ghrelin plays a role in modulating the pre-existing 
pulsatile GH secretion pattern is unclear and requires further investigation. 
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1.7 Hypothesis and aims 
 
In this thesis, I hypothesised that acyl-ghrelin modulates the pulsatile release of growth 
hormone relative to age and adiposity. 
 
To address the overarching hypothesis, experiments aim to demonstrate: 
 
1) The effects of increased adiposity on spontaneous release of GH in mice 
 
2) The relationship between key modulators of food intake and peripheral factors that 
signal adiposity with spontaneous release of GH in mice 
 
3) The role of endogenous acyl-ghrelin in regulating pulsatile GH secretion in adult mice 
relative to adiposity 
 
4) The role of endogenous acyl-ghrelin in regulating pulsatile GH secretion relative to 
age 
 
5) The role of endogenous acyl-ghrelin on the patterning of GH release 
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Chapter 2 Materials and methods 
2.1 Animal care 
All experiments were performed on male mice obtained from The University of 
Queensland Biological Resources. Transgenic homozygous ghrelin-O-acyltransferase 
(GOAT) knockout mice (goat-/-) were backcrossed to C57/BL6J background strain and 
age-matched wild-type (WT) mice were bred on the same strain. Homozygous goat-/- 
mice were obtained from homozygous breeding pairs. These mice had germline deletion 
of the gene encoding GOAT (Yang et al. 2008). All mice were housed either in pairs or as 
trios. Experimental and holding room temperature (RT) was maintained at 25.0±2.0 °C 
and 50.00±5% humidity on a fixed 12 h light/dark cycle (lights on at 0600 h). All mice 
were acclimatised to experimental procedures (i.e. sequential tail-tip blood collection) to 
reduce stress by daily handling. Mice had free access to standard chow diet (19.6% 
protein and 4.6% fat) or a commercial high fat diet (22.6% protein and 23.5% fat; 
Specialty Feeds, Glen Forrest, WA, AUS), and water throughout the study. All 
experimental procedures were approved by the University of Queensland Animal Ethics 
Committee and performed in accordance with national guidelines. 
 
2.2 Serial blood sampling for the assessment of pulsatile GH secretion 
Mice were acclimated to daily handling two to three weeks prior to sequential blood 
collection by emulating the experimental procedure. This is to limit potential stress-
induced alteration of pulsatile GH secretion. Mice were handled within a cardboard roll 
and held by the base of the tail during each blood collection (<1 min per mouse). 
Measures were collected based on previously established methodology (Steyn et al. 
2011). A total of 36 sequential tail-tip blood samples were collected at 10 min intervals 
over a 6 h sampling period. Approximately 0.5 mm of the distal portion of the tail was 
cleaned with 70% ethanol and removed using a sterile surgical blade (L056; ProSciTech, 
QLD, AUS) at the first time-point of sampling. Subsequently, the tip of the tail was 
immersed in physiological saline (AHF7124; Sodium Chloride 0.9%; Baxter, NSW, AUS) 
to prevent cross contamination from previous sampling and blood was collected from the 
same wound. A layer of thin clot formation was removed using the edge of a surgical 
blade if necessary. 2 μl of whole blood was collected into 58 μl (dilution of 1:30) of 1X 
Phosphate Buffered Solution with 0.05% Tween-20 (1X PBS-T) per sample from the 
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same tail-tip wound throughout the procedure by gently massaging along the tail vein. 
Samples were immediately mixed by vortex, placed on dry ice and stored at –80 °C for 
batch analysis. Given an approximate total blood volume of 2.1 ml per mouse (7% of 
blood volume relative to body weight), blood loss was restricted to < 5% of total blood 
volume over a 6 h sampling period. The amount of blood loss is well within the 
physiological limit and has no significant welfare issues on the well-being of mice 
(Parasuraman, et al. 2010; Raabe, et al. 2011). 
 
2.3 Collection of tissue and plasma for hormone or metabolites analysis 
Terminal blood and tissue samples of interest were collected at the time of sacrifice. 
Given the ultradian patterns of secretion and variations in circulating factors assessed in 
this thesis, collection time was kept between 0900 and 1200 h. Mice were weighed and 
anaesthetised with a single intra-peritoneal (i.p.) injection of sodium pentobarbitone (32.5 
mg/kg, 1PO643-1; Virbac Animal Health, Milperra, NSW, AUS). Pedal withdrawal reflex 
was assessed to ensure that mice were fully sedated. Terminal cardiac whole blood 
samples were collected into ethylenediaminetetraacetic acid (EDTA)-coated tubes 
(41.1395.005; Sarstedt Australia Pty Ltd, SA, AUS) using 26 G (0.45 mm x 13 mm) 
needle (302002; BD PrecisionGlideTM, New Jersey, USA) attached to a 1 ml syringe 
(SS+01NA; TERUMO® Syringe, Tokyo, JP). Plasma and red blood cells were 
immediately separated by centrifugation (2000 g for 3-4 min at RTP). For the assessment 
of acyl-ghrelin and total ghrelin, aliquots of plasma were treated with 10 mg/ml 
phenylmethylsulfonyl fluoride (PMSF, P7626; Sigma-Aldrich, Castle Hill, NSW, AUS) and 
1 M hydrochloride acid (HCL). Abdominal fat pads were excised immediately following 
cardiac puncture and weighed. Tissue of interest (i.e. brain, pituitary glands, abdominal 
fat, liver and gastrocnemius muscles) and aliquots of plasma were snap-frozen on dry ice 
and stored at –80 °C for future batch analysis. 
 
2.4 Protein extraction, hormone and metabolites analysis 
The left lateral lobe of the liver and gastrocnemius muscle of the left hind limb were 
ground on dry-ice using a mortar and pestle, thus ensuring tissues remain frozen during 
processing. Whole pituitary gland, ground liver and gastrocnemius muscles were lysed in 
buffer containing 50 mM HEPES (pH7.4), 150 mM NaCl, 10 mM EDTA (pH 8.0), 1 mM 
Na3VO4, 30 mM NaF, 10 mM Na4P2O7, 1% Triton-X and protease inhibitor cocktail tablets 
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(05892970001; cOmplete ULTRA Tablets, Mini, EASYpack; Roche, Mannheim, 
Germany). Following extraction, protein samples (with a dilution of 1:5 for livers and 
gastrocnemius muscles) were assayed on respective commercial ELISAs (Enzyme-
linked immunosorbent assays) and normalised to total protein content (23225; Pierce 
BCA Protein assay kit; Thermo Scientific, Rockford, IL, USA). Analyses of pituitary GH 
content (with a dilution of 1:1 000 000 for whole pituitary glands) and sequential GH 
levels (detailed in section 2.2) were performed using an in-house GH ELISA (see section 
2.5). A volume of 50 μl out of the 60 μl of tail-tip whole blood per sample was used to 
assess pulsatile GH levels (detailed in section 2.2). The remaining 10 μl of whole blood 
fractions were pooled and assayed for corticosterone levels. Resulting measurements 
are indicative of corticosterone levels during serial blood collection (detailed in section 
2.2). Details of all commercial kits used to assess circulating levels of hormones or 
metabolites are listed in the table 2.1. 
 
Table 2.1 List of commercial ELISA/colorimetric kits for the assessment of 
hormones or metabolites 
 
 
 
Hormone/Metabolite Cat. No. & Name of the Kit Company
Acyl-ghrelin
EZRGRA-90K Rat/Mouse Ghrelin 
(Active) ELISA
Millipore
Total ghrelin
EZRGRT-91K Rat/mouse Ghrelin 
(Total) ELISA
Millipore
Corticosterone ab108821 Corticosterone ELISA Abcam
Non-esterified free fatty 
acid (NEFA)
279-75401 NEFA-C Assay Wako
Glucose 10009582 Glucose Assay Cayman
Insulin
EZRMI-13K Rat/Mouse Insulin 
ELISA
Millipore
Insulin-like growth 
factor-1 (IGF-1)
SMG100 Mouse/rat IGF-1 
Quantikine ELISA
R&D System
Leptin EZML-82K Mouse Leptin ELISA Millipore
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2.5 In-house GH sandwich ELISA 
A sensitive GH sandwich in-house ELISA as previously published (Steyn et al. 2011) was 
used for the quantification of GH in sequential whole blood samples and pituitary GH 
content. The ELISA plate was placed in a humidified chamber and incubated in RT on an 
orbital shaker at 60 rpm, unless otherwise stated. Each well of a 96-well plate (CLS9018; 
Corning Inc., NY, USA) was coated with 50 μl capture antibody (AFP411S, National 
Institute of Diabetes and Digestive and Kidney diseases (NIDKK)-National Hormone and 
Pituitary Program (NHPP)-anti-rat GH (rGH)-IC-1 (monkey), Torrance, CA, USA) diluted 
in 1X PBS at 1:40, and incubated in 4 °C overnight (16-18 h) in a humidified container 
without agitation. Following overnight incubation, wells were blocked for 2 h in 200 μl of 
5% skim milk powder dissolved in 1X PBS-T to minimise non-specific binding. 50 μl of 
blood samples and standards were added to each well and incubated for 2 h. A 9-point 
standard curve was generated using 2-fold serial dilution (8 ng/ml to 0.03125 ng/ml) of 
mouse GH (AFP-10783B; mGH reference preparation; NIDDK-NHPP) in 1X PBS-T 
supplemented with 0.2% bovine serum albumin (BSA). 50 μl of detecting antibodies 
(AFP5672099; rabbit anti-serum rGH, NIDDK-NHPP) were added to each well at 1:40 
000 dilutions in blocking buffer and incubated for 1.5 h. Each well of the bound complex 
was incubated with 50 μl of HRP (NA934; ECL™ Anti-Rabbit IgG, Horseradish peroxidase 
linked whole antibody from donkey; GE Healthcare, Little Chalfont, Bucks, UK) at 1:2000 
dilution in 50% blocking buffer and 50% 1XPBS for 1.5 h. Plates were washed 3 times 
with 200μl 1X PBS-T at 3 min intervals between incubations. O-phenylenediamine (OPD, 
00-2003; Invitrogen, Camarillo, CA, USA) was dissolved in 12 ml citric phosphate buffer 
(pH 5.0) supplemented with 0.03% hydrogen peroxide. Development of the enzymatic 
reaction was visualised by adding 100μl of the ODP substrate solution to each well. The 
reaction was stopped after 30 min of incubation by adding 50μl of 3 M HCL into each 
well. Plates were read at wavelength 490 nm with reference to 650 nm using a 
spectrophotometer (Sunrise 96-well monochromatic micro-plate reader; TECAN, VIC, 
AUS). Final concentration of GH was quantified by extrapolating values against a non-
linear standard curve generated by sigmoidal dose-response (variable slope). 
 
2.6 Micro-punch dissection of the hypothalamus 
To determine gene expression of key regulators of GH release located in the 
hypothalamus, specifically the arcuate nucleus (ARC) and periventricular nucleus (PeVN) 
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regions, collection of brain tissue biopsies were isolated to the ARC/PeVN complex using 
a modified micro-punch dissection technique (Palkovits 1973). Whole brain was mounted 
onto the specimen holder using Tissue-Tek® optimum cutting temperature (O.C.T.) 
compound (Sakura Finetek Inc., Torrance, CA, USA), by positioning the hypothalamus to 
be perpendicular to the specimen holder. The temperature of the cryostat (Hyrax C60) 
was set at −16 °C during sectioning, while the specimen holder and blade were set at 
−12 °C and −10 °C respectively. Thick frozen serial coronal brain sections were cut at 
300 μm and mounted onto conventional glass slides by slightly thawing sections at RT 
and immediately refreezing on the freezing stage of cryostat. Tissue biopsies, 
representative of the ARC and PeVN located between bregma −0.94 to −2.14 mm (Fig. 
2.1), were obtained by micro-punch dissection of brain nuclei using a uniformly blunted 
19 G (0.9 × 25 mm) needle (305186; BDTM Regular Bevel, New Jersey, USA). Punch 
biopsies were collected using a microscope, and isolated tissues ejected using a 0.35 
mm thick insert and homogenised into 1ml Trizol (15596-026; Invitrogen, CA, USA). 
Tissues were stored at −80 °C for further processing. 
 
 
 
 
Figure 2.1 Regions of brain (red) illustrating tissues collected between bregma -
0.94 to -2.14 from mice. 
Micro-punch biopsies collected were representative of pooled regions of the arcuate 
nucleus (ARC) and periventricular nucleus (PeVN) of the hypothalamus of mice. 
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2.7 Real-time quantitative polymerase chain reaction (qPCR) 
2.7.1 Real-time qPCR of hypothalamic gene expression 
To maximise the amount of RNA obtained from micro-punched tissue samples, DNA 
carrier (46-6026; PureLink™ DNAse Carrier; Invitrogen, CA, USA) was added into each 
sample containing 1 ml TRIzol (15596-026; Invitrogen, CA, USA) prior to RNA extraction 
(12183-016; PureLink™ RNA Micro Kit; Invitrogen, CA, USA). The concentration and 
quality of RNA were measured using a spectrophotometer (NanoDrop™, ND-1000; 
Thermo Scientific, Wilmington, DE, USA). cDNA was synthesised (amplification 
conditions: 25 °C for 10 min; 42 °C for 60 min; termination: 85 °C for 5 min; and holding: 
4 °C for 60 min) from 100 ng of total RNA using the SuperScript® VILO™ cDNA synthesis 
kit (11754-050; Life Technologies, CA, USA). The following Taqman® polymerase 
primers (Life Technologies, CA, USA) were used to complete experiments contributing to 
this thesis: Ghrh (assay ID: Mm00439100_m1), Srif (assay ID: Mm00436671_m1), Npy 
(assay ID: Mm03048253_m1), Ghsr1 (assay ID: Mm00616415_m1), and 
Glyceraldehyde-3-phosphate dehydrogenase (Gapdh; assay ID: Mm99999915_g1). 
Gene expression was determined by Taqman® PCR technology. Primers, master mix 
(4444556; Taqman® Fast Advanced Master Mix; Invitrogen, CA, USA) and cDNAs were 
mixed into a 384-well plate (4309849; Micro-Amp® Optical 384-well reaction plate with 
barcode, Life Technologies, CA, USA). PCR was performed using the QuantStudio™ 7 
Flex system (Life Technologies, CA, USA) under these conditions – holding: 2 min at 50 
°C; polymerase activation: 20 secs at 95 °C; denaturing and annealing: 1 sec at 95 °C 
and 20 secs at 60 °C respectively for 40 cycles. 
 
2.7.2 Real-time qPCR of liver gene expression 
To assess the effect of altered GH pulse patterning on liver gene expression, 
approximately 100 mg of ground liver tissues were lysed and homogenised using QIAzol 
lysis reagent (1023537; QIAGEN GmbH, Hilden, Germany). Total RNA was extracted 
from the supernatant using RNeasy® Microarray Tissue mini kit (73304; QIAGEN GmbH, 
Hilden, Germany). The concentration and quality of RNA were measured using a 
spectrophotometer (NanoDrop™, ND-1000; Thermo Scientific, Wilmington, DE, USA). 
cDNA was synthesised from 250 ng of total RNA using the RT2 HT First Strand kit 
(330411; QIAGEN Sciences, Maryland, USA) according to manufacturers’ instructions. 
SYBR green mastermix (330522; RT2 SYBR® Green ROX™ qPCR Mastermix; QIAGEN 
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Sciences, Maryland, USA) and cDNAs were added into a customised RT2 Profiler PCR 
gene expression array (330131; QIAGEN Sciences, Maryland, USA), pre-coated with 
primers directed towards Mup1, Cyp2d9, Cyp3a44, Cyp4a12b, Cyp7b1 (details of 
individual specification are listed in Table 2.2). PCR was performed using the 
QuantStudio™ 7 Flex system (Life Technologies, CA, USA). The thermal cycling 
conditions were set at 95 °C for 10 min for polymerase activation, and 40 cycles of 
denaturing and annealing at 95 °C for 15 seconds and at 60 °C for 1 min. 
 
Table 2.2 List of custom mouse RT2 Profiler™ PCR gene array 
 
 
2.8 Data and statistical analysis 
All data are presented as mean ± SEM, unless otherwise stated. Concentrations of 
hormones or metabolites were analysed and calculated against linear regressions 
generated by respective standard curves. The concentrations of GH were analysed using 
non-linear regression of the standard curve. The secretory rate/pattern, and clearance 
rate of GH were determined by deconvolution analysis (The MathWorks, Natick, MA, 
USA) based on serial measurements (Hindmarsh et al. 1990; Veldhuis et al. 2008a). The 
regularity of serial GH levels was calculated by ApEn analysis as described previously 
Gene UniGene
Reference Squence 
(RefSeq)
Major urinary protein 1 
(MUP1)
Mm.422695 NM_031188.2
Cytochrome P450, family 2, 
subfamily d, polypeptide 9 
(Cyp2d9)
Mm.226708 NM_010006.2
Cytochrome P450, family 3, 
subfamily a, polypeptide 44 
(Cyp3a44)
Mm.425301 NM_177380.3
Cytochrome P450, family 4, 
subfamily a, polypeptide 12B 
(Cyp4a12b)
Mm.448292 NM_172306.2
Cytochrome P450, family 7, 
subfamily b, polypeptide 1 
(Cyp7b1)
Mm.316000 NM_007825.4
  73 
(Veldhuis, et al. 2001). All measures (excluding deconvolution analysis) were performed 
on Prism v6.0c (GraphPad Software Inc., San Diego, CA, USA). Correlations were 
determined by linear regression and Spearman correlation coefficient. For quantitative 
PCR, data was extrapolated from the software. Final results of gene expressions were 
normalised to either Gapdh (hypothalamic gene expression) or β-actin (liver gene 
expression), and presented as percentage relative to age-matched control groups. All 
comparisons between and within groups were determined by unpaired two-tailed 
Student’s t-test or two-way ANOVA by multiple comparisons using Bonferroni post-hoc 
analyses. Further extrapolation of study-specific data analysis and statistical 
interpretation are included in subsequent chapters accordingly. Statistical significant was 
considered at p < 0.05. 
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Chapter 3 Increased adiposity and insulin correlates with the progressive 
suppression of pulsatile GH secretion during weight gain (Experiments to address 
Aim 1 and 2) 
(This chapter was reproduced from published observations – Steyn & Xie, et al. 2013) 
3.1 Brief introduction  
Growth hormone (GH) is a key anabolic hormone that regulates body composition and 
energy homeostasis. Attainment of peak GH secretion in early adulthood (Balercia, et al. 
2011), and sustained GH secretion throughout adulthood is associated with improved 
metabolism, maintenance of healthy body composition, and improved quality of life 
(Jorgensen, et al. 2011; Park, et al. 2011). Conversely, GH deficiency is associated with 
increased adiposity, reduced bone mass, and reduced lean muscle mass (de Boer et al. 
1995). Both dietary- and age-associated increases in adiposity are associated with a 
reduction in spontaneous (Vahl et al. 1997; Veldhuis et al. 1991; Veldhuis et al. 1995) 
and stimulated (Cordido, et al. 2010; Cordido, et al. 1995; Makimura, et al. 2008; Renier, 
et al. 1990; Williams et al. 1984) GH release. This results in an overall reduction in 
circulating levels of GH. The cause for impaired GH secretion following dietary-induced 
weight gain is under intense investigation, with some studies suggesting loss of GH 
release in obesity as a consequence of endocrine dysfunction (Girod and Brotman 2003). 
 
 Factors produced in proportion to adipose mass or changes in endocrine function 
that accompany increased adiposity are thought to contribute to impaired GH secretion in 
obesity. In line with this, impaired GH secretion is reversed following weight loss 
(Rasmussen et al. 1995; Williams et al. 1984). Correlative studies assessing the 
relationship between adiposity and the secretion of GH provide essential information to 
identify potential factors that suppress GH secretion in obesity (Gill et al. 1997a; Vahl et 
al. 1997; Veldhuis et al. 2009; Veldhuis et al. 2011). Recent measures demonstrate that 
impairments in pulsatile GH secretion in humans precede dietary-induced weight gain 
(Cornford et al. 2011) and that the suppression of GH secretion with excess calorie 
consumption and insulin secretion improves meal tolerance (Cornford et al. 2012). 
Previous observations (Huang et al. 2012) have demonstrated significant decline in 
pulsatile GH secretion associated with dietary-induced weight gain in mice. Although the 
progressive decline in GH secretion may exacerbate dietary-induced weight gain and 
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may ultimately contribute to the development of obesity, it remains unclear whether low 
levels of GH release beget obesity or a reduction in the amount of GH released occurs as 
a result of obesity. Therefore, to address this, the chapter aims to demonstrate the 
relationship between pulsatile GH secretion and factors associated with obesity.  
 
3.2 Experimental approach 
3.2.1 Animals and dietary intervention 
Eight-week old WT C57Bl/6J mice were randomly assigned and maintained on either a 
standard diet (n=16, 19.6% protein and 4.6% fat) or a commercial high fat diet (HFD, 
n=12; 22.6% protein and 23.5% fat; SF04-001, Specialty Feeds, Glen Forest, WA, AUS). 
Room and housing conditions were as detailed in section 2.1. Mice had free access to 
food and water for the duration of all experiments 
 
3.2.2 Assessment of pulsatile GH secretion relative to dietary intervention 
At 16 weeks of age (following 8 weeks of dietary intervention), pulsatile GH secretion was 
assessed as described previously (Steyn et al. 2011). Briefly, 36-sequential tail-tip blood 
samples (4μl/sample) were collected 10 min intervals over a 6 h sampling period, 
commencing at 0700 h (detailed in section 2.2). Following collection, samples were 
immediately placed on dry ice and transferred to −80 °C for the analysis of GH (detailed 
in section 2.5). 
 
3.2.3 Collection of adipose tissue and plasma samples for leptin, insulin, NEFAs, 
and glucose analysis 
Following assessment of pulsatile GH secretion, mice were given 2-5 days to recover 
before sacrificing. Mice were sacrificed as detailed in section 2.3. Epididymal fat pads 
were excised and weighed as a representative depot for total body adipose mass 
(Rogers and Webb 1980). Terminal cardiac blood samples were collected using a 
heparinised syringe (100 IU/ml). Red blood cells content and plasma were immediately 
separated via centrifugation (2000 g for 3 min at RT), placed on dry ice, and stored at 
−80 °C for the analysis of leptin, insulin NEFAs and glucose (detailed in Table 2.1). The 
within- and between-assay coefficients of variations for all ELISA assays were > 9% and 
> 3% respectively. 
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3.2.4 Data and statistical analysis 
The kinetics and secretory patterns of pulsatile GH secretion were determined by 
deconvolution analysis following parameters established previously (Steyn et al. 2011). A 
series of correlation analyses were then performed to assess the relationship between 
body weight and adiposity relative to circulating levels of leptin, insulin, NEFAs and 
glucose and measures of pulsatile GH secretion, as well as correlations between 
measures of GH secretion and circulating levels of leptin, insulin, NEFAs and glucose. 
Correlation analyses were limited to data collected from all mice, irrespective of dietary 
intervention (complied data, n=28). Correlations were determined by linear regression 
and Spearman correlation coefficient (CV). Data are presented as mean ± SEM. 
Differences between groups were determined by unpaired two-tailed Student’s t-test. All 
measures (excluding deconvolution analysis) were performed using GraphPad Prism 
v6.0a. For all measures, a p value < 0.05 denotes statistical significance. 
 
3.3 Results 
3.3.1 High-fat feeding results in weight gain and changes in body composition and 
circulating factors released proportional to fat mass 
As shown in Figure 3.1, high-fat feeding resulted in significant weight gain (p < 0.01). 
This was accompanied by a significant increase in epididymal fat mass (p < 0.01) and an 
elevation in circulating levels of leptin (p < 0.01) and insulin (p < 0.01). Circulating levels 
of NEFAs (p = 0.74) and glucose (p = 0.50) were not significantly different between 
control and HFD fed mice. Data are summarised in Table 3.1. 
 
3.3.2 High-fat feeding resulted in the suppression of pulsatile GH secretion in mice 
Total, pulsatile, and basal GH secretion rates, the mass of GH secreted per burst (mass 
per pulse (MPP)), and the number of GH pulses observed over the 6 h sampling period 
varied considerably amongst 16-week old in mice maintained on a standard diet (control; 
n=16) or HFD (n=12) are summarised in Table 3.1. In accordance with previous 
observations (Huang et al. 2012), dietary-induced weight gain was associated with a 
significant decline in pulsatile GH secretion in mice. Relative to controls (Fig. 3.2A), data 
show a significant decline in total and pulsatile GH secretion rate, as well as the MPP in 
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HFD fed mice (Fig. 3.2B). Dietary intervention did not impact basal GH secretion rate or 
the number of pulses observed over the 6 h sampling period. 
 
 
 
 
Figure 3.1 Measurements of body composition and circulating factors in 16-week 
old C57Bl/6J male mice maintained on standard chow diet and high-fat diet (HFD) 
Body weight (A), epididymal fat mass (B), circulating levels of leptin (C) and insulin (F) 
increased in HFD fed mice at 8 weeks of dietary intervention. Circulating levels of non-
esterified fatty acids (NEFAs; D) and glucose (E) are not significantly different between 
HFD fed (n=12) and control (n=16) mice. Data are presented as mean ± SEM in Table 
3.1. *P < 0.05 was considered statistically significant. 
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Figure 3.2 Representative examples of pulsatile GH secretion in 16-week old 
C57Bl/6J mice maintained on a standard diet (A) or HFD (B).  
Left panels demonstrate profiles of circulating levels of whole blood GH measured in 36 
consecutively collected blood samples (4 μl/sample). Blood samples were collected at 
10-min intervals, starting at 0700 h. Right panels illustrate output figures of GH secretion 
profiles following deconvolution analysis. Output parameters demonstrate the secretion 
rate of GH throughout the 6 h sampling period (ng/ml). Arrows denote the onset of peak 
periods of GH secretion. Parameters relating to pulsatile GH secretion between control 
and HFD fed mice following deconvolution analysis are summarised in Table 3.1. 
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Table 3.1 Body weight; epididymal fat weight; circulating levels of leptin, NEFAs, 
glucose, and insulin; and deconvolution analysis of GH secretion from 16-week old 
C57Bl/6J mice maintained on standard diet (control) or a HFD.  
 
 
3.3.3 Measures of circulating leptin and insulin increase relative to body weight 
and epididymal fat mass regardless of dietary intervention 
Regression with Spearman correlation analysis was performed to assess the relationship 
between body weight and adiposity (epididymal fat) relative to circulating levels of leptin, 
NEFAs, glucose, and insulin in 16-week old mice maintained on standard chow diet 
(open circles) and HFD (closed circles). Assessments for complied data sets (control and 
HFD; n=28) are illustrated in Figure 3.3. Circulating levels of leptin (Fig. 3.3A) and insulin 
(Fig. 3.3D) increased relative to increased body weight. As with body weight, circulating 
levels of leptin and insulin increased relative to epididymal fat mass (Fig. 3.3E and H 
respectively). Circulating levels of NEFA (Fig. 3.3B and F) and glucose (Fig. 3.3C and G) 
did not change relative to increased epididymal fat mass or body weight. Overall 
observations confirm that measures of body weight and epididymal fat mass in mice 
predict circulating levels of leptin and insulin, while circulating levels of NEFA and 
glucose remain unchanged, regardless of weight gain or adiposity. 
 
MPP, mass per pulse; NEFAs, non-esterified fatty acids; HFD, high-fat diet. P values 
<0.05 were considered significant. 
Control (n = 16) HFD (n = 12) P value 
Body weight (g) 30.0±0.53 34.1±1.10  <0.01 
Epididymal fat weight (g) 0.63±0.05 1.29±0.10 <0.01 
Leptin (ng/ml) 9.78±1.03 26.2±3.27 <0.01 
NEFAs (mEq/L) 0.16±0.01 0.17±0.02 0.74 
Glucose (mg/dL) 229±7.60 219±12.7 0.50 
Insulin (ng/ml) 0.91±0.10 1.73±0.25 <0.01 
Total GH secretion rate (ng/ml/6 h) 387±37.7 246±23.8 <0.01 
Pulsatile GH secretion rate (ng/ml/6 h) 361±38.1 225±19.7 <0.01 
Mass of GH secreted/burst (MPP, ng/ml) 118±12.3 69.0±8.54 <0.01 
Basal GH secretion rate (ng/ml/6 h) 26.7±6.82 20.7±5.16 0.51 
Number of pulses/6 h 3.31±0.29 3.58±0.31 0.53 
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Figure 3.3 Representative examples of linear regression of body weight and 
epididymal fat mass relative to circulating levels of leptin, non-esterified fatty acids 
(NEFAs), glucose and insulin for in mice maintained on a standard diet (open 
circles) or high fat diet (HFD; closed circles). 
Spearman correlation analysis was performed to assess the relationship between body 
weight (A, B, C and D) and epididymal fat mass (E, F, G and H), and circulating levels of 
leptin (A and E), NEFAs (B and F), glucose (C and G) and insulin (D and H). The solid 
line denotes the relationship between parameters for complied data sets (standard diet 
and HFD fed mice). Inserts: r and p values as determined by Spearman correlation. P < 
0.05 was considered statistically significant; n=28 for complied data set. 
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3.3.4 Pulsatile GH secretion in mice decreases relative to increased body weight, 
adiposity, and circulating levels of leptin regardless of dietary intervention 
The relationship between total GH secretion, pulsatile GH secretion and the mass of GH 
secreted per burst (mass per pulse (MPP)) relative to body weight, epididymal fat mass, 
and circulating level of leptin is illustrated in Fig. 3.4. Regression with Spearman 
correlation analysis was performed to assess the relationship between parameters of 
pulsatile GH secretion relative to body weight; epididymal fat mass; and circulating levels 
of leptin, NEFAs, glucose, and insulin. Assessment was done for compiled data sets (Fig. 
3.4 and 3.5) and control data sets (independent of HFD fed mice; Table 3.2). 
 
The relationship between total GH secretion, pulsatile GH secretion and the mass 
of GH secreted per burst MPP relative to circulating levels of NEFAs, glucose, and insulin 
is presented in Fig. 3.5. The assessment was done on compiled data sets (control and 
HFD). While total and pulsatile GH secretion rates, and the MPP decreased relative to an 
increase in body weight (Fig. 3.4A, B and C), epididymal fat mass (Fig. 3.4D, E and F), 
and circulating levels of leptin (Fig. 3.4G, H and I) and insulin (Fig. 3.5G, H and I), these 
parameters did not change relative to circulating levels of NEFAs (Fig. 3.5A, B and C) 
and glucose (Fig. 3.5D, E and F) regardless of dietary intervention (complied data sets). 
 
Basal GH secretion rate and number of pulses did not change relative to body 
weight (r = −0.163; p = 0.404 and r = 0.280; p = 0.150 respectively); epididymal fat weight 
(r = −0.134; p = 0.497 and r = 0.078; p = 0.691 respectively); circulating levels of leptin (r 
= −0.117; p = 0.553 and r = 0.119; p = 0.546 respectively); NEFAs (r = 0.254; p = 0.192 
and r = 0.171; p = 0.383 respectively); glucose (r = −0.283; p = 0.145 and r = −0.331; p = 
0.085 respectively) and insulin (r = 0.113; p = 0.569 and r = 0.273; p = 0.160 
respectively; figures not shown). 
 
As with the compiled data sets (control and HFD), total and pulsatile GH secretion 
rates, and the MPP were negatively associated with body weight, epididymal fat mass, 
circulating levels of leptin and insulin in mice maintained on standard chow diet, 
independent of HFD fed mice. Similarly, parameters of pulsatile GH secretion did not 
change relative to circulating levels of NEFAs and glucose in control mice. Assessment 
done for control data sets are summarised in Table 3.2. Collectively, observations show a 
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decline in pulsatile measures of GH secretion relative to an increase in body weight and 
adiposity, with these changes also observed in control non-obese mice. 
 
 
 
Figure 3.4 Representative examples of linear regression of measures of pulsatile 
GH secretion and body weight, epididymal fat mass and circulating levels of leptin 
in C57Bl/6J male mice regardless of dietary intervention. 
Linear regression of total GH secretion rate (A, D and G), pulsatile GH secretion rate (B, 
E and H) and mean peak per GH pulse (MPP; C, F and I) in mice maintained on a 
standard diet (open circles) or HFD (closed circles). Spearman correlation analysis was 
performed to assess the relationship between measures of pulsatile GH secretion 
following deconvolution analysis and body weight (A, B and C), epididymal fat mass (D, E 
and F), and circulating levels of leptin (G, H and I). The solid line denotes the relationship 
between parameters of complied data sets (standard diet and HFD fed mice). Inserts: r 
and p values as determined by Spearman correlation. P < 0.05 was considered 
statistically significant; n=28 for complied data set. 
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Figure 3.5 Representative examples of linear regression of measures of pulsatile 
GH secretion and non-esterified fatty acids (NEFAs), glucose and insulin in 
C57Bl/6J male mice regardless of dietary intervention. 
Linear regression of total GH secretion rate (A, D and G), pulsatile GH secretion rate (B, 
E and H) and mean peak per GH pulse (MPP; C, F and I) in mice maintained on a 
standard diet (open circles) or HFD (closed circles). Spearman correlation analysis was 
performed to assess the relationship between measures of pulsatile GH secretion 
following deconvolution analysis and circulating levels of NEFAs (A, B and C), glucose 
(D, E and F), and insulin (G, H and I). The solid line denotes the relationship between 
parameters of complied data sets (standard diet and HFD fed mice). Inserts: r and p 
values as determined by Spearman correlation. P < 0.05 was considered statistically 
significant; n=28 for complied data set. 
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Table 3.2 Spearman correlation analysis of deconvolution parameters of pulsatile 
GH secretion with body weight; epididymal fat weight; and circulating levels of 
leptin, non-esterified fatty acids (NEFAs), glucose, and insulin from 16-week old 
C57Bl/6J male mice maintained on a standard diet. 
 
 
 
3.4 Discussion 
Impaired GH secretion in obesity is characterised by a reduction in the number of GH 
secretory bursts and GH secretion rate (Veldhuis et al. 1991). Given that impaired GH 
secretion is reversed following weight loss, it is thought that impaired GH secretion is a 
consequence of obesity (Nam and Marcus 2000; Rasmussen et al. 1995; Williams et al. 
1984). Recent data, however, demonstrate the rapid suppression of GH secretion relative 
to excess calorie consumption (Cornford et al. 2011). In this context, impairments to GH 
secretion may precede obesity, while contributing to normal endocrine adaptations that 
minimize the physiological impact of sustained positive energy balance. Hence, factors 
produced in proportion to adipose mass or changes in endocrine function that 
accompany increased adiposity altered GH release during dietary-induced progressive 
weight gain. 
 
GH secretion declines relative to an increase in body mass index (BMI), 
suggesting that BMI predicts GH secretory dynamics (Savastano, et al. 2006; Veldhuis et 
For GH, samples were collected at 10-min intervals between 0700 h and 1300 h. P values of less than 0.05 were accepted 
as significant. n=16. 
  Body weight (g)  
Epididymal fat 
weight (g)  
Leptin (ng/ml)  FFA (mEq/L)  Glucose (ng/dL) Insulin (ng/ml) 
  r  p value    r  p value  r  p value  r p value  r p value  r p value  
Total GH 
secretion rate 
(ng/ml/6 h) 
-0.575 0.021 -0.832 <0.001 -0.868 <0.001 0.166 0.536 -0.332 0.208 -0.458 0.075 
Pulsatile GH 
secretion rate 
(ng/ml/6 h)  
-0.586 0.019 -0.803 <0.001 -0.850 <0.001 0.163 0.543 -0.315 0.235 -0.505 0.047 
Mass of GH 
secreted/burst 
(MPP, ng/ml)  
-0.514 0.043 -0.585 0.019 -0.629 0.011 -0.387 0.137 0.165 0.541 -0.458 0.075 
Basal GH 
secretion rate 
(ng/ml/6 h)  
-0.093 0.727 -0.062 0.822 -0.026 0.926 0.508 0.047 -0.335 0.204 0.333 0.207 
Number of 
pulses/6 h  0.136 0.612 -0.047 0.752 -0.150 0.483 0.426 0.100 -0.380 0.107 0.062 0.819 
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al. 2011). Our data confirm this inverse relationship and are in agreement with previous 
measures where GH output significantly decreased relative to increased body weight in 
rats (De Schepper et al. 1998). Observations were extended to show that body weight in 
C57Bl/6J mice predicts parameters of pulsatile GH secretion regardless of dietary 
intervention. As C57Bl/6J mice are prone to weight gain (as fat) regardless of dietary 
intervention (Collins, et al. 1997), the change in GH secretion relative to body weight in 
C57Bl/6J mice presumably reflects measures of GH secretion relative to adiposity. In line 
with this, impairment of GH secretion exists before dietary intervention in rats that are 
prone to weight gain (as fat) (Lauterio et al. 1998). 
 
In humans, fat mass is a dominant negative correlate of pulsatile GH secretion in 
obese (Savastano et al. 2006) and lean populations (Vahl et al. 1997). This correlation is 
stronger when isolating observations to specific fat depots. For example, the amount of 
visceral adipose tissue (VAT) in humans better reflects parameters of pulsatile GH 
secretion when compared with sc or total body fat mass percentage (Hindmarsh et al. 
1990). Conversely, GH treatment in GH-deficient individuals (Jorgensen, et al. 1996) and 
in acromegaly (Brummer, et al. 1993) markedly reduced VAT mass. Of particular interest, 
an increase in VAT mass in humans is more closely associated with metabolic syndrome 
than sc mass and is an independent predictor of mortality in overweight men (Kuk, et al. 
2006a; Kuk, et al. 2006b). Thus, impaired GH secretion in obesity may directly contribute 
to the aggregation of VAT mass and consequently obesity-associated pathologies. 
Genetic modifications in mice resulting in extremes of GH signalling alter whole-body fat 
mass. Over-expression of bGH in mice results in a decrease in body fat percentage 
(Berryman, et al. 2004; Li, et al. 2003) and a near significant 40% reduction in epididymal 
fat mass relative to body weight (Berryman et al. 2004). Accordingly, increased GH 
secretion in mice during adulthood results in a decrease in epididymal and sc fat mass, 
whereas a reversal of increased GH secretion results in a greater increase in epididymal 
fat mass relative to sc fat mass (Oberbauer, et al. 1997; Pomp, et al. 1996). Our data 
confirm that a decrease in GH secretion in mice occurs in parallel with an increase in 
epididymal fat mass. This association is true regardless of dietary-induced weight gain 
and confirms that, as in humans (Vahl et al. 1997), visceral adiposity in predicts levels of 
GH mice. Measures that assess the relationship between pulsatile GH secretion and 
different adipose depots are needed to further clarify depot-specific effects of adipose on 
GH secretion in adult mice. 
  86 
Leptin circulates in proportion to fat mass (Frederich, et al. 1995a; Maffei, et al. 
1995b), and obesity is associated with an elevation in circulating levels of leptin (Liuzzi, 
et al. 1999). As for humans (Gill, et al. 1997b), circulating levels of leptin increased 
specific to epididymal fat mass in mice. This agrees with previous observations showing 
a close correlation between epididymal expression of leptin mRNA and circulating levels 
of leptin (Villafuerte, et al. 2000). As leptin acts to maintain GH secretion (Tannenbaum et 
al. 1998a) circulating levels of leptin should directly predict GH secretion in mice. 
However, observations show that circulating levels of leptin in mice increased relative to 
a decrease in total and pulsatile GH secretion rate and the MPP. As with epididymal fat 
mass, these associations were observed independent of dietary-induced weight gain. 
Accordingly, elevated levels of leptin in obesity do not directly contribute to the 
suppression of GH secretion (Ozata, et al. 2003). Rather, impaired leptin signalling, 
and/or the development of central leptin resistance (as is characteristic of obesity 
(Munzberg, et al. 2005)), may contribute to reduced GH secretion (Furuhata, et al. 2000). 
Thus, the observed correlations between circulating levels of leptin and parameters of 
pulsatile GH secretion better reflect the role of leptin as a marker of adiposity. In 
agreement with this, reduced adiposity as a consequence of GH treatment occurs 
alongside a decrease in circulating levels of leptin (Janssen, et al. 1997). 
 
An elevation of circulating levels of NEFAs is known to suppress circulating levels 
of GH, presumably via the direct suppression of pituitary GH release (Alvarez et al. 1991; 
Briard et al. 1998; Casanueva et al. 1987) or hypothalamic-stimulated GH secretion 
(Briard et al. 1998). Accordingly, it is thought that the suppression of GH secretion in 
obesity occurs in response to an elevation of circulating NEFAs (Bays 2005; Boden and 
Shulman 2002; Girod and Brotman 2003; Langin, et al. 2005). In contrast, recent 
comprehensive assessments of NEFA kinetics in obese humans revealed that the rate of 
NEFA release into circulation is reduced (McQuaid, et al. 2011; Mittendorfer, et al. 2009), 
while the rate of clearance of NEFAs from plasma is increased (Mittendorfer et al. 2009). 
Consequently, circulating levels of NEFAs are maintained within a relatively narrow 
range, regardless of an increase in adiposity. This relationship was corroborated in a 
recent meta-analysis of 1064 publications showing relatively stable circulating levels of 
NEFAs regardless of a change in BMI (Karpe et al. 2011). In this regard, adipose tissue 
provides a storage site for excess dietary fat and may act as a buffer for fatty acid flux 
(Frayn 2002). This ultimately prevents adverse metabolic consequences associated with 
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elevated circulating levels of NEFAs (Boden and Zhang 2006; Zimmermann, et al. 2004). 
Accordingly, data show that circulating levels of NEFAs in mice throughout progressive 
weight gain do not change significantly, regardless of increased adiposity. Rather, data 
demonstrate that the suppression of GH secretion occurred in the absence of a change 
in circulating levels of NEFAs. This agrees with observations from humans (Mittendorfer 
et al. 2009) and provides further evidence to suggest that an elevation of circulating 
levels of NEFAs is not a dominant feature during the early development of obesity 
(McQuaid et al. 2011). Presumably, an increase in circulating levels of NEFAs should 
only be observed following a complete disruption to the mechanisms that sustain NEFA 
balance. In humans, GH treatment results in an increase in lipolysis and a subsequent 
rise in plasma NEFAs (Gravholt, et al. 1999; Moller et al. 2003), while GH-deficient 
patients have reduced lipolysis and an associated reduction in plasma NEFA 
concentrations (Boyle, et al. 1992). Acting through lipoprotein lipase and hormone 
sensitive lipase, circulating GH and insulin are thought to sustain the balance between 
stored and circulating fatty acids (Lafontan and Langin 2009). To our knowledge, 
potential direct interactions between GH and adipose triglyceride lipase (ATGL, the key 
enzyme that initiates triglyceride hydrolysis (Zimmermann et al. 2004)) are yet to be 
confirmed. Thus, it remains unknown whether the progressive suppression of GH 
secretion following weight gain would directly contribute to the overall slowing of ATGL-
mediated NEFA flux. Regardless of the mechanisms of action, the inverse relationship 
between GH and circulating levels of NEFAs is well defined. Hence it is unlikely that the 
progressive suppression of GH secretion following an increase in adiposity, and 
presumably in obesity, occurs as a direct consequence of an elevation in circulating 
levels of NEFAs. Rather, given the opposing actions of GH and insulin in sustaining 
NEFA exchange, it is proposed that impairments in GH secretion that accompany an 
increase in adiposity is a physiological adaptation that facilitates the homeostatic balance 
of circulating NEFAs. Given this, one would anticipate an inverse relationship between 
circulating levels of GH and the secretion of insulin.  
 
An inverse correlation between insulin and pulsatile GH secretion was reported in 
non-obese healthy humans (Clasey et al. 2001), whereas a study in rats revealed no 
significant correlation (De Schepper et al. 1998). The validity of measures in the rat was, 
however, limited by the use of small sample size. In this study, a significant inverse 
relationship between measures of GH secretion and circulating levels of insulin was 
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observed in mice. This relationship was strengthened by inclusion of high fat fed mice 
and demonstrates the opposing effect of dietary-induced weight gain on circulating levels 
of insulin and GH. Overeating (Brons, et al. 2009) and elevated GH levels (Barbour, et al. 
2005) impairs insulin signalling, contributing to insulin resistance. Collective observations 
suggest that the maintenance of GH/insulin balance throughout extended periods of 
excess calorie consumption provides a key physiological mechanism to cope with 
prolonged positive energy balance. Accordingly, it was found that the suppression of GH 
secretion following excess food consumption in humans ameliorates insulin resistance 
and sustains optimal meal tolerance (Cornford et al. 2012). Thus, the suppression of GH 
secretion during periods of excess food consumption appears to be a pivotal 
physiological adaptation to promote insulin-driven lipogenesis, thereby preventing 
hyperlipidaemia (Cornford et al. 2012).  
 
Given the proposed interaction between GH and insulin in sustaining meal 
tolerance (Cornford et al. 2011) one may speculate that insulin contributes to the 
suppression of GH secretion following weight gain and obesity. Within the hypothalamus, 
insulin may impact GH secretion indirectly by stimulating the production of somatostatin 
to inhibit GHRH-induced GH secretion (Sauter, et al. 1983). Involvement of the 
hypothalamus in the progressive decline of GH secretion relative to weight gain has, 
however, not been directly assessed. Moreover, human and animal studies provide 
compelling evidence to suggest that the hypothalamus may not be the principle site for 
altered GH secretion in obesity. Hypothalamic gene expression for GHRH and 
somatostatin does not change in DIO rats, regardless of pituitary insensitivity to GHRH 
(Cattaneo et al. 1996), while chronic GHRH treatment coupled with arginine (to suppress 
endogenous SRIF release) does not recover GH secretion in DIO patients (Ghigo et al. 
1993). Consequently, it seems that impairments of GH secretion in obesity occur 
independent of changes in hypothalamic control of GH secretion. Rather, suppressed GH 
secretion in obesity is thought to occur predominantly in response to systemic signals 
acting directly on somatotrophs. Insulin suppresses GH release from isolated 
somatotrophs (Luque and Kineman 2006; Melmed 1984; Melmed et al. 1985; Melmed 
and Slanina 1985) by acting on pituitary insulin receptors (Luque and Kineman 2006). 
These effects persist regardless of the development of systemic insulin resistance 
(Luque and Kineman 2006), confirming that somatotrophs remain insulin sensitive in 
obesity. In this context, it is likely that the progressive rise of insulin in response to 
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dietary-induced weight gain promotes the progressive suppression of GH secretion. 
Moreover, these effects are sustained via continual pituitary insulin responsiveness. 
 
Anecdotal evidence from T1DM patients further demonstrates the inverse 
relationship between endogenous GH secretion and insulin, wherein GH secretion is 
markedly elevated relative to a matched non-diabetic control population (Amiel et al. 
1984; Asplin et al. 1989; Hansen and Johansen 1970; Hayford et al. 1980). Moreover, 
intensive insulin treatment markedly reduces GH secretion in juvenile T1DM patients 
(Amiel et al. 1984). Of interest, the suppression of GH secretion following insulin 
treatment in T1DM patients might occur due to a change in circulating levels of IGF-1. 
Circulating measures of IGF-1 are reduced in T1DM patients (Amiel et al. 1984; Asplin et 
al. 1989) and recover following intensive insulin treatment (Amiel et al. 1984). 
Accordingly, insulin-induced IGF-1 may feedback to normalise GH secretion in these 
patients. It should be noted, however, that the assessment and accurate interpretation 
IGF-1 measures require careful consideration of the bioavailability of IGF1, and 
particularly the co-assessment of IGFBPs. To this extent, a major caveat of this chapter 
is the lack of data demonstrating interactions between pulsatile GH secretion and 
measures of free, bound, and tissue-specific IGF-1 expression and measures of 
circulating IGFBPs. It is of critical importance to address the role of IGF-1 as a key 
inhibitor of GH secretion following progressive weight gain and the consideration of 
potential direct and indirect interactions with insulin in future studies. 
 
Collectively, data confirm that weight gain (as adiposity) results in a progressive 
reduction in total GH secretion rate, pulsatile GH secretion rate, and the mass of GH 
secreted per secretory event/pulse in mice regardless of dietary intervention. Thus, it is 
unlikely that GH deficiency observed in obesity occurs due to obesity-associated 
endocrine dysfunction. Rather, the progressive suppression of GH secretion is observed 
alongside developing weight gain and hyperinsulinemia. Presumably, this subverts the 
opposing physiological roles of GH and insulin in modulating NEFA flux and glucose 
homeostasis, where the suppression of GH secretion relative to an elevation in insulin is 
an essential physiological adaptation to sustain NEFA and glucose balance. Additionally, 
given that acyl-ghrelin (one of the factors associated to food intake) stimulates the 
release of GH (Kojima et al. 1999), further investigations needs to address the 
association between acyl-ghrelin and GH. 
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Chapter 4 Effect of GOAT deletion on pulsatile release of growth hormone relative 
to adiposity (Experiments to address Aim 3) 
4.1 Brief introduction 
As discussed in Chapter 1, the release of GH from somatotrophs in the APG requires 
reciprocal stimulatory and inhibitory actions of GHRH- and SST-expressing neurons 
within the hypothalamus. This underlies the characteristic pulsatile pattern of GH 
secretion (Frohman et al. 1992). Although GHRH and SST are principal regulators of GH 
secretion, additional factors may influence the release of GH. As such, acyl-ghrelin was 
found to potently stimulate GH release (Kojima et al. 1999) through the GHS-R1a (Sun et 
al. 2004a), which is largely expressed in the hypothalamus and pituitary. 
 
Ghrelin is a gastrointestinal peptide hormone predominantly produced from the 
oxyntic glands of the gastric fundus (Kojima and Kangawa 2002). The post-translational 
octanoylation of Serine 3 is unique to the conversion from the inactive form of ghrelin 
(desacyl-ghrelin) to acyl-ghrelin (Gutierrez et al. 2008; Mohan and Unniappan 2013; 
Yang et al. 2008). While exogenous ghrelin-induced GH release is augmented by bolus 
administration and the synergistic response of GHRH (Arvat et al. 2000b; Arvat et al. 
2001; Hataya et al. 2001; Veldhuis et al. 2012), the acylation of ghrelin derives from the 
systemic circulation is essential to elicit biological and physiological functions on GHS-
R1a located in the ARC of hypothalamus to regulate GH release (Guan et al. 1997; 
Shuto, et al. 2002; Willesen et al. 1999; Wren, et al. 2000b), particularly stimulating the 
GHRH-expressing neurons while inhibiting SST-expressing neurons (Popovic et al. 
2003). Additionally, the binding of acyl-ghrelin to its receptors expressed on 
somatotrophs in the APG (Gnanapavan et al. 2002; Guan et al. 1997) stimulates the 
release of GH in humans (Hataya et al. 2001; Takaya et al. 2000) and animals (Malagon 
et al. 2003).  
 
Apart from its role in stimulating GH release, acyl-ghrelin is capable of increasing 
adiposity (Tschop et al. 2000). Given the negative association between adiposity and 
pulsatile GH secretion was demonstrated in the previous chapter, this implies a 
perplexed role of acyl-ghrelin in the regulation of GH release. For example, a single i.v. 
injection or a continuous 24 h acyl-ghrelin infusion induces acute GH release (Arvat et al. 
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2000b; Peino, et al. 2000) and increase pulsatile GH secretion (Veldhuis et al. 2008b), 
whereas chronic infusion with ghrelin agonists is associated with weight gain and 
increased fat mass (Strassburg, et al. 2008). Based on the premise that GH levels in 
mice declines with adiposity (as observed in Chapter 3), pulsatile GH secretion was 
assessed in germline goat-/- mice relative to adiposity-related factors. Therefore, this 
chapter aims to document the relationship between GH release and adiposity in the 
absence of endogenous acyl-ghrelin in mice. 
 
4.2 Experimental approach 
4.2.1 Animals 
To assess the relationship between measures of pulsatile GH secretion relative to 
adiposity in the absence of acyl-ghrelin, 16-week old WT and goat-/- male mice (WT, n=7; 
goat-/-, n=10) on C57Bl/6J background (Gutierrez et al. 2008). Mice were housed in 
groups of 2-3 in a 12 h light, 12 h dark cycle (lights on at 0630 h and off at 1830 h) as 
detailed in Section 2.1. 
 
4.2.2 Assessment of pulsatile GH secretion 
At 16 weeks of age, pulsatile GH secretion was assessed in ad lib fed mice on standard 
chow diet as described previously (Steyn et al. 2011). Briefly, whole blood from tail-tip 
was collected at 10-min intervals, commencing at 0700 h over a 6 h sampling period. 
Samples were collected between 0700 and 1250 h as detailed in Section 2.2.  
 
4.2.3 Assessment of adiposity and hormone analysis 
Mice were allowed 2-5 days to recover prior to tissue and blood collection as detailed in 
Section 2.3, with tissues processed as detailed throughout Chapter 2. Epigonadal fat 
pads were excised and weighed as a representative depot for total body adipose mass 
(Rogers and Webb 1980). Terminal cardiac blood samples were collected into EDTA 
tubes for single measurements of ad lib fed circulating levels of leptin, acyl-ghrelin and 
total ghrelin. Red blood cell content and plasma were immediately separated via 
centrifugation, and stored at −80 °C prior to batch analysis. Analysis of GH was 
performed using an in-house mouse GH ELISA as detailed in Section 2.5. The within- 
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and between-assay coefficients of variations for all commercial ELISA assays were < 
10% and < 5.5% for in-house GH ELISA. 
 
4.2.4 Data and statistical analysis 
The kinetics and secretory patterns of pulsatile GH release were determined by 
deconvolution analysis as described in Section 2.8. Approximate entropy (ApEn) analysis 
was determined as described previously (Veldhuis et al. 2001). Briefly, ApEn monitors 
the strength and complexity of interactions between feedback systems that drive pulsatile 
GH release, and thus represents a quantitative measure that defines the orderliness of 
serial GH measurements over time. ApEn values approaching 1 denote greater 
irregularity, and thus a loss in stability of feedback between pulse generators. To assess 
the relationship between measures of circulating levels of ghrelin relative to body weight, 
epigonadal fat mass and circulating levels of leptin or measures of pulsatile GH 
secretion, correlation analyses were performed by linear regression and spearman 
correlation coefficient. All measures (excluding deconvolution analysis) were performed 
using GraphPad Prism v6.0a. Data are presented as mean ± SEM. For all measures, p 
value < 0.05 denotes statistical significance. 
 
4.3 Results 
(Part of this section was reproduced from published observations – Xie et al. 2015) 
4.3.1 Deletion of Goat results in impaired peak pulsatile GH release and the 
derangement of pulse pattern 
Data confirms that deletion of Goat results in a loss of circulating levels of acyl-ghrelin 
(Table 4.1). Representative pulsatile GH secretion profiles are shown in Fig. 4.1 (left 
panels), indicating pituitary GH output for respective animals following deconvolution and 
ApEn analysis. Data confirmed the lack of acyl-ghrelin and identified a reduction in total 
and pulsatile GH secretion, MPP, basal GH secretion, and an increase in pulse number 
and ApEn in goat-/- mice (Fig. 4.1A) compared to WT mice (Fig. 4.1B). Output figures for 
corresponding pituitary GH release demonstrate distinct periods of spontaneous GH 
secretion (right panels; the onset of secretory events is defined by arrows). Measures for 
pulsatile GH secretion, following deconvolution analysis, in WT and goat-/- mice at 16 
weeks of age is summarised in Table 4.1. Total and pulsatile GH secretion, the mass of 
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GH secreted per burst (MPP), and basal GH secretion rate was lower in goat-/- mice 
when compared to age-matched WT mice. Interestingly, a rise in the number of GH 
secretory events (pulse number) and approximate entropy (increased irregularity) was 
observed in goat-/- mice. 
 
 
 
Figure 4.1 Representative examples of pulsatile growth hormone (GH) secretion 
from wild-type (WT) and goat-/- mice at 16 weeks of age. 
Circulating levels of whole blood GH were measured in 36 consecutive tail-tip blood 
samples (2 μl) collected at 10 min intervals, starting at 07 00 h. For WT (A) and goat-/- 
mice (B), the regular periodicity of pulsatile GH secretion was characterised by peak 
secretion periods dispersed by inter-pulse stable low baseline periods (left panels). 
Corresponding secretion rate of GH throughout the 6 h sampling period (right panels), as 
determined through deconvolution analysis. Open circles (x-axis, right) denote the onset 
of a GH secretory burst. 
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4.3.2 Deletion of Goat results in a modest increase in adiposity and circulating 
levels of leptin 
Measures for body weight, body length, epididymal fat weight and circulating levels of 
leptin in WT and goat-/- mice at 16 weeks of age are summarised in Table 4.1. Although 
body weight and body length were comparable between the genotypes, a modest 
elevation in epididymal fat weight and circulating levels of leptin were observed in goat-/- 
mice. 
 
Table 4.1 Parameters of pulsatile growth hormone (GH) secretion 
following deconvolution analysis, and measures of body weight, body 
length, epididymal fat weight and circulating levels of leptin between 
wild-type (WT) and goat-/- mice, and validation of the absence of 
circulating levels of acyl-ghrelin in goat-/- mice at 16 weeks of age.  
 
 
 
Regression plots of epididymal fat mass and circulating levels of leptin relative to body 
weight and epididymal fat mass are illustrated in Fig 4.2. As seen in WT mice, circulating 
p value
Total GH secretion rate (ng/ml/6 h) 0.02
Pulsatile GH secretion rate (ng/ml/6 h) 0.02
Mass of GH secreted/burst (MPP, ng/ml) <0.01
Basal GH secretion rate (ng/ml/6 h) 0.06
Number of pulses/6 h <0.01
Body weight (g) 0.78
Body length (cm) 0.02
Epididymal fat weight (g) 0.05
Leptin (ng/ml) 0.1
Acyl-ghrelin (pg/ml) <0.01
Total ghrelin (ng/ml) 0.56
WT goat-/-
337±65.2 190±21.6
386±75.7 209±23.7
49.5±14.6 18.8±4.52
108±17.7 46.9±6.97
3.14±0.27 4.74±0.38
34.1±1.51 33.6±1.46
1.13±0.26 1.49±0.12
9.76±0.17 9.32±0.14
133±12.7 0.00±0.00
15.0±5.10 21.6±2.91
For GH, samples were collected at 10-min intervals between 0700 h and 1300 h. 
Data are presented as mean ± SEM. P values <0.05 were accepted as significant. 
Measures for acyl- and total ghrelin were included for confirmation of phenotype 
of goat-/- mice.
1.55±0.23 1.75±0.21
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levels of leptin in goat-/- mice increased with body weight and epididymal fat weight. As 
previously documented in Chapter 3, a significant correlation is observed between 
circulating levels of leptin and epididymal fat mass regardless of genotype. This suggests 
that the positive association between ad-lib fed circulating levels of leptin and epididymal 
fat mass is not altered by the absence of acyl-ghrelin. 
 
 
 
 
Figure 4.2 Representative examples of linear regression analysis of body weight 
and epididymal fat mass relative to circulating levels of leptin in 16-week old WT 
and goat-/- mice. 
Linear regression of body weight (A) and epididymal fat mass (B) relative to circulating 
levels of leptin in WT (dotted line, open circles) and goat-/- (solid line, shaded circles) 
mice. Insets: r2 and p values as determined by linear regression. P < 0.05 was 
considered statistically significant; n=6-10 mice per group. Data specific to correlations 
following Spearman regression analyses for body weight and epididymal fat mass 
relative to circulating levels of leptin are summarised in Table 4.2. 
 
 
 
Table 4.2 Spearman correlation analysis of circulating levels 
of leptin with body weight and epididymal fat weight in WT 
and goat-/- mice (left columns), and between WT and goat-/- 
mice (right column). 
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WT goat-/- 
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4.3.3 Peak GH release declines with increased adiposity regardless of genotype 
Spearman correlation data for epididymal fat weight and circulating levels of leptin 
relative to all GH parameters are summarised in Table 4.3. Total and pulsatile GH 
release declined relative to epididymal fat mass and circulating levels of leptin in WT and 
goat-/- mice. For MPP of GH release and basal secretion rate, this inverse relationship did 
not reach significance regardless of genotype. The number of pulses for WT and goat-/- 
mice did not change relative to epididymal fat weight or circulating levels of leptin. As 
assessed by the slope of the regression analyses, no deviations of the rate of decline in 
all parameters of pulsatile GH secretion between goat-/- and WT mice were observed. 
This reflects a similarity in regression of pulsatile GH secretion with increased adiposity in 
both genotypes. 
 
 
Table 4.3 Spearman correlation analysis comparing epididymal fat weight and 
circulating levels of leptin with parameter of pulsatile GH secretion following 
deconvolution analysis in WT (n=6) and goat-/- (n=8) mice (left columns), and the 
deviation between WT and goat-/- mice (right column) at 16 weeks of age. 
 
 
 
 
4.4 Discussion 
Studies in humans and animals (Arvat, et al. 2000a; Date et al. 2002; Seoane et al. 2000; 
Wren et al. 2001a) demonstrate the synergistic actions of ghrelin and GHRH on GH 
release (Hataya et al. 2001; Popovic et al. 2003; Takaya et al. 2000), while ensuing 
observations from rats confirmed that ghrelin acts centrally and peripherally to amplify 
Epididymal fat weight (g) r p value r p value Slope p value
  Total GH secretion rate (ng/ml/6 h) -1.00 < 0.02 -0.93 < 0.02 -157±71.3 vs. -77.1±31.2 0.30
  Pulsatile GH secretion rate (ng/ml/6 h) -1.00 < 0.02 -0.93 < 0.02 -129±50.2 vs. -41.6±12.7 0.10
  Mass of GH secreted/burst (MPP, ng/ml) -0.80 0.13 -0.46 0.41  -19.9±13.2 vs. -13.3±5.30 0.63
  Basal GH secretion rate (ng/ml/6 h) -0.80 0.14 -0.43 0.56 -21.5±19.4 vs. -21.9±11.0 0.99
  Number of pulses/6 h -0.71 0.40 0.01 0.98 -0.48±0.55 vs. -0.62±1.90 0.64
Leptin (ng/ml) r p value r p value Slope p value
  Total GH secretion rate (ng/ml/6 h) -1.00 < 0.02 -0.89 < 0.02 -6.52±0.98 vs. -5.91±1.92 0.78
  Pulsatile GH secretion rate (ng/ml/6 h) -1.00 < 0.02 -0.94 < 0.02 -5.12±0.66 vs. -3.09±0.78 0.11
  Mass of GH secreted/burst (MPP, ng/ml) -0.80 0.13 -0.49 0.36 -0.99±0.15 vs. -0.51±0.55 0.38
  Basal GH secretion rate (ng/ml/6 h) -0.80 0.13 -0.50 0.38 -1.04±0.49 vs. -0.38±1.09 0.58
  Number of pulses/6 h -0.70 0.40 0.12 0.84 -0.02±0.02 vs. -0.03±0.14 0.94
Table 5.1 Spearman correlation analysis comparing epididymal fat weight and circulating levels of leptin with parameters 
of pulsatile GH secretion following deconvolution analysis in WT (n=6) and goat-/- (n=8) mice (left columns), and 
between WT and goat-/- mice (right column).
WT goat-/- WT vs. goat-/-
For GH, samples were collected at 10-min intervals between 0700 h and 1300 h. Differences between WT and goat-/- mice were 
defined by a significant deviation between the slope of epididymal fat or leptin associated changes in GH secretion parameters. P 
values <0.05 were accepted as significant.
  97 
peak GH secretion (Arvat et al. 2000a; Date et al. 2002; Seoane et al. 2000; Wren et al. 
2001a). While identifying multiple sites for ghrelin action, majority of these studies relied 
on exogenous ghrelin administration, whereas attempts to verify the endogenous actions 
of ghrelin on pulsatile GH release have been less successful. Assessment of GH release 
in the rat comprehensively demonstrated that pulsatile GH secretion is modestly affected 
relative to endogenous fluctuations in total ghrelin secretion (Tolle et al. 2002). However, 
this does not exclude the potential role of endogenous acyl-ghrelin in modulating peak 
GH release. Conflicting observations suggest a relationship (Koutkia et al. 2004; Nass, et 
al. 2014; Nass et al. 2008a) and no relationship between endogenous ghrelin release 
and the pulsatile appearance of GH in circulation under fed conditions (Avram et al. 
2005; Tolle et al. 2002). 
 
This chapter sought to provide evidence to corroborate that endogenous acyl-
ghrelin is a key mediator of pulsatile GH release by using a knockout mouse line deficient 
of acyl-ghrelin. Observations in this current study demonstrate a significant reduction in 
total and pulsatile GH secretion, and the mass of GH secreted per GH secretory event in 
goat-/- mice at 16 weeks of age. These observations are in accordance with one-off 
measures of GH secretion following genetic disruption of ghrelin signalling (Sun et al. 
2004a), and recapitulate pharmacological assessment of the role of acyl-ghrelin in 
promoting GH release. To the best of our knowledge, measures that assess the role of 
endogenous acyl-ghrelin in pulsatile GH release in mice do not exist. 
 
While recapitulating the role of ghrelin in regulating peak GH secretion, data also 
show an elevation in pulse numbers in goat-/- mice. This was unexpected given that most 
pharmacological studies in rodents only document changes in peak GH amplitude. In 
humans, continuous infusion of ghrelin resulted in an overall rise in peak GH amplitude, 
pulse numbers and the consequential derangement of pulse pattern (Broglio et al. 2008; 
Veldhuis et al. 2008b). Discordant observations between pharmacological measures may 
simply reflect functional differences between acyl- versus desacyl-ghrelin. Observations 
pose an interesting avenue for further investigation of the importance of acyl-ghrelin on 
the GH axis. Of interest, disruption of acyl-ghrelin signaling in rats (through antagonism 
of GHS-R1a) or in ghrelin knockout mice decreases GH peak amplitude but does not 
alter GH secretory pattern (Hassouna et al. 2014; Zizzari et al. 2005). Given that no other 
study has reported the pulsatile pattern of GH release following germline deletion of acyl-
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ghrelin, it is difficult to address the complexities. Alternatively, one may infer that should 
acyl-ghrelin mediate hypothalamic control of GH release, these effects are more likely to 
be established during a critical developmental period (Chanoine 2005; Tong and 
D'Alessio 2015). However, evidence presented here are insufficient to confirm the role of 
acyl-ghrelin in the generation of GH pulse patterning. 
 
As documented in Chapter 3, circulating levels of leptin are positively correlated 
with increased adiposity and weight gain is observed in WT mice. Studies also revealed a 
relationship between leptin and overall adiposity (Minocci, et al. 2000; Ramachandran, et 
al. 1997) as well as BMI (Monti, et al. 2006). In agreement with this, the association 
between circulating levels of leptin and epididymal fat mass is conserved in goat-/- mice. 
Given that leptin is associated with food intake (Kentish, et al. 2013), direct comparisons 
with animals on dietary interventions cannot be made as current observations were 
collected from normal chow ad-lib fed mice. As such, data is interpreted with the notion 
that steady-state leptin levels in circulation are predominantly a reflection of overall 
amount of adiposity rather than prandial status in these mice.  
 
Given that ghrelin induces adiposity and weight gain (as fat) (Tschop et al. 2000), 
it is surprising to observe modest increment in epididymal fat mass and circulating levels 
of leptin in goat-/- mice. Studies have also shown that ghrelin-deficient mice (Sato, et al. 
2008; Sun et al. 2003) as well as goat-/- mice (Kirchner, et al. 2013; Kouno et al. 2016b), 
do not contribute to changes in body weight when compared to WT mice. Additionally, 
the attenuation of ghrelin signalling prevents excessive weight gain (Asakawa et al. 
2003), and hinders the development of obesity in mice (Zigman, et al. 2005). These 
observations suggest that a progressive rise in overall adiposity may be coupled with a 
decline in parameters of pulsatile GH secretion independent of acyl-ghrelin. Alternatively, 
it is proposed that the disproportionate culmination of lean muscle mass and fat mass in 
the goat-/- mice may contribute to no significant change in body weight between the 
genotypes. Similar associations were demonstrated by correlation analyses between 
adiposity and parameters of GH secretion regardless of genotypes. Moreover, data show 
no deviations of the rate of decline in all parameters of pulsatile GH relative to epididymal 
fat weight or circulating levels of leptin were observed between the genotypes. Of 
interest, a reduction in acyl-ghrelin is relative to a decline in pulsatile GH secretion 
following dietary-induced weight gain (Castaneda et al. 2010). These observations 
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suggest that the markedly overall reduction in peak GH secretion in the goat-/- mice at 16 
weeks of age is predominantly contributed by the absence of acyl-ghrelin, alongside the 
modest rise in adiposity which exacerbates the decline in GH secretion. 
 
While studies across modified-ghrelin mouse models (Ariyasu and Akamizu 2015) 
suggest that the functionality of ghrelin is age-dependent (Al Massadi, et al. 2015), it is 
uncertain whether a change in the magnitude of the rate of decline in pulsatile GH 
secretion relative to age would occur in the absence of acyl-ghrelin, alongside a 
continued decline in pulsatile GH secretion with increased adiposity. Moreover, ghrelin 
deficiency is thought to protect mice from an age-associated (Lin, et al. 2011) increase in 
adiposity. Hence further investigations are needed to clarify the physiological relevance 
of endogenous role of ghrelin in modulating the GH axis relative to age. 
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Chapter 5 Effect of deletion of GOAT on growth hormone pulse patterning in mice 
regardless of age (Experiments to address Aims 4 & 5) 
(This chapter was reproduced from published observations – Xie et al. 2015) 
5.1 Brief introduction 
The release of GH from somatotrophs is governed by the reciprocal coordination 
between peripheral and hypothalamic networks. This results in the archetypal pulsatile 
pattern of GH secretion (Frohman et al. 1992), which is conserved across all species 
characterised to date. Although GHRH and SRIF are principal regulators of GH secretion, 
ghrelin is one of the essential stimuli that contribute to ultradian and circadian patterns of 
GH release. The peripheral and central actions of ghrelin are mediated by specific 
binding of the octanoylated form of ghrelin (acyl-ghrelin) to the GHS-R1a, following 
acetylation of desacyl-ghrelin by ghrelin-o-acyltransferase (GOAT) (Gutierrez et al. 2008; 
Yang et al. 2008). Functional deletion of the gene encoding Goat produces mice with 
negligible levels of acyl-ghrelin, whilst desacyl-ghrelin remains in circulation (Gutierrez et 
al. 2008). 
 
Pharmacological observations show that acyl-ghrelin regulates the release of GH 
by amplifying GHRH-induced GH secretion (Kojima et al. 1999). Although an increase in 
circulating levels of ghrelin in humans in the fed state is correlated with an overall rise in 
peak pulsatile GH secretion (Nass et al. 2008a), it is still not known whether acyl-ghrelin 
directly contributes to peak endogenous GH release, or ultradian and circadian GH 
patterning. Indeed, germline deletion of ghrelin or GHS-R1a in mice does not impair 
linear growth (Sun et al. 2003; Sun et al. 2004b), suggesting that loss of ghrelin signalling 
may not significantly compromise GH output or GH-mediated pubertal linear growth. 
While the loss of all preproghrelin-derived signalling through deletion of the Ghrl gene 
contributes to a reduction in peak GH release in young mice (Hassouna et al. 2014), 
selective contribution of acyl-ghrelin to pulsatile GH secretion remains to be established. 
Using mice with germline loss of Goat, this chapter will explore the impact of selective 
loss of acyl-ghrelin on GH release relative to age.  
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5.2 Experimental approach 
5.2.1 Animals 
Experiments were performed on 8- and 36-week old homozygous goat-/- mice (Gutierrez 
et al. 2008) (backcrossed to the WT C57Bl/6J background strain) and age-matched WT 
mice bred on the same background strain. Once weaned, animals were housed in groups 
of two or three per cage. 
 
5.2.2 Assessment of pulsatile GH secretion in goat-/- and WT mice 
Output measures for age-related changes in GH release (Huang et al. 2012) were 
assessed at 8 (WT, n=15; goat-/-, n=15) and 36 (WT, n=14; goat-/-, n=16) weeks of age. 
Mice were acclimated to handling and blood sample collection for 2 weeks prior to the 
assessment of GH release. To account for possible effects of handling stress, remaining 
whole blood samples not used for the assessment of GH levels were pooled and 
assayed for levels of corticosterone, thereby representing mean corticosterone levels 
during the first (0–2 h) and final 2 h (4–6 h) of the GH sampling period. For GH, 
measures were collected as described previously, strictly adhering to established 
guidelines (Steyn et al. 2011) (as detailed in Section 2.2). 
 
5.2.3 Sample collection 
Terminal blood and tissue samples were collected (as detailed in Chapter 2) from 
animals at 8 and 36 weeks of age. Subsequently, epigonadal fat pads were isolated 
immediately following death and weighed, and plasma levels of leptin determined as 
representative measures for overall adiposity (Rogers and Webb 1980). Whole brains 
were frozen on dry ice, and stored at −80 °C for future micro-dissection and analysis. 
Whole pituitary gland, the left lateral lobe of the liver and the gastrocnemius muscle of 
the left hind-limb were excised, rapidly frozen on dry ice and stored at −80 °C for batch 
analysis. Prior to hormone assays, pituitary glands, livers and muscle tissue were 
incubated in lysis buffer. Levels of IGF-1 in the liver and muscle were normalised to total 
protein content, while pituitary GH content was expressed relative to the whole gland.  
 
5.2.4 Hormone analysis 
Analysis for GH was performed using an in-house mouse GH ELISA (Steyn et al. 2011) 
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(as detailed in Section 2.5). Levels of circulating acyl-ghrelin, total ghrelin, leptin, total 
unbound IGF-1 and whole blood corticosterone levels were determined by commercial 
ELISA kits (see Table 2.1), in accordance with the manufacturer’s instructions. The 
within- and between-assay coefficients of variation for all commercial ELISA assays were 
< 10% and < 5.5% for the in-house GH ELISA. 
 
5.2.5 Real-time qPCR measurement of hypothalamic gene expression 
To determine the mRNA expression of Ghrh, Srif, Npy and Ghsr in the ARC/PeVN 
complex, brain tissue biopsies were collected using a micro-punch brain dissection 
method as detailed previously (Steyn et al. 2012). Frozen serial coronal brain sections 
were collected onto a slide, and biopsies collected (as detailed and illustrated in Section 
2.6, Fig. 2.1) using a 19 G dissection needle. Samples were suspended in 1 ml TRIzol. 
RNA was isolated and gene expression determined (as detailed in Section 2.7.1). 
Results were normalised to Gapdh. Final measures are reported as relative levels of 
normalised gene expression. 
 
5.2.6 Real-time qPCR measurement of liver gene expression 
To determine liver mRNA expression of GH/Stat5 dependent sexually dimorphic liver 
genes [Mup1, Cyp2d9, Cyp3a44, Cyp4a12 and Cyp7b1 (Clodfelter, et al. 2006; 
Holloway, et al. 2007; Holloway, et al. 2006; Sakuma, et al. 2002; Wauthier, et al. 2010; 
Zhang and Klaassen 2013)] (Table 2.2), the left lateral lobe of the liver of each mouse 
was processed as detailed in Section 2.7.2. Final measures are reported as relative 
levels of gene expression, normalised to -actin. 
 
5.2.7 Data and statistical analysis 
The kinetics and secretory patterns of pulsatile GH secretion were determined by 
deconvolution analysis using MATLAB (The MathWorks, Natick, MA, USA) (Steyn et al. 
2011; Steyn et al. 2012). The ApEn was determined as described previously (Veldhuis et 
al. 2001). ApEn monitors the strength and complexity of interactions between feedback 
systems that drive pulsatile GH release, and provides a quantitative measure of the 
orderliness of serial GH measurements over time. A higher absolute ApEn denotes 
greater irregularity, and thus a loss in stability of feedback. All measures (excluding 
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deconvolution analysis) were performed using PRISM, version 6.0f (GraphPad Software 
Inc., San Diego, CA, USA). To further assess patterned GH release, the proportion of 
samples that fell below the limit of detection for the GH assay for each secretion trace 
were defined as baseline (percentage of time below detection). Representative examples 
of patterned GH release from WT and goat-/- mice are provided in Fig. 5.5. This measure 
provides an added a proxy to differentiate between characteristic male and female GH 
secretion patterning (Adams, et al. 2015; Jansson et al. 1985; Norstedt and Palmiter 
1984; Sinha, et al. 1977; Waxman, et al. 1991). The mean duration of the baseline 
interval (Fig. 5.5A, ‘A’) and the mean duration of a secretory episode interval (Fig. 5.5A, 
‘B’) were calculated. For baseline and secretory episode intervals, duration was only 
considered when either period was flanked by a secretory episode (baseline periods) or 
baseline events (secretory episodes). Given that each secretory episode is characterised 
by numerous secretory events (as defined by deconvolution analysis), the number of 
secretory events was further calculated within each secretory episode. Based on these 
characteristics, two characteristic patterns of GH release were identified: biphasic GH 
secretion episodes (defined by characteristic biphasic secretory events during a single 
episode; Fig. 5.5A; left) and polyphasic secretory episodes (defined by ≥ 3 GH secretory 
events within a single secretory episode; Fig. 5.5A, right). Differences across age and 
genotypes were identified by two-way ANOVA, and between genotypes (within age) and 
age (within genotype) by multiple comparisons, using Bonferroni post-hoc analysis. 
Relationships between parameters for GH release and circulating levels of IGF-1 in WT 
and goat-/- mice were assessed by linear regression. P < 0.05 was considered statistically 
significant. 
 
5.3 Results 
5.3.1 Impaired peak pulsatile GH release in young goat-/- mice 
As observed in mice, GH release decreases between 8 and 16 weeks of age (Huang et 
al. 2012; Tan et al. 2013), while in humans (Hersch and Merriam 2008), a reduction in 
acyl-ghrelin is thought to contribute to the decline in GH release with advanced age 
(Nass et al. 2014). To determine whether germline loss of Goat will reverse age-
associated decline in GH pulsatility, GH release from WT and goat-/- mice was assessed 
at 8 and 36 weeks of age. 
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Representative pulsatile GH secretion profiles (left) and pituitary GH output (right) 
from WT and goat-/- mice at 8 and 36 weeks of age, respectively are shown in Fig. 5.1A 
and B. Assessment by two-way ANOVA revealed a decrease in total (Age, p < 0.001, F = 
27.82; Genotype, p = 0.003, F = 9.762; Interaction, p = 0.013, F = 6.594) (Fig. 5.2A) and 
pulsatile GH secretion (Age, p < 0.001, F = 25.06; Genotype, p = 0.003, F = 9.399; 
Interaction, p = 0.015, F = 6.246) (Fig. 5.2B), and the mass of GH secreted per burst 
(MPP; Age, p < 0.001, F = 19.51; Genotype, p < 0.001, F = 13.48; Interaction, p = 0.014, 
F = 6.430) (Fig. 5.2C) relative to age and genotype, whereas basal GH secretion (Age, p 
= 0.004, F = 9.321; Genotype, p = 0.143, F = 2.211; Interaction, p = 0.157, F = 2.053) 
(Fig. 5.2D) decreased relative to age only. 
 
Multiple comparison analysis relative to genotype revealed a decrease in total (p < 
0.001), pulsatile (p < 0.001) and MPP (p < 0.001) GH release in goat-/- mice, relative to 
WT mice at 8 weeks of age. Basal GH release decreased; however, this did not reach 
statistical significance (p = 0.0867). Total (p > 0.999), pulsatile (p > 0.999), MPP (p = 
0.851) and basal (p > 0.999) GH release did not differ between goat-/- and WT mice at 36 
weeks of age. An age-associated decrease was observed in total (p < 0.001), pulsatile (p 
< 0.001), MPP (p < 0.001) and basal (p = 0.006) GH release in WT mice. Given low 
levels of GH release at 8 weeks of age, the age associated decrease in GH release was 
greatly diminished in goat-/- mice, and did not reach statistical significance: total (p = 
0.113), pulsatile (p = 0.159), MPP (p = 0.363) and basal (p = 0.498). Collectively, 
observations suggest that acyl-ghrelin plays a critical role in the amount of GH released 
in young adult mice. 
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Figure 5.1 Representative examples (left panels) of pulsatile growth hormone (GH) 
secretion from wild-type (WT) and goat-/- mice at 8 (A) and 36 (B) weeks of age. 
Circulating levels of whole blood GH were measured in 36 consecutive tail-tip blood 
samples (2 μl) collected at 10 min intervals, starting at 07 00 h. For WT (top) and goat-/- 
mice (bottom), the regular periodicity of pulsatile GH secretion was characterised by peak 
secretion periods dispersed by inter-pulse stable low baseline periods. Corresponding 
secretion rate of GH throughout the 6 h sampling period (right), as determined through 
deconvolution analysis. Open circles (x-axis, right) denote the onset of a GH secretory 
burst. 
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Figure 5.2 Altered pulsatile growth hormone (GH) secretion in goat-/- mice at 8 and 
36 weeks of age. 
Total GH secretion (A), pulsatile GH secretion (B), the mass of GH secreted per burst 
(MPP) (C) and basal GH secretion (D), number of pulses (E) and approximate entropy 
(ApEn, where ApEn values approaching 1 denote greater irregularity) (F). Data are 
presented as mean ± SEM. Differences between genotypes and across ages were 
identified by 2-way ANOVA (p values for interaction, age and genotype are presented in 
the Results section 5.3.1 and 5.3.2). Differences between ages (within genotype) and 
between genotypes (within ages) were determined by multiple comparisons analysis with 
Bonferroni post-hoc analysis. P < 0.05 was considered statistically significant; n=7-16 
mice per group. *Significance between genotypes, within age; #Significance between 
ages, within genotype as determined by multiple comparisons test. 
 
 
 
5.3.2 Derangements in GH pulse pattern in goat-/- mice occur regardless of age 
A derangement in GH pulse patterning was observed in goat-/- mice. Assessment by 2-
way ANOVA revealed an interaction for pulse number (p < 0.001, F = 18.79) (Fig. 5.2E) 
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and for ApEn (p = 0.002, F = 10.42) (Fig. 5.2F) specific to genotype. Pulse number (p = 
0.166, F = 1.973; Interaction, p = 0.602, F = 0.275) (Fig. 5.2E) and ApEn (p = 0.558, F = 
0.348; Interaction, p = 0.579, F = 0.312) (Fig. 5.2F) did not change relative to age. 
Multiple comparison analysis relative to genotype at 8 and 36 weeks of age revealed an 
increase in pulse number in goat-/- mice at 8 (p = 0.018) and 36 weeks (p = 0.002) of age 
compared to WT mice. Relative to genotype, data shows greater irregularity of GH pulses 
(ApEn) in goat-/- mice at 8 (p = 0.019) weeks of age. The increase in ApEn in goat-/- 
compared to WT mice at 36 weeks of age did not reach statistical significance (p = 
0.129). The change in pulse dynamics was also seen in 16-week old goat-/- mice (Table 
5.1), confirming that germline loss of Goat alters the pattern of GH release regardless of 
age. Multiple comparison analysis excluded an effect of age on pulse number (p = 0.370, 
WT; p > 0.999, goat-/- mice) and ApEn (p > 0.999, WT; p > 0.825, goat-/- mice). 
 
5.3.3 Reduced GH release in goat-/- mice occurs alongside a loss in circulating 
levels of acyl-ghrelin and increased total ghrelin 
Circulating levels of acyl-ghrelin in goat-/- mice were undetectable at 8 and 36 weeks of 
age (Fig. 5.3A). Total ghrelin was increased in goat-/- mice relative to WT mice 
(Genotype, p < 0.001, F = 20.93) (Fig. 5.3B) regardless of age. The increase in total 
ghrelin levels in goat-/- mice presumably occurred because of an increase in levels of 
desacyl-ghrelin (36). Acyl- (p = 0.670, F = 0.184) (Fig. 5.3A) and total ghrelin (p = 0.093, 
F = 2.938) (Fig. 5.3B) levels did not change relative to age for WT mice, suggesting that 
the age-associated reduction in GH secretion in WT mice does not occur as a 
consequence of altered ghrelin release. 
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Figure 5.3 Circulating levels of acyl-ghrelin (A), total ghrelin (B), epigonadal fat 
mass (C) and leptin levels (D) in goat-/- mice at 8 and 36 weeks of age compared to 
age-matched wild-type (WT) mice. 
Data are presented as mean ± SEM. Differences between genotypes and across ages 
were identified by 2-way ANOVA with multiple comparisons (P values for interactions are 
presented in the Results section 5.3.4). Differences between ages (within genotype) and 
between genotypes (within ages) were determined by multiple comparisons analysis with 
Bonferroni post-hoc analysis. P < 0.05 was considered statistically significant; n=7-16 
mice per group. *Significance between genotypes, within age; #Significance between 
ages, within genotype as determined by multiple comparisons test. N.D., not detected. 
 
 
5.3.4 Reduced GH release in goat-/- mice does not occur in response to increased 
fat mass 
Adiposity strongly predicts peak GH release in humans (Vahl et al. 1997) and mice 
(Berryman et al. 2004), and measures of pulsatile GH release decrease relative to 
epigonadal fat mass and circulating levels of leptin [an indicator of total adiposity (Maffei 
et al. 1995a)] in mice (Steyn, et al. 2013). To determine whether reduced GH output in 
goat-/- mice occurs due to increased adiposity, epigonadal fat mass and circulating levels 
of leptin were compared between WT and goat-/- mice at 8 and 36 weeks of age. 
Epigonadal fat mass (Fig. 5.3C) did not differ between genotypes (p = 0.507, F = 0.448) 
at either age. The overall decline in GH release in WT and goat-/- mice with age (Fig. 
5.2A–D) occurred alongside an increase in epigonadal fat mass (p < 0.001, F = 243.7; 
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Interaction, p = 0.054, F = 3.956) (Fig. 5.3C) and circulating levels of leptin (P < 0.001, F 
= 255.4; Interaction, p = 0.458, F = 0.559) (Fig. 5.3D) in both genotypes. 
 
Spearman correlation data for epididymal fat weight and circulating levels of leptin 
relative to all GH parameters are summarised in Table 5.1. Total, pulsatile and MPP of 
GH release declined relative to epididymal fat mass and circulating levels of leptin, 
regardless of genotype. For basal secretion rate, this inverse relationship only reached 
significance for epididymal fat weight and circulating levels of leptin in WT mice. The 
number of pulses and approximate entropy for WT and goat-/- mice did not change 
relative to epididymal fat weight or circulating levels of leptin. The rate of decline in all 
parameters of pulsatile GH secretion (other than pulse number or approximate entropy) 
in goat-/- mice deviated significantly from WT mice. This deviation most likely reflects the 
reduced magnitude of change in pulsatile GH secretion seen relative to age, coupled with 
a continued decline in pulsatile GH secretion with increased adiposity. 
 
Table 5.1 Spearman correlation analysis comparing epididymal fat weight and 
circulating levels of leptin with parameters of pulsatile GH secretion following 
deconvolution analysis in WT and goat-/- mice (left columns), and between WT and 
goat-/- mice (right column) at 8 and 36 weeks of age. 
 
 
Epididymal fat weight (g) r p value r p value Slope p value
  Total GH secretion rate (ng/ml/6 h) -0.82 < 0.01 -0.49 < 0.01 -239±59.9 vs. -95.3±31.1 0.02
  Pulsatile GH secretion rate (ng/ml/6 h) -0.82 < 0.01 -0.41 0.01 -178±40.9 vs. -84.3±29.1 0.05
  Mass of GH secreted/burst (MPP, ng/ml) -0.73 < 0.01 -0.30 0.07 -63.6±23.0 vs. -13.9±8.39 0.02
  Basal GH secretion rate (ng/ml/6 h) -0.83 < 0.01 -0.17 0.31 -61.0±21.2 vs. -11.0±6.40 < 0.01
  Number of pulses/6 h 0.04 0.88 -0.23 0.18 -0.18±0.35 vs. -0.42±0.46 0.70
  Approximate entropy (1,0.35) 0.15 0.54 -0.24 0.15 0.02±0.06 vs. -0.09±0.06 0.22
Leptin (ng/ml) r p value r p value Slope p value
  Total GH secretion rate (ng/ml/6 h) -0.85 < 0.01 -0.6 < 0.01 -12.2±2.54 vs. -4.25±1.06 < 0.01
  Pulsatile GH secretion rate (ng/ml/6 h) -0.85 < 0.01 -0.49 < 0.01 -9.16±1.73 vs. -3.72±1.02 < 0.01
  Mass of GH secreted/burst (MPP, ng/ml) -0.755 < 0.01 -0.45 < 0.01 -3.19±0.97 vs. -0.78±0.26 < 0.01
  Basal GH secretion rate (ng/ml/6 h) -0.66 < 0.01 -0.27 0.09 -3.03±0.90 vs. -0.52±0.23 < 0.01
  Number of pulses/6 h -0.06 0.77 -0.02 0.92 -0.01±0.02 vs. -0.00±0.02 0.61
  Approximate entropy (1,0.35) 0.11 0.59 -0.07 0.69 0.00±0.00 vs. -0.00±0.00 0.62
Table 5.1 Spearman correlation analysis comparing epididymal fat weight and circulating levels of lep in with parameters 
of pulsatile GH secretion following deconvolution analysis in WT (n=18-25) and goat-/- (n=36-39) mice (left columns), and 
between WT and goat-/- mice (right column).
WT goat-/- WT vs. goat-/-
For GH, samples were collected at 10-min intervals between 0700 h and 1300 h. Differences between WT and goat-/- mice were 
defined by a significant deviation between the slope of epididymal fat or leptin associated changes in GH secretion parameters. P 
values <0.05 were accepted as significant.
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5.3.5 Goat-/- mice do not have altered hypothalamic Srif, Ghrh, Npy or Ghsr mRNA 
expression, or altered pituitary GH content 
Derangements in GH pulse patterning in goat-/- mice compared to WT mice suggest that 
germline loss of Goat may modify hypothalamic interactions between SRIF and GHRH 
and the pituitary gland. To address this, hypothalamic Ghrh and Srif (somatotropin 
release inhibiting factor) gene expression and pituitary GH content from age-matched WT 
and goat-/- mice were assessed, as well as extending the assessment to include Npy 
mRNA expression because NPY-expressing neurones may facilitate pulsatile GH release 
(Steyn 2015) and modulate GH pulse patterning relative to food provision in the mouse 
(Huang et al. 2014). The assessment of Ghsr gene expression was also included to 
examine whether loss of acyl-ghrelin impacts the expression of ghrelin receptors. Gene 
expression of Ghrh (p = 0.401, F = 0.732) (Fig. 5.4A), Srif (p = 0.735, F = 0.117) (Fig. 
5.4B), Npy (p = 0.187, F = 0.185) (Fig. 5.4C) and Ghsr (p = 0.798, F = 0.067) (Fig. 5.4D) 
in the ARC/PeVN complex of goat-/- mice was similar to that documented in WT mice at 8 
or 36 weeks of age. Although hypothalamic Ghsr expression increased with age (p < 
0.001, F = 23.09; Interaction, p = 0.867, F = 0.029), the abundance of relative Ghrh (p = 
0.053, F = 4.154; Interaction, p = 0.861, F = 0.031), Srif (p = 0.627, F = 0.243; 
Interaction, p = 0.678, F = 0.177) and Npy (p = 0.308, F = 1.088; Interaction, p = 0.500, F 
= 0.468) mRNA expression within genotypes remained constant relative to age. 
Additionally, no change was observed in pituitary GH content (Fig. 5.4E) between 
genotypes or across age (Age, p = 0.346, F = 0.913; Genotype, p = 0.701, F = 0.150; 
Interaction, p = 0.542, F = 0.380). 
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Figure 5.4 Hypothalamic Ghrh, Srif, Npy and Ghsr mRNA expression, and growth 
hormone (GH) content in whole pituitary glands from goat-/- mice at 8 and 36 weeks 
of age compared to age-matched wild-type (WT) mice. 
Hypothalamic tissue containing the ARC and PeVN were collected from 300 μm thick 
frozen brain sections. Brain sections used for tissue collection were illustrated in Fig. 2.1. 
Ghrh (A), Srif (B), Npy (C) and Ghsr (D) mRNA expression was normalised to Gapdh 
mRNA expression. Pituitary GH content was expressed relative to the entire gland (E). 
Data are presented as mean ± SEM. Differences between genotypes and across ages 
were identified by 2-way ANOVA with multiple comparisons. Differences between ages 
(within genotype) and between genotypes (within ages) were determined by multiple 
comparisons analysis with Bonferroni post-hoc analysis. P < 0.05 was considered 
statistically significant; n=6 mice per group for hypothalamic gene expression and n=8-15 
mice per group for pituitary GH content; #Significance between ages, within genotype as 
determined by multiple comparisons test. 
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5.3.6 Derangement of GH secretion patterning in goat-/- mice is characterised by an 
increase in GH secretory events but is not associated with changes in sex-specific 
liver gene expression 
Analysis of GH release was extended to determine whether loss of Goat feminised GH 
secretion patterning. To discount possible age-associated effects of altered amounts of 
GH release, assessment was limited to measures collected at 36 weeks of age. 
Compared to WT mice, data show an increase in the occurrence of polyphasic GH 
secretory episodes in goat-/- mice (Fig. 5.5B). The percentage of samples below assay 
detection appeared more variable in goat-/- mice compared to WT mice (Fig. 5.5C). This 
was accompanied by a significant decrease in the mean duration of baseline GH release 
interval (Fig. 5.5D), a rise in the mean duration of a secretory episode interval (Fig. 5.5E) 
and a rise in the number of GH secretory events (pulses) during a single secretory 
episode (Fig. 5.5F). Collectively, such observations suggest that germline loss of Goat 
contributes to a significant derangement in GH secretion patterning, resulting in an 
extension in the mean duration of secretory episodes and a rise in the number of events 
(pulses) during each episode. Impairments in regulators of GH release results in the 
derangement of GH pulse patterning. For example, germline loss of SRIF signalling in 
mice results in feminised GH secretion patterning and a feminised liver gene expression 
profile (Low et al. 2001).  
 
To test the premise that a change in GH pulse patterning in goat-/- mice may 
contribute to a similar shift in GH-dependent liver function, a subset of liver genes 
expression that are sexually dimorphic and predominantly regulated by GH/Stat5b 
signalling was assessed. Gene targets were isolated to the P450 gene family (including 
Cyp2d9, Cyp3a44, Cyp4a12b, Cyp7b1) and Mup1, a member of the major urinary gene 
family (Clodfelter et al. 2006; Holloway et al. 2007; Holloway et al. 2006; Sakuma et al. 
2002; Wauthier et al. 2010; Zhang and Klaassen 2013). Gene expression was 
comparable between genotypes (Fig. 5.6A), suggesting that a derangement in GH 
secretion patterning was not sufficient to feminise liver gene expression of male goat-/-
mice. 
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5.3.7 Derangements in GH pulse pattern in goat-/- mice occur in the absence of a 
significant change in circulating levels of corticosteroids 
The effects of stress on GH secretion and patterning are well documented. For example, 
stress suppress the secretion of GH in the male rat (Terry, et al. 1976). To confirm that 
altered GH release patterning between WT and goat-/- mice does not occur in response to 
altered stress responses during handling, the amount of whole blood corticosterone 
levels was determined during the same period that pulsatile GH release was assessed. 
Handling during the assessment period contributed to a rise in corticosteroid levels in 
both WT (P = 0.003) and goat-/- (p = 0.003) mice (Fig. 5.6B). Measures are well within the 
physiological range of natural diurnal variations of corticosterone release, and within a 
similar range that is seen during automated blood collection in mice (Adams et al. 2015). 
Therefore, the potential role for a rise in corticosterone levels in modifying GH pulse 
patterning in the goat-/- mice was excluded. 
 
5.3.8 Derangements in GH pulse frequency in goat-/- mice occur alongside 
increased circulating levels of IGF-1 
GH deficiency results in reduced pubertal linear growth (Gahlot, et al. 2012). Given 
reduced peak and total GH secretion in 8-week old goat-/- mice, it was anticipated that 
goat-/- mice would be shorter compared to age-matched WT mice. However, body weight 
(p = 0.910, F = 0.013) (Fig. 5.7A) and length (p = 0.594, F = 0.288) (Fig. 5.7B) were 
comparable between WT and goat-/- mice at 8 and 36 weeks of age. Body weight (p < 
0.001, F = 164.7; Interaction, p = 0.901, F = 0.016) and body length (p < 0.001, F = 
32.05; Interaction, p = 0.052, F = 4.001) increased similarly with age in WT and goat-/- 
mice. Linear growth is regulated by combined actions of GH and IGF-1 (45). 
Subsequently, circulating levels of total IGF-1 and liver and muscle IGF-1 content were 
assessed. Compared to WT mice, goat-/- mice had significantly higher levels of circulating 
total IGF-1 regardless of age (p < 0.001, F = 25.74) (Fig. 5.7C), whereas liver IGF-1 
content was elevated in goat-/- mice at 8 weeks of age (p = 0.044) (Fig. 5.7D). Circulating 
levels of total IGF-1 increased with age in goat-/- (p = 0.0531) and WT mice (p = 0.121); 
this did not reach statistical significance. Muscle-specific IGF-1 levels were comparable 
between WT and goat-/- mice (p = 0.454, F = 0.571; Interaction, p = 0.072, F = 3.415) and 
decreased with age in goat-/- (p = < 0.001) and WT mice (p = < 0.001) (Fig. 5.7E). The 
relationship between GH secretion and circulating levels of IGF-1 was assessed to 
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determine whether altered GH pulse frequency in goat-/- mice contribute to altered 
production of IGF-1 from the liver. Analysis was conducted in animals at 36 weeks of age 
as the amount of GH released in WT and goat-/- mice at this age was similar, thus 
excluding a potential effect of the amount of GH released on circulating IGF-1 levels.  
 
 
 
Figure 5.5 Assessment of baseline secretion patterning in 36-week old wild-type 
(WT) and goat-/- mice 
Representative examples of growth hormone (GH) pulse patterning in goat-/- (right) and 
WT mice (A). Compared to biphasic secretory events observed during a single secretory 
episode (left), germline deletion of Goat resulted in a GH pulse patterning representative 
of polyphasic secretory episodes (right). Baseline secretion periods were defined by 
measures of GH release that fell below the level of detection of the GH ELISA (red arrow; 
‘A’). Secretory episodes (blue arrows; ‘B’) are comprised of multiple GH secretion events 
(indicated by an asterisk). The frequency of appearance of biphasic and polyphasic GH 
secretory episodes increased in goat-/- mice compared to WT mice (B). (C–F) Although 
the time of baseline events (defined as measures below detection of GH) did not change 
between WT and goat-/- mice (C), a significant reduction in the mean duration of baseline 
interval (D), a decline in the mean duration of a secretory episode interval (E), as well as 
a rise in the number of GH secretion events (pulses) during a single secretory episode 
(F) were observed. For (C) to (F), differences between genotypes were defined by 
unpaired t-tests. P < 0.05 was considered statistically significant; n ≤ 6 mice per group. 
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Figure 5.6 Assessment of liver gene expression and circulating levels of 
corticosterone in 36-week old wild-type (WT) and goat-/- mice 
Altered GH patterning did not cause the feminisation of liver gene expression (A). 
Assessment of GH patterning was associated with a modest rise in circulating levels of 
corticosterone (in both WT and goat-/- mice) (B); however, corticosterone levels were 
comparable between genotypes. For (A) differences between genotypes were defined by 
unpaired t-tests. For liver mRNA, expression in goat-/- mice are presented relative to age-
matched WT mice. For (H), differences between genotypes and time were identified by 2-
way ANOVA with multiple comparisons. Data are presented as mean ± SEM. P < 0.05 
was considered statistically significant; n ≤ 6 mice per group. *Significance within 
genotype over time as determined by multiple comparisons test. 
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Figure 5.7 Body weight, body length, plasma insulin-like growth factor (IGF) 1 
levels, liver-specific IGF-1 and muscle-specific IGF-1 in goat-/- mice at 8 and 36 
weeks of age. 
Body weight (A), body length (B), plasma IGF-1 levels (C), liver-specific IGF-1 (D) and 
muscle-specific IGF-1 in goat-/- mice (shaded bars) and WT mice (white bars) at 8 and 36 
weeks of age. Levels of IGF-1 in the liver and muscle were normalised to total protein 
content. Data are reported as mean ± SEM. Differences between genotypes and across 
ages were identified by 2-way ANOVA with multiple comparisons. Differences between 
ages (within genotype) and between genotypes (within ages) were determined by 
multiple comparisons with Bonferroni post-hoc analysis. P < 0.05 was considered 
statistically significant; n=7-16 mice per group. *Significance between genotypes, within 
age. #Significance between ages, within genotype as determined by multiple 
comparisons test. 
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Figure 5.8 Representative example of linear regression analysis of measures of 
pusaltile GH secretion relative to insulin-like growth factor 1 (IGF-1) in 36-week old 
goat-/- mice and wild-type (WT) mice.  
Regression analysis of total growth hormone (GH) secretion (A), pulsatile GH secretion 
(B), the mass of GH secreted per burst (MPP; C), basal GH secretion (D), number of 
pulses (E) and approximate entropy (ApEn; F) relative to insulin-like growth factor 1 (IGF-
1) in goat-/- (dotted line; shaded circles) and WT mice (solid line; open circles). Insets: r2 
and p values as determined by linear regression. P < 0.05 was considered statistically 
significant; n=15-16 mice per group. 
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(Fig. 5.8B) and circulating IGF-1 levels in goat-/- mice, whereas data demonstrate an 
inverse relationship between IGF-1 and MPP (Fig. 5.8C). Compared to WT mice, the 
decline in MPP relative to an increase in IGF-1 levels was diminished, as illustrated by a 
lower r2 value. Circulating IGF-1 and basal GH secretion was not related in WT or goat-/- 
mice (Fig. 5.8D). Of interest, the number (Fig. 5.8E) and pattern (ApEn) (Fig. 5.8F) of GH 
secretory events (as assessed by deconvolution analysis) in goat-/- mice were positively 
correlated with circulating IGF-1, whereas the number (Fig. 5.8E) and pattern (Fig. 5.8F) 
of GH secretory events in WT mice were not correlated with circulating levels of IGF-1. 
 
 
5.4 Discussion 
In line with Chapter 4, the present study demonstrates that loss of endogenous acyl-
ghrelin through germline deletion of Goat contributes to a reduction in peak and total GH 
release in male mice. This is consistent with previous observations showing that loss of 
all preproghrelin-derived peptides, including acyl-ghrelin, desacyl-ghrelin and obestatin, 
is also associated with a reduction in peak GH secretion (Hassouna et al. 2014). In 
addition, the present data highlight a potential novel role for endogenous acyl-ghrelin in 
establishing the frequency and patterning of pulsatile GH release. The overall reduction 
in total, pulsatile, MPP and basal GH release demonstrated that germline loss of Goat 
predominantly impacts the amount of GH released in young goat-/- mice when compared 
to WT mice. Although the amount of GH release declines with age, the magnitude of 
change is greatly diminished given the low levels of GH within these animals at 8 weeks 
of age in goat-/- mice. As acyl-ghrelin levels in WT mice remain similar between 8 and 36 
weeks of age, and increase only by 22 months of age in mice (Lin, et al. 2014a), it is 
unlikely that a reduction in circulating levels of acyl-ghrelin will contribute to the observed 
age-associated decline in GH release in adult 36-week old WT mice. In humans, reduced 
levels of GH in old age (62–74 years old) are associated with a reduction in endogenous 
acyl-ghrelin and dissociation between ghrelin and GH secretion (Nass et al. 2014). 
 
As occurs with age, a progressive decline in the amount of GH secreted is closely 
coupled with a progressive rise in adiposity and circulating levels of leptin (Clasey et al. 
2001; Steyn et al. 2013; Vahl et al. 1997; Veldhuis et al. 2009). Although a modest 
elevation in circulating levels of leptin was observed in 36-week old goat-/- mice compared 
to age-matched WT mice, epigonadal fat mass and circulating levels of leptin did not 
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differ between genotypes. It is thus unlikely that reduced GH secretion in young adult 
goat-/- mice occurred due to an increased fat mass, and therefore feedback mechanisms 
associated with increased adiposity. Although the finding that adiposity is comparable 
between WT and goat-/- mice agrees with some observations (Kirchner et al. 2013), 
ghrelin deficiency is considered to protect mice from an age-associated (Lin et al. 2011) 
and dietary-induced (Wortley et al. 2005) increase in adiposity. This is corroborated by 
current observations, wherein the increase in epigonadal fat mass in goat-/- mice relative 
to age is somewhat diminished compared to WT mice. This observation must be 
interpreted cautiously as this study did not account for total adiposity or other adipose 
depots. 
 
The elevation in GH pulse number and derangement of pulse pattern (represented 
by an increase in ApEn) in goat-/- mice suggest that acyl-ghrelin is a significant regulator 
of GH secretion patterning, and repeats prior observations that establish a role for ghrelin 
in GH pulse patterning (Klover and Hennighausen 2007). Indeed, an increase in 
secretion episode duration and a decrease in the mean duration of baseline intervals 
were coupled with an increase in the number of secretory events during each secretory 
episode. Collectively, observations suggest that germline loss of acyl-ghrelin may distort 
interactions between hypothalamic GH pulse generators. Because the derangement in 
pulse patterning exists regardless of age, it is plausible that acyl-ghrelin contributes to the 
establishment of hypothalamic interactions facilitating GH output during key 
developmental stages, or throughout adulthood. This is of particular interest, given that 
most pharmacological studies in rodents document changes solely in peak GH release 
(Kojima et al. 1999; Seoane et al. 2000). 
 
A progressive change in GH pulse pattern between 4 and 16 weeks of age was 
previously documented in C57Bl/6J mice. In this study, pubertal maturation was coupled 
with the establishment of regular secretory events associated with a significant reduction 
in pulse number between 4 and 8 weeks of age (Tan et al. 2013). Although only 
investigated GH secretion in early-adult mice, increased secretory events and irregularity 
in goat-/- mice suggest that acyl-ghrelin may aid the transition from pubertal GH patterning 
to GH patterning characteristic of adulthood. The disruption of acyl-ghrelin signalling in 
adult male rats (through antagonism of GHS-R1a) decreases the amplitude of GH 
release but does not impair the pulsatile pattern of GH secretion (Zizzari et al. 2005), 
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confirming that loss of acyl-ghrelin signalling specific to adulthood does not impact GH 
patterning. 
 
Neuronal projections within the mouse hypothalamus are established during the 
first 3 weeks following birth (Bouret 2010). In mice, acyl-ghrelin stimulates synaptic 
network formation at a higher rate during postnatal development in vitro (Stoyanova and 
le Feber 2014) and the release of GH as early as the first week of postnatal life (Pinilla, et 
al. 2003). Therefore, GH secretory dynamics may stem from early postnatal 
developmental changes in hypothalamic integration. Indeed, acyl-ghrelin may facilitate 
the maturation of hypothalamic components of the GH axis, as has been proposed for 
mechanisms of feeding and energy homeostasis (Steculorum and Bouret 2011). 
Assessment of hypothalamic Ghrh, Srif, Npy and Ghsr mRNA expression in the 
ARC/PeVN complex revealed comparable levels between WT and goat-/- mice at 8 and 
36 weeks of age. In addition, this study confirmed similar levels of pituitary GH content in 
goat-/- mice relative to WT mice. Collectively, observations suggest that the loss of acyl-
ghrelin may not impact the presence of hypothalamic components of the GH axis that are 
essential to modulate pulsatile GH release (Steyn 2015) and that reduced peak GH 
release in goat-/- mice does not occur because of pituitary GH deficiency. Steady-state 
assessment of Ghrh, Srif, Npy and Ghsr mRNA does not provide a comprehensive 
account of hypothalamic control of GH release, and thus current measures cannot 
accurately define interactions between these components that may account for altered 
GH pulse patterning. However, the robust change in GH secretory pattern observed in 
goat-/- mice suggests that the loss of germline acyl-ghrelin alters interactions between 
these primary hypothalamic components of the GH axis. Future studies that define 
hypothalamic interactions between GHRH- and SRIF-expressing neurons in goat-/- 
animals are needed to confirm this hypothesis. 
 
As in rats (Jansson et al. 1985) and humans (Veldhuis and Bowers 2003), the 
secretory pattern of GH varies considerably between male and female mice (Norstedt 
and Palmiter 1984; Sinha et al. 1977). Compared to males, female GH secretion is 
characterised by an overall rise in baseline and increased GH pulse frequency. This 
deviation in GH pulse patterning contributes to sex-specific divergence in the expression 
of numerous liver genes (Waxman et al. 1991), including genes that regulate the 
expression of liver proteins belonging to the cytochrome P450-linked steroid hydroxylase 
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family, and major urinary protein gene family (Gustafsson, et al. 1983; Jansson and 
Frohman 1987; Waxman 1988). Divergence in sex-specific liver gene expression is 
largely determined by inter-pulse trough levels of GH release (the mean duration of GH 
secretory interval) and, by proxy, the frequency of GH secretory events (Waxman et al. 
1991). This ‘off time’ is assumed to allow sufficient refractory time in male hepatocytes to 
reset intracellular mechanisms that were activated following GH binding (Doglio, et al. 
1989; Rogers and Hammerman 1989; Stred, et al. 1990). As an example, a reduction in 
the mean duration of GH secretory intervals of only 35 min in male rats results in a 
change in liver gene expression to resemble that normally seen in female rats (Waxman 
et al. 1991). In male mice, germline deletion of Sst results in a shortening of the mean 
duration of the GH secretory interval and a similar change in liver gene expression to 
reflect expression patterns that are normally observed in female mice (Adams et al. 
2015). 
 
 Assessment of inter-pulse frequency and the number of secretory events within a 
single secretory episode in goat-/- mice confirms a shortening of the period of inter-pulse 
GH trough levels (reminiscent of female mice (Adams et al. 2015)); however, a change in 
sex-dependent liver gene expression was not observed. Although the extent of 
alterations in GH patterning in goat-/- mice suggests an insufficient capacity to alter 
sexually dimorphic liver gene expression, this requires further validation. Compared to 
existing measures of pulsatile GH release in the female mouse (Adams et al. 2015), GH 
release patterning in male goat-/- mice may not comprehensively represent the absence of 
stable inter-pulse secretory periods as is seen in female mice.  
 
Current observations discount the potential effects of stress on GH release (as 
suggested by comparable corticosterone levels between WT and goat-/- mice); however, 
measures of GH release were not collected in the complete absence of human 
intervention. Automated sampling for an extended period of time (approximaely 12 h; as 
conducted recently (Adams et al. 2015) in sst-/- mice) may highlight critical aspects of GH 
release not currently considered. 
 
Compared to WT mice, circulating levels of IGF-1 increased in goat-/- mice. Given 
the inhibitory actions of IGF-1 on GH release (Ceda, et al. 1987; Romero et al. 2010; 
Tannenbaum et al. 1983), it was anticipated that the rise in IGF-1 levels in goat-/- mice 
  122 
may contribute to reduced GH release. In 36-week old WT mice, total and pulsatile GH 
release, and also MPP of GH release decreased as circulating levels of IGF-1 increased. 
By contrast, a rise in circulating levels of IGF-1 in goat-/- mice was not associated with a 
decrease in total or pulsatile GH release, and the inverse relationship between MPP and 
circulating IGF-1 in goat-/- mice was greatly diminished. Moreover, compared to WT mice, 
the rise in circulating levels of IGF-1 at 36 weeks of age in goat-/- mice did not translate 
into a further suppression of GH release. Observations suggest that feedback interactions 
where IGF-1 should suppress GH release in goat-/- mice may be diminished, or largely 
disrupted. Alternatively, it is considered that distorted GH patterning might have impacted 
the hepatic production of IGF-1. 
 
Delivery of GH to mimic endogenous pulsatile GH secretion in hypophysectomised 
rats increases liver Igf-1 mRNA expression, as well as liver and serum IGF-1 levels. By 
contrast, continuous infusion of GH to achieve a similar daily dosage does not increase 
liver Igf-1 mRNA levels to the same extent (Maiter, et al. 1992). Although not specifically 
addressing the impact of endogenous GH pulse frequency on liver-derived IGF-1, these 
observations show that an intermittent change in GH exposure (reminiscent of 
endogenous pulsatile GH release) is critical for liver-derived IGF-1 production; thus, the 
pattern of GH release may predict the amount of IGF-1 in circulation. Increased GH pulse 
frequency and patterning in goat-/- mice were associated with an increase in circulating 
levels of IGF-1. Collective observations imply a potential role for acyl-ghrelin in regulating 
levels of IGF-1. Whether altered GH patterning (and the number of GH secretory events) 
following germline loss of Goat contributes to increased IGF-1 release remains 
completely unexplored. Liver-derived IGF-1 is not required for postnatal linear growth in 
mice, suggesting that locally produced IGF-1 mediates linear growth (Ohlsson et al. 
2000; Sjögren et al. 1999). In rats, intermittent and not continuous administration of GH 
promotes a rise muscle Igf-1 mRNA expression (Isgaard, et al. 1988a). Thus, patterned 
GH release may enhance muscle Igf-1 expression to regulate linear growth. A loss of 
Goat did not impact muscle-derived IGF-1 levels. Thus, although the amount of GH 
released in goat-/- mice at 8 weeks of age may have decreased, the patterned release of 
GH in these animals was likely sufficient to maintain muscle IGF-1 levels, and thus 
maintained muscle and possibly linear growth. 
 
Maternal ghrelin passes the placental barrier to access foetal circulation in rodents 
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(Kodomari, et al. 2009; Nakahara, et al. 2006) and thus maternal-derived ghrelin may 
impact prenatal development. Furthermore, maternal milk contains ghrelin (Aydin, et al. 
2006; Kierson, et al. 2006) and levels of acyl and desacyl-ghrelin in maternal milk are 
positively correlated with serum ghrelin levels in breastfed infants (Ilcol and Hizli 2007). 
Thus, maternal-derived ghrelin may enter neonate circulation, or may modify the 
neonatal production of ghrelin. To this extent, ghrelin signalling in the hypothalamus 
during the neonatal period exerts profound lifelong effects on mice (Steculorum, et al. 
2015), potentially in response to maternally derived ghrelin. To avoid potential effects of 
maternal-derived acyl-ghrelin on the development of the somatotroph axis, measures 
were collected from homozygous-derived mice. Although ensuring the complete absence 
of acyl-ghrelin, some experimental variables remain unexplored. For example, the loss of 
Goat resulted in a rise in total ghrelin levels, likely reflecting a rise in the amount of 
desacyl-ghrelin in circulation. Although direct actions of desacyl-ghrelin on GH release 
are yet to be confirmed, reports suggest that desacyl-ghrelin may regulate skeletal 
muscle function independent of activation of the GH/IGF-1 axis (Porporato, et al. 2013), 
whereas an elevation of desacyl-ghrelin significantly impairs linear growth, potentially 
acting via the suppression of GH axis function (Ariyasu, et al. 2005). Current 
observations cannot differentiate between the effects of a complete loss of acyl-ghrelin 
and a possible rise of desacyl-ghrelin on GH axis function, comprising changes in 
mechanisms that modulate IGF-1 release or the consequential effects on linear growth. 
Additional studies are needed to define distinct roles of GH patterning, and the selective 
effects of life-long and age-specific changes in acyl- and desacyl-ghrelin on mechanisms 
that regulate growth. 
 
To conclude, results from this chapter confirm that acyl-ghrelin predominantly 
contributes to the generation of peak GH release in young adult mice, demonstrating that 
homozygous germline loss of Goat results in diminished amount of GH released in young 
adult mice. Importantly, germline loss of Goat results in a rise in GH pulse frequency and 
altered GH pulse patterning regardless of age, suggesting that acyl-ghrelin may regulate 
hypothalamic interactions that facilitate the pattern of GH release. Given that data 
demonstrated a maintained expression of hypothalamic Srif, Ghrh, Npy and Ghsr mRNA, 
the hypothalamic components needed to maintain GH release are likely present. Altered 
GH release patterning did not impact GH-dependent sexually dimorphic liver gene 
expression. While a rise in IGF-1 levels relative to the number of GH secretory events 
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specifically in goat-/- mice was observed, comparison of circulating, liver and muscle IGF-
1 levels suggest that altered GH patterning may contribute to increased or sustained IGF-
1 production, thereby potentially accounting for normal linear growth in goat-/- mice. 
Furthermore, these results suggest that acyl-ghrelin may facilitate the integration of 
hypothalamic regulators of GH release without impacting pituitary GH content. 
Observations highlight novel roles for acyl-ghrelin in regulating interactions between GH 
and IGF-1, and demonstrate that acyl-ghrelin may be essential for the maturation and 
development or integration of hypothalamic or peripheral GH pulse generators. The 
necessities of the orderliness and frequency of pulse patterning for optimal effects of GH 
on growth and metabolism need to be further addressed. 
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Chapter 6 Conclusions and future directions  
In summary, observations presented throughout this thesis demonstrate that: 
 
6.1 Dietary-induced weight gain in mice results in a suppression of the amplitude 
of pulsatile GH secretion without altering the frequency or regularity of GH pulses 
Similar observations were demonstrated following the analysis of 24 h GH secretion 
profiles in obese and non-obese individuals (Riedel, et al. 1995b). Given that GH 
patterning remains intact, it is proposed that reduction in the amplitude of GH secretion 
following dietary induced weight gain is likely attributed to an impairment in the 
responsiveness of somatotrophs to hypothalamic GH regulators and/or the efficiency of 
somatotrophs to produce or release GH, rather than direct impairments in the central 
mechanisms that regulate peak GH release or patterning. Moreover, hypothalamic gene 
expressions of Sst and Ghrh are not altered following high fat feeding in mice (Luque and 
Kineman 2006). 
 
6.2 An inverse relationship was observed between leptin and insulin, and pulsatile 
GH secretion regardless of dietary intervention 
The suppression in GH release is observed alongside increased body weight (mostly 
contributed by the accumulation of epididymal fat mass). While accompanied by elevated 
circulating levels of plasma insulin and leptin (secreted proportionate to fat mass), 
plasma glucose and NEFAs did not change. Although it is commonly thought that 
elevated levels of NEFAs suppress GH release in obesity (Andreotti et al. 1994; 
Bjorntorp, et al. 1969; Quabbe, et al. 1972), a meta-analysis revealed sustained levels of 
NEFAs regardless of increased adiposity (Karpe et al. 2011). Likewise, no significant 
changes in NEFA levels were observed alongside weight gain and the decline in GH 
secretion during a short period of overeating in humans (Cornford et al. 2011). 
 
As with the reduction in pulsatile GH secretion, a significant correlation was 
demonstrated with increasing levels of leptin and insulin when assessed collectively in 
mice maintained on HFD and standard show diet. Previous study showed that the 
reduction in GH secretion coupled with increased levels of insulin improves meal 
tolerance (Cornford et al. 2012). This suggests that low levels of GH released might be 
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an essential adaptive physiological response to elevated levels of insulin, thereby 
sustaining fatty acid flux and blood glucose levels (Steyn et al. 2013). Moreover, insulin 
inhibits the release of GH from primary cultures of pituitary tissues from mice (Gahete, et 
al. 2013a). Although mice with somatotroph-specific knockout of insulin receptors display 
elevated levels of GH release (Gahete et al. 2013a), this did not prevent the reduction in 
pituitary GH expression following DIO (Gahete et al. 2013a), and weight gain alongside 
increased levels of insulin (Brothers, et al. 2010). These observations suggest that the 
rise in insulin levels following excess calorie intake largely contributes to the impairment 
of glucose metabolism in lieu of a direct causative role in inhibiting GH release. Therefore 
given that GH decreases the rate of glucose uptake (Rabinowitz, et al. 1965), the 
suppression of GH release might be a physiological response to facilitate the efficiency of 
glucose uptake during over-nutrition, thereby improving capacity to maintain blood 
glucose homeostasis. 
 
Leptin, an anorexigenic hormone, regulates the hypothalamic feeding circuitry 
(Bouret 2010; Kim, et al. 2014), and mediates long-term changes in hypothalamic control 
of food intake. Evidently, the complete ablation or selective deletion of leptin signalling in 
rodents undesirably impacts overall body composition and the regulation of food intake 
(Cohen, et al. 2001; Huan, et al. 2003; Wang, et al. 2014). Although measures of GH 
release are negatively correlated to circulating levels of leptin, the latter does not directly 
contribute to the decline in GH release (Ozata et al. 2003). Despite the inhibitory effect of 
leptin on pituitary somatotrophs (Roh et al. 1998; Roh et al. 2001), the arguable role of 
leptin in regulating the amplitude of GH release (Cocchi, et al. 1999; Saleri et al. 2004; 
Tannenbaum et al. 1998a; Watanobe and Habu 2002) suggest that leptin may play a 
major role in facilitating the GH axis relative to nutrient status. 
 
Hence collective observations proposed the notion that altered GH release 
coupled with dietary intake is a physiological response to weigh gain (as adiposity). 
Given that the reduced GH release precedes the onset of obesity in obesity-prone rats 
(Lauterio et al. 1998) and mice (current observations), long-term reductions in GH 
release may eventually be detrimental to the physiological system and thus contribute to 
the development of obesity (Girod and Brotman 2003). Further investigations need to 
clarify the cascade of physiological events that alters GH secretion in relation to food 
intake. In this instance, studies show that ghrelin is a key regulator of GH release, and 
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thus the association between circulating ghrelin levels and factors related to weight gain 
was further interrogated. 
 
6.3 Germline loss of ghrelin reduces peak GH release in young mice, while 
disrupting GH secretion patterning regardless of age or adiposity 
The germline deletion of Goat prevents the catalytic conversion of desacyl-ghrelin 
(inactive form of ghrelin) to acyl-ghrelin (active form of ghrelin), hence eliminating acyl-
ghrelin in the central and peripheral systems (Zhao et al. 2010). Data confirm negligible 
levels of acyl-ghrelin in goat-/- mice. Results confirmed a significant reduction in the 
amplitude of GH secretion in young adult goat-/- mice. This is cohesive with various 
pharmacological studies demonstrating dose-dependent stimulatory effects of ghrelin on 
peak GH release (in humans and in rodents; (Arvat et al. 2000b; Kojima et al. 1999; 
Peino et al. 2000; Popovic et al. 2003; Seoane et al. 2000). Furthermore, observations in 
goat-/- mice show increased frequency and irregular GH secretory events or pulses. This 
implies that loss of Goat contributes to a derangement in GH pulse patterning. 
 
Given that derangements in GH pattering were seen regardless of age, it is likely 
that loss of acyl-ghrelin contributes to the disruption of hypothalamic mechanisms that 
contribute to GH pulse patterning. In transgenic mouse model, it is plausible that the 
complete loss of ghrelin exposure (due to loss of acyl-ghrelin in lactating mothers and 
prodigy) may contribute to alterations in the maturation of critical circuitry essential for the 
regulation of GH release. In turn, this may impact downstream effects of GH. Despite a 
reduction in the amplitude of GH release was observed in goat-/- mice, the ablation of 
acyl-ghrelin did not alter pituitary GH content. This indicates that the action of GHRH on 
GH production is intact while acyl-ghrelin does not involve in the synthesis/production of 
GH in the somatotrophs. Rather, acyl-ghrelin contributes to the augmentation of GH 
release at the level of somatotrophs. Similarly, gene expressions of the key hypothalamic 
regulators (Ghrh and Sst) of GH release, as well as Ghsr, display no significant 
differences between goat-/- and WT mice. As such, it remains unclear why pulse 
patterning changes in goat-/- mice. 
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6.4 Circulating levels of IGF-1 correlates with parameters associated to GH pulse 
patterning in goat-/- mice 
In contrast to the WT mice, the amplitude of GH release did not correlate with circulating 
levels of IGF-1 in goat-/- mice. This may indicate disruption of the hypothalamo-pituitary-
GH pathway, given that IGF-1 is a key feedback regulator of the GH axis – acting at the 
level of pituitary (Romero, et al. 2012) and hypothalamus (Bermann et al. 1994). Taking 
into consideration of the integration of potential factors associated to food intake and 
adiposity, further detailed investigations are needed to understand the molecular 
mechanisms wherein acyl-ghrelin interacts with key regulators of the GH axis. Given that 
no significant changes were observed in body weight and body length in goat-/- mice, the 
association between GH pulse patterning and circulating IGF-1 in the goat-/- mice reveals 
the possibility of a pre-programmed compensatory mechanism for maintained linear 
growth, in which normal growth occurs in the absence of optimal GH levels. It is 
proposed that sustained circulating levels of IGF-1 observed in the goat-/- mice may 
account for normal growth. In this instance, maintenance of normal IGF-1 levels may be 
coupled to the derangement in GH pulse patterning (Fig 5.8E & F). Given that SST 
modulates GH pulse patterning (Low et al. 2001; Stroh, et al. 2009); elevated levels of 
IGF-1 in circulation may contribute to alterations in the activity and abundance of SST 
neurons relative to GHRH neurons. While it remains completely unclear how alterations 
in GH patterning may arise in goat-/- mice, a synergistic effect or compensatory effect 
between acyl-ghrelin and IGF-1 may be anticipated. 
 
6.5 Future directions 
Further studies are needed to assess the impact of loss of acyl-ghrelin on interactions 
between GHRH and SST neurons, and how disruption of these mechanisms may alter 
patterned GH release throughout life. In light of current results, it is proposed that 
developmental changes in the establishment of hypothalamic circuitry that control GH 
release may contribute to this. Recent studies demonstrate a rise in acyl-ghrelin prior to 
puberty, with these changes contributing to the maturation and integration of 
hypothalamic circuitry involved in appetite control (Collden, et al. 2015; Steculorum et al. 
2015). Given that differentiation of GH pulse patterning between males and females is 
established during pubertal maturation (Steyn, et al. 2016), changes in the exposure of 
acyl-ghrelin during pubertal maturation may contribute to alterations in hypothalamic GH 
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network formation. Hence it is presumed that endogenous levels of acyl-ghrelin will vary 
significantly during pubertal development. 
 
As a first step towards establishing this theoretical role of endogenous acyl-ghrelin 
exposure on the pubertal establishment of GH pulse patterning, circulating levels of acyl-
ghrelin were assessed in C57Bl/6J male mice from postnatal through to post-pubertal 
age. A gradual rise in circulating levels of acyl-ghrelin was observed prior to pubertal 
maturation, with acyl-ghrelin levels peaking by 5 weeks of age (Fig. 6.1). 
 
 
Figure 6.1 Weekly measurements of plasma acyl-ghrelin starting at 1 week of age 
through to 8 weeks of age in C57Bl/6J male mice 
Data were presented as mean ± SEM. Measures of plasma acyl-ghrelin were assessed 
in C57Bl/6J male mice between 1 and 8 weeks of age. All samples were collected 
between 1200 h and 1300 h. Differences in circulating levels of acyl-ghrelin between 
ages were identified by 1-way ANOVA multiple comparisons with Bonferroni post-hoc 
analysis. P < 0.05 was considered statistically significant; n=4-13 mice per group. The 
statistical significance of acyl-ghrelin levels between ages is denoted by respective 
alphabet as determined by multiple comparisons test. 
 
 
Although not assessed in this thesis, studies within the laboratory (unpublished 
data) show divergence in male and female GH pulse patterning, thereby further 
supporting the notion that the elevation in acyl-ghrelin levels during this critical 
developmental period might contribute to gender differentiation of GH pulse patterning. 
Evidently, female GH pulses are characterised by more GH secretory events, and a 
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higher ApEn (Steyn et al. 2016), reminiscent of what was seen in goat-/- mice (Fig. 5.2). 
Additionally, neonatal ghrelin administration impairs sexual maturation in rats 
(Hayashida, et al. 2002), further suggesting that the timing of hypothalamic exposure to 
changes in acyl-ghrelin may impact widespread neuronal integration of circuitries that 
control growth, reproduction and food intake; confirming that the physiological relevance 
of ghrelin exposure is age-dependent (Al Massadi et al. 2015). Indeed, recent 
observations show that ghrelin exerts profound organisation effects on neural projections 
within the hypothalamus, where reduced ghrelin action results in enhanced densities of 
neural projections during pre-weaning stage (Steculorum et al. 2015). Furthermore, 
alterations in ghrelin levels during development may undesirably impact long-term 
physiological function (Steculorum and Bouret 2011). For example, excess or lack of 
ghrelin during early life results in abnormally high or low hypothalamic ARC neural 
projections associated with similar long-term metabolic perturbations (Collden et al. 2015; 
Steculorum and Bouret 2011; Steculorum et al. 2015). Based on collective observations, 
acyl-ghrelin may shape the architecture of hypothalamic neuronal network that modulates 
the patterning of GH release (illustrated in Fig 6.2). 
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Figure 6.2 Schematic diagram of a proposed action of acyl-ghrelin in regulating 
axonal growth of key regulators of growth hormone (GH) secretion during critical 
periods of development in mice 
(A) Densely populated neuronal connections between GHRH- and SST-expressing 
neurons located in the ARC and PeVN respectively reflects a disorganised synaptic 
formation prior to puberty. This results in a derangement in pulsatile GH secretion (Tan et 
al. 2013). The peripheral production of acyl-ghrelin predominantly from the stomach 
travels to the hypothalamus via the vagus nerve may hypothetically act as a 
developmental switch that halt axon growth following puberty. (B) An appropriate integrity 
of hypothalamic neuronal network must be established during critical developmental 
stages to achieve an optimal pulsatile pattern of GH release. Specifically, it is proposed 
that acyl-ghrelin may aid the fundamental termination of excessive axon growth during 
puberty to facilitate the optimal development of hypothalamic GHRH and SST neural 
projections; thereby the neuronal interaction of GHRH and SST is in sync to elicit a 
classic pulsatile GH profile. However, the molecular mechanism of acyl-ghrelin in 
facilitating the maturation of hypothalamic neuronal network of the GH axis remains to be 
determined. APG, anterior pituitary gland; ARC, arcuate nucleus; GH, growth hormone; 
GHRH, growth hormone releasing hormone; ME, median eminence; PeVN, 
periventricular nucleus; SST, somatostatin. 
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